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ABSTRACT 
   
Ryan A. Yoder  
   
CHIRAL PROTON CATALYSIS: DESIGN AND DEVELOPMENT OF 
ENANTIOSELECTIVE AZA-HENRY AND DIELS-ALDER REACTIONS 
   
The proton (H+) is arguably Nature's most common Lewis acid and is utilized by 
many enzymes to carry out asymmetric transformations. These “natural” Brønsted acid 
catalysts have served as an inspiration to synthetic organic chemists for the development 
of both regioselective and stereoselective bond forming reactions. Inspired by Nature’s 
elegance and motivated by the demand for inexpensive, robust and environmentally 
friendly catalysts, a Brønsted acid catalyst called the chiral proton was developed. This 
catalyst relies upon polar ionic hydrogen bonding for substrate activation and as a 
primary control element for enantioselection. The catalyst system was based on a 
coordination complex between a proton and a chiral, C2-symmetric BisAMidine ligand 
(BAM).  
This complex has demonstrated the ability to both activate and control the absolute 
and relative stereochemistry in the addition of silyl nitronates to Boc-protected imines. It 
was further demonstrated that nitroalkanes could be used in place of silyl nitronates (aza-
Henry reaction), eliminating the need for preformation of the nucleophile. In the latter 
reaction, the amount of catalyst could be reduced to as low as 1 mol% without loss of 
enantioselectivity, attesting to the BAM ligand’s ability to sequester protons from bulk 
solvent. The products of this reaction provide access to enantioenriched 1,2-diamines. 
vi 
Furthermore, this catalyst system has been successfully applied to the enantioselective 
synthesis of both syn and anti α,β-diamino acids.  
The chiral BAM-protic acid complexes were further applied to the stereoselective 
intramolecular hetero-Diels-Alder reactions of azadienes. These catalysts were found to 
influence both the endo/exo selectivity, as well as the facial selectivity of the [4+2] 
cycloadditions. The azadienes used in this study were modeled after the putative Diels-
Alder precursors in the biosynthesis of the brevianamide class of natural products. In 
addition, a novel Diels-Alder reaction was hypothesized as an alternative route to the 
synthesis of oseltamivir phosphate (Tamiflu). A model system was chosen to examine the 
effectiveness of this route. The chiral proton catalyst was shown to catalyze this model 
reaction to produce the desired exo Diels-Alder adduct. 
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Chapter 1. Chiral Proton Catalysis and Activation Using 
Hydrogen Bonds: An Overview 
1.1. How Nature Serves as an Inspiration for Asymmetric 
Catalysis 
Understanding the biosynthesis of natural products provides chemists a glimpse at 
how nature establishes complexity into large molecules. This process and its typical 
complexity can guide the synthetic chemist in the discovery of new bond forming 
reactions that are both regioselective and stereoselective. Understanding how nature is 
able to build these complex molecules can also provide insight into unique methods for 
small molecule activation. 
Among biosynthetic reactions, the cascade cyclization of squalene to various 
triterpene natural products is a prominent example of a complexity-generating, 
asymmetric chemical transformation that is unmatched by any synthetic catalyst/reaction 
combination. Since Woodward and Bloch’s proposal in 1953,1 and the introduction of the 
Stork-Eschenmoser hypothesis soon thereafter,2,3 biomimetic cascade cyclizations have 
been an inspiration for synthetic chemists. In the past 10 years, biochemists have made 
significant progress in the understanding of how nature converts squalene to hopene 
enantioselectively in bacteria.4 There have been equally outstanding developments in the 
area of non-enzymatic enantioselective π-cation cascade cyclizations over the past 
decade. These remarkable mechanistic and synthetic accomplishments have been recently 
reviewed5 and will be highlighted in Sections 1.1.1 and 1.1.2. 
1.1.1. Probing the Role of the Enzyme 
Biochemists have recently employed sophisticated tools to elucidate how an 
enzyme’s active site can control a cascade cyclization (Figure 1). Among them is the site-
                                                 
1 Woodward, R. B.; Bloch, K. J. Am. Chem. Soc. 1953, 75, 2023. 
2 Stork, G.; Burgstahler, A. W. J. Am. Chem. Soc. 1955, 77, 5068. 
3 (a) Gamboni, G.; Schinz, H.; Eschenmoser, A. Helv. Chim. Acta 1954, 37, 964. Note: translation of 
original text provided by Professor Eschenmoser (ETH), private communication. (b) Eschenmoser, A.; 
Ruzika, L.; Jegger, O.; Arigoni, D. Helv. Chim. Acta. 1955, 38, 1890. 
4 It should be noted that the corresponding process in eukaryotes (the cascade cyclization of oxidosqualene 
to lanosterol) is a diastereoselective process. 
5 Yoder, R.A.; Johnston, J. N. Chem. Rev. 2005, 105, 4730. 
1 
directed mutagenesis studies initially reported by Poralla in 1996.6 The following year 
(1997) Schulz reported the first X-ray crystal structure of squalene-hopene cyclase (SHC) 
refined to 2.9 Å resolution7 and later to 2.0 Å resolution.8 In 2004 Schulz successfully 
cocrystallized SHC with the known inhibitor 2-azasqualene in the active site.9 In 
conjuction with site-directed mutagenesis, the key residues and the role they play can 
now be better understood. 
Figure 1. Enzymatic control over cascade cyclization 
 
In order to probe the SHC active site for key residues, Poralla mutated Asp376, the 
residue believed to initiate cyclization by protonation of squalene (Figure 2). 
Replacement of Asp376 with Glu significantly diminished the relative activity of the 
cyclase to just 10% of the wild-type, while replacement of Asp376 with Gln or Arg 
resulted in complete loss of all enzyme activity. Although replacement with Gly showed 
some activity, it was 0.1% that of wild-type. Furthermore, Asp377 was also exchanged 
with Glu, Gln, Gly, and Arg, dropping activities to less than 1% in all cases. 
Figure 2. X-Ray crystal structure of 2-azasqualene-bound SHC illustrating residues necessary for 
activation (protonation) 
 
                                                 
6 Feil, C.; Sussmuth, R.; Jung, G.; Poralla, K. Eur. J. Biochem. 1996, 242, 51. 
7 Wendt, K. U.; Poralla, K.; Schulz, G. E. Science 1997, 277, 1811. 
8 Wendt, K. U.; Lenhart, A.; Schulz, G. E. J. Mol. Biol. 1999, 286, 175. 
9 Reinert, D. J.; Balliano, G.; Schulz, G. E. Chem. Biol. 2004, 11, 121. 
2 
At the front of the active site cavity are Asp374 and Asp377 which are important to 
catalysis and conserved throughout the cyclases. These residues are believed to bear a 
negative charge to balance the positive charge of Asp376 and His451. Moreover, the role 
of the protonated histidine is to activate the aspartic acid residue by increasing its acidity, 
and therefore the electrophilicity of the proton for C3 of squalene. The resulting positive 
charge at squalene C2 is in turn stabilized by the squalene 6,7-olefin that has already 
arranged conformationally for the cascade reaction. 
Rohmer and Poralla also determined the importance of the His451 residue using site-
directed mutagenesis in 1999.10 Replacement of His451 with Ala provided the same 
product pattern as the wild-type, but at a much slower rate. This presumably follows from 
the acid-strengthening effect of His451 on Asp376 but its otherwise innocuous steric 
influence. It is significant to note that His451 is not a conserved residue among SHCs, so 
complete inactivation was not expected by this mutation. It is often replaced by Arg in 
other cyclases and believed to function analogously. 
Site-directed mutagenesis has also indicated the existence of a secondary support 
mechanism that provides activation of residues along the front line. For example, 
substitution of Tyr495 by Phe resulted in complete loss of activity due simply to removal 
of the hydroxyl group. However, when Tyr495 is replaced with Ala, the mutant activity 
was attenuated by 48% relative to native enzyme, despite the lack of a hydrogen-bond 
donor.11 The suggestion then followed that Tyr495 activates Asp376 prior to the initial 
protonation through hydrogen bonding between the phenolic hydroxyl group, a water 
molecule, and the aspartic acid residue.12,13  
Although the existence of discrete carbenium ion intermediates has yet to be 
unequivocally confirmed or eliminated from consideration, the large number of aromatic 
residues resident in the active site has led to the suggestion that they may stabilize any 
positive charge(s) that develops (Figure 3). Loss of this stabilization might lead to 
                                                 
10 Merkofer, T.; Pale-Grosdemange, C.; Wendt, K. U.; Rohmer, M.; Poralla, K. Tetrahedron Lett. 1999, 40, 
2121. 
11 Sato, T.; Hoshino, T. Biosci. Biotechnol. Biochem. 2001, 65, 2233. 
12 Wendt, K. U.; Schulz, G. E.; Corey, E. J.; Liu, D. R. Angew. Chem. Int. Ed. 2000, 39, 2812. 
13 Füll, C.; Poralla, K. FEMS Microbiol. Lett. 2000, 183, 221. 
3 
truncated polycycles that result from premature termination of the carbenium ion. The 
role of these aromatic residues was examined by Poralla as well as Hoshino.14
Figure 3. X-Ray crystal structure of 2-azasqualene-bound SHC illustrating residues necessary for charge 
stabilization during polycyclization 
 
Phe365 is highly conserved among both prokaryotic and eukaryotic species of cyclase 
enzymes. When Phe365 is mutated to Ala, bicyclic products are obtained, presumably 
from loss of stabilization of the bicyclic carbocation. In order to test this hypothesis, 
Hoshino replaced Phe365 with the more electron rich Tyr and observed a 41-fold 
acceleration in rate compared to the wild-type.15  
Tyr609 is also positioned in the active site to stabilize the bicyclic carbenium ion. 
Mutagenesis experiments that replaced Tyr609 with Ala produced bicyclic compounds, 
suggesting that Tyr609 may in fact also serve to stabilize the bicyclic carbocation. 
However, mutation of Tyr609 with Ala only produced these bicyclic products in 50% 
yield, whereas Phe365 replacement by Ala formed them in 96% yield. Furthermore, 
replacement of Tyr609 with Phe does not stop the cascade process at the bicyclic 
carbocation. This suggests that the aromatic π-electrons, rather than the hydroxyl group, 
are necessary for stabilization of the bicyclic carbenium ion by Phe365. 
Phe601 is also a highly conserved residue in both species of squalene cyclases 
(Figure 4). This residue is believed to stabilize the C19 carbenium ion that results from a 
                                                 
14 Hoshino, T.; Sato, T. Chem. Commun. 2002, 291. 
15 Hoshino, T.; Sato, T. Chem. Commun. 1999, 2005. 
4 
5-exo Markovnikov D-ring closure. This stabilization allows for ring expansion, followed 
by E-ring closure. 
Figure 4. X-Ray crystal structure of 2-azasqualene-bound SHC illustrating residues necessary for charge 
stabilization during polycyclization 
 
Poralla and Hoshino16 replaced Phe601 by Ala and the resulting product distribution 
was significantly different from that of the native enzyme. There was a significant 
increase in the formation of the 5-exo D-ring closure product, supporting the theory that 
the D-ring closure is initially a 5-exo process followed by ring expansion and E-ring 
closure.  
Phe605 is present in all prokaryotic squalene-hopene cyclases that form the 
pentacyclic hopene skeleton, but it is not conserved in lanosterol synthase in which a 
tetracyclic skeleton is formed. When Phe605 was mutated to Ala, the activity decreased 
by 67% relative to the native enzyme.17 However, when Phe605 was mutated to either of 
the more electron rich Tyr and Trp residues, the relative activity increased by 165% and 
256%, respectively. This increase in rate was interpreted as Phe605’s facilitation of the 5-
membered D-ring expansion to the 6-membered D-ring. Moreover, Phe605 may be 
involved in stabilization of the hopanyl cation prior to loss of proton and formation of the 
neutral product.  
1.1.2. Enantioselective Biomimetic Organic Syntheses 
“Can truly enantioselective biomimetic cyclization of isoprenoids be achieved in 
vitro?”18 This question was raised by de la Torre and Sierra in their recent review on 
                                                 
16 Hoshino, T.; Kouda, M.; Abe, T.; Ohashi, S. Biosci. Biotechnol. Biochem. 1999, 63, 2038. 
17 Hoshino, T.; Kouda, M.; Abe, T.; Sato, T. Chem. Commun. 2000, 1485. 
18 De la Torre, M. C.; Sierra, M. A. Angew. Chem. Int. Ed. 2004, 43, 160. 
5 
biomimetic organic synthesis. The best answer to that question to date can be found in the 
work of Yamamoto using a Lewis acid-assisted chiral Brønsted acid (LBA, Figure 5). 
Figure 5. Yamamoto's LBA catalysts 
 
In 1999, Yamamoto developed the first enantioselective biomimetic cyclization of a 
polyprenoid using LBA 1 as an artificial cyclase to synthesize (-)-ambrox (4).19 The 
cyclization of homofarnesol (3) promoted by LBA 1 proceeded with 42% ee (Scheme 1, 
eq 1). This enantioselective cyclization was further improved in 2002 using LBA 2 as the 
promoter.20 The ether (-)-4 was obtained in 54% yield with 75% ee and 3:1 dr from 3 
utilizing an enantioselective cyclization, silylation, and diastereoselective cyclization 
sequence. 
Scheme 1. Yamamoto's enantioselective olefin protonation-initiated polycyclization 
 
Yamamoto also applied LBA 2 to the enantioselective cyclization of polyprenoids in 
which the terminating group is an aromatic ring instead of the more nucleophilic 
hydroxyl terminator which was present in homofarnesol. LBA 2 promotes the cyclization 
of 6 to a mixture of 7 and 8 (Scheme 2).  
                                                 
19 Ishihara, K.; Nakamura, S.; Yamamoto, H. J. Am. Chem. Soc. 1999, 121, 4906. 
20 Ishihara, K.; Ishibashi, H.; Yamamoto, H. J. Am. Chem. Soc. 2002, 124, 3647. 
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Scheme 2. Yamamoto's enantioselective synthesis of (5S,10S)-7 
 
The mixture was then treated with an achiral Lewis acid (boron trifluoride etherate) in 
order to complete the cyclization to tricycle 7. The first two rings are formed in 
approximately 78% ee. Since (±)-7 had previously been reported by King21 and Ghatak 
en route to the total synthesis of ferruginol (9),22 this marked the first formal synthesis of 
enantioenriched ferruginol. 
In an early review by van Tamelen, he defined a biogenetic-type or biomimetic 
synthesis as “an organic synthesis designed to follow, in at least its major aspects, 
biosynthetic pathways proved, or presumed, to be used in the natural construction of the 
end product.”23 In the spirit of this definition, Yamamoto et al. have completed 
biomimetic, and for the first time enantioselective, formal syntheses of several natural 
products. Although not all LBA catalyzed total syntheses will be listed here,24, , ,25 26 27 
perhaps Yamamoto’s most impressive enantioselective cyclization to date was on 
substrate 10 (Scheme 3). Again, he utilized his two-step procedure of initial 
enantioselective formation of the A ring, followed by diastereoselective formation of the 
B ring. This sequence provided product 14 in a remarkable 89% yield and 75% ee. This 
compound is easily converted to 15 which is an intermediate in the total syntheses of 
isophyllocladene, phyllocladene, hibaone, manool, sclareol, manoyl oxide, isoabienol, 
                                                 
21 King, F. E.; King, T. J.; Topliss, J. G. J. Chem. Soc. 1957, 573. 
22 Banik, B. K.; Chakraborti, A. K.; Ghatak, U. R. J. Chem. Res. (S) 1986, 3391. 
23 Van Tamelen, E. E. Fortscr. Chem Org. Naturst. 1961, 19, 242. 
24 Nakamura, S.; Ishihara, K.; Yamamoto, H. J. Am. Chem. Soc. 2000, 122, 8131. 
25 Ishihara, K.; Ishibashi, H.; Yamamoto, H. J. Am. Chem. Soc. 2001, 123, 1505. 
26 Ishibashi, H.; Ishihara, K.; Yamamoto, H. Chem. Rec. 2002, 2, 177. 
27 Kumazawa, K.; Ishihara, K.; Yamamoto, H. Org. Lett. 2004, 6, 2551. 
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trans-abienol, and anticopelic acid.28 Remarkably, this represents the enantioselective 
formal syntheses of nine naturally occurring compounds. 
Scheme 3. Yamamoto's enantioselective synthesis of (5S,10S)-14 
 
The realization of a truly enantioselective biomimetic cyclization is arguably among 
the greatest contributions to this field to date. The idea that induction from a 
noncovalently-bound source of asymmetry could control an entire cascade of events 
leading to multiple ring formation as well as controlling several asymmetric centers may 
have been previously thought to be unachievable without the size and complexity of a 
protein. This concept also goes a long way toward supporting the theory of minimal 
enzymatic assistance, which states that the enzyme may only activate the substrate for 
cyclization and prevent alternative modes of cyclization from occurring.29
This new frontier is presented to us by the same chemistry that inspired chemists for 
decades. Incredible advances have been made in the last ten years both in the 
understanding of how nature performs such elegant reactions, as well as in the laboratory 
in the development of nonenzymatic enantioselective total syntheses. Fifty years after the 
Stork-Eschenmoser hypothesis, chemists continue to be inspired by the complex 
molecules made by Nature as well as by the catalysts which enable Nature to make those 
molecules. 
                                                 
28 Jannsen, C. G.; Godefroi, E. F. J. Org. Chem. 1982, 47, 3274. 
29 Abe, I.; Rohmer, M.; Prestwich, G. D. Chem. Rev. 1993, 93, 2189. 
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1.2. Asymmetric Brønsted Acid Catalysis  
Through the process of evolution, Nature has developed sophisticated protein 
catalysts to produce a seemingly unlimited library of chiral complex molecules. As 
mentioned in Section 1.1.1, Nature has established hydrogen bonding as a powerful 
method to both activate and orient substrates for a chemical reaction. Perhaps inspired by 
Nature’s elegant peptide catalysts, chemists have dramatically increased the successful 
use of hydrogen bonds in asymmetric catalysis. In large part, this interest stems from the 
ability to accelerate a reaction in the same way as traditional Lewis acids, but without the 
need of a heavy metal. As such, these so-called organic catalysts (or ‘organocatalysts’) 
are both environmentally friendly and cost-effective alternatives to traditional Lewis acid 
catalysts. Although Brønsted acids have been known to catalyze many organic reactions 
since the 19th century, the area of metal-free asymmetric Brønsted acid catalysis has 
remained unexplored until recent years.  
The history of chiral organocatalysis can be traced back to the pioneering work of 
Hajos and Parrish at Hoffmann La Roche,30 and Eder, Sauer, and Wiechert at Schering.31 
During the 1970’s, these two industrial groups discovered that proline was an effective 
enantioselective catalyst in classic aldol condensations. More recently others have 
expanded this methodology to a number of reactions including Michael additions, Diels-
Alder cycloadditions, and Mannich reactions.32 These catalysts have been shown to 
function by covalently bonding to the substrate, forming chiral intermediates such as 
enamines and iminium ions, which in turn facilitate diastereoselective reactions. 
Although there has been extensive research in the area of proline-catalyzed asymmetric 
reactions, the focus here will remain on chiral Brønsted acid catalysis, as this relates more 
directly to our research efforts. Specifically, the discussion will focus on the use of 
hydrogen bonds to both accelerate the rate of a reaction as well as serve as the primary 
source of stereocontrol. 
                                                 
30 Hajos, Z. G.; Parrish, D. R. J. Org. Chem. 1974, 39, 1615. 
31 Eder, U.; Sauer, G.; Wiechert, R. Angew. Chem., Int. Ed. Engl. 1971, 10, 496. 
32For reviews of proline asymmetric catalysis see (a) List, B. Tetrahedron 2002, 58, 5573. (b) Dalko, P.; 
Moisan, L. Angew. Chem. Int. Ed. 2001, 40, 3726. (c) Dalko, P.; Moisan, L. Angew. Chem. Int. Ed. 2004, 
43, 5138. (d) Jarvo, E.; Miller, S. Tetrahedron 2002, 58, 2481. (e) Groger, J.; Wilken, J. Angew. Chem. Int. 
Ed. 2001, 40, 529. 
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1.2.1. Brønsted Acids in Enantioselective Protonations 
In 1977 Dunhamel et al. reported the enantioselective protonation of lithium enolate 
17 using chiral Brønsted acid 18 in 58% ee (eq 3).33
 
Although many reports have described asymmetric protonation, the focus here will be on 
enantioselective Brønsted acid catalyzed reactions. Specifically outlined here will be the 
use of hydrogen bonds to accelerate the rate of a reaction, while at the same time 
controlling enantioselection. Hydrogen bonding has been evoked as a secondary control 
element in several enantioselective reactions.34 However, this again falls outside the 
scope of what is to be described here, i.e. hydrogen bonds as the primary source of 
asymmetric induction. 
This young field was pioneered by Yamamoto in the mid-1990’s using his Lewis acid 
assisted chiral Brønsted acid (LBA) (Chart 1). This is similar to his earlier work when he 
used Brønsted acid assisted chiral Lewis acids (BLA).  
 
Chart 1. Yamamoto’s chiral BLA and LBA complexes 
 
 
There is an important distinction between the two chiral complexes. A BLA is presumed 
to both activate and direct a substrate using the chiral Lewis acid center, while the 
Brønsted acid acts as a secondary control element. In contrast, an LBA activates the 
                                                 
33 (a) Duhamel, L.; Plaquevent, J. Tetrahedron Lett. 1977, 26, 2285-2288. (b) Duhamel, L.; Plaquevent, J. 
J. Am. Chem. Soc. 1978, 100, 7415. 
34 (a) Ishihara, K.; Yamamoto, H. J. Am. Chem. Soc. 1994, 116, 1561. (b) Ishihara, K.; Miyata, M.; Hattori, 
K.; Tada, T.; Yamamoto, H. J. Am. Chem. Soc. 1994, 116, 10520. 
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substrate through the chiral Brønsted acid, while the Lewis acid serves only as a means 
by which the Brønsted acid is activated. 
Yamamoto began using LBA 21 in the enantioselective protonation of silyl enol 
ethers and later ketene disilyl acetals.35 Shortly thereafter, 21 was shown to protonate 
prochiral allyltrimethyltins with up to 89% ee (eq 4).36
 
Yamamoto further developed the LBA concept and in 1999 published his landmark 
report of biomimetic polyprenoid cyclizations as discussed in detail in Section 1.1.2. 
1.2.2. O-H Based Chiral Brønsted Acid Catalysts 
Since Yamamoto’s pioneering work, several chiral alcohols have been used as 
asymmetric hydrogen bond donors. In 2003, Schaus reported an enantioselective Morita-
Baylis-Hillman reaction using a chiral Brønsted acid.37,38 Although BINOL only provided 
minimal enantioselection (32% ee), modification of the asymmetric hydrogen bond donor 
to 24 afforded excellent enantioselection (Chart 2). 
 
Chart 2. Schaus’ BINOL-Derived Chiral Brønsted Acid 
 
 
                                                 
35 (a) Ishihara, K.; Kaneeda, M.; Yamamoto, H. J. Am. Chem. Soc. 1994, 116, 11179. (b) Nakamura, S.; 
Kaneeda, M.; Ishihara, K.; Yamamoto, H. J. Am. Chem. Soc. 2000, 122, 8120. (c) Ishihara, K.; Nakashima, 
D.; Hiraiwa, Y.; Yamamoto, H. 2003, 125, 24. 
36 Ishihara, K.; Ishida, Y.; Nakamura, S.; Yamamoto, H. Synlett 1997, 758. 
37 (a) McDougal, N. T.; Schaus, S. E. J. Am. Chem. Soc. 2003, 125, 12094. (b) McDougal, N. T.; Trevellini, 
W.; Rodgen, S. A.; Kliman, L. T.; Schaus, S. E. Adv. Synth. Catal. 2004, 346, 1231. 
38 In 2004 Nagasawa reported a bis-thiourea catalyst that afforded MHB products with moderate ee.  
Sohtome, Y.; Tanatani, A.; Hashimoto, Y.; Nagasawa, K. Tetrahedron Lett. 2004, 45, 5589. 
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While aromatic aldehydes provided moderate enantioselection, aliphatic aldehydes 
typically gave better enantiomeric excess, as high as 96% ee (eq 5). 
 
Also inspired by the BINOL framework was a novel phosphoric acid catalyst 
discovered independently by Akiyama39 and Terada40 in 2004. By substituting the 3-
position of the naphthyl ring with aromatic groups, both investigators were able to 
achieve excellent enantioselection in their respective Mannich reactions (Scheme 4). 
 
Scheme 4. Initial Reports by Akiyama and Terada of Chiral Phosphoric Acids in Asymmetric Catalysis 
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Since these initial reports, both authors have expanded the applications of these 
relatively more acidic Brønsted acid catalysts to a number of asymmetric transformations 
(Scheme 5 and Scheme 6). 
 
                                                 
39 Akiyama, T.; Itoh, J.; Yokata, K.; Fuchibe, K. Angew. Chem. Int. Ed. 2004, 43, 1566. 
40 Uraguchi, D.; Terada, M. J. Am. Chem. Soc. 2004, 126, 5356. 
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Scheme 5. Chiral Phosphoric Acid Catalyzed Asymmetric Reactions Reported by Akiyama 
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Scheme 6. Chiral Phosphoric Acid Catalyzed Asymmetric Reactions Reported by Terada 
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Among the most notable transformations effected by asymmetric hydrogen bond 
catalysis is the enantioselective hetero-Diels-Alder reaction reported by Rawal in 2003.41 
Using chiral alcohol 62, asymmetric hetero-Diels-Alder reactions provided products 64 in 
good yields and excellent enantioselectivity for a variety of substrates (eq 15). 
 
Rawal compares this type of catalysis to enzymatic catalysis, suggesting that the above 
transformation is a more biomimetic form of traditional Lewis acid catalysis. Since 
reporting the asymmetric hetero-Diels-Alder reaction, Rawal has extended the use of 
                                                 
41 Huang, Y.; Unni, A. K.; Thadani, A. N.; Rawal, V. H. Nature, 2003, 424, 146. 
14 
these TADDOL catalysts to the asymmetric Mukaiyama aldol reaction in which he is 
able to achieve good diastereo- and enantioselection.42
1.2.3. N-H Based Chiral Brønsted Acid Catalysts 
As organic catalysts became popularized in asymmetric catalysis, one reaction in 
particular served as an inspiration for new catalyst design. The Strecker reaction, which is 
the hydrocyanation of imines leading to α-amino acids, had not been asymmetrically 
catalyzed until the mid-1990s. 
 
Prior to the hydrocyanation of imines, Inoue reported that dipeptide 67 (Chart 3) was 
able to catalyze the asymmetric addition of hydrogen cyanide to benzaldehyde (eq 16). 
Remarkably, after 30 minutes the cyanohydrin product 66 was obtained in 90% ee. 
However, if allowed to react longer, the cyanohydrin product would racemize. For 
example, after 72 hours only a 12% ee was obtained with 80% conversion.  
 
Chart 3. Inoue and Lipton’s Dipeptide Catalysts 
 
 
In 1996 Lipton et al. reported the first enantioselective catalyst for the Strecker 
reaction, dipeptide 68 (Chart 3). Lipton was able to achieve excellent enantioselectivity, 
greater than 99% ee for several substrates, but the generality was low (eq 17). 
 
                                                 
42 (a) McGilvra, J. D.; Unni, A. K, Modi, K.; Rawal, V. H. Angew. Chem. Int. Ed. 2006, 45, 6130. (b) 
Gondi, V. B.; Gravel, M.; Rawal, V. H. Org. Lett. 2005, 7, 5657. 
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In the years following Lipton’s initial efforts in this area, Corey and Grogan (71),43 as 
well as Sigman and Jacobsen (72 and 73),44 reported novel organocatalysts for the 
Strecker reaction (Chart 4).  
 
Chart 4. Corey’s Guanidine and Jacobsen’s Urea / Thiourea Chiral Catalysts 
N
N
H
N
71
H
N
N
H
N
H
O
X
N
HO
tBu OC(O)tBu
tBu
R
72 R = polystyrene, X = S
73 R = Ph, X = O  
 
These catalysts afforded the α-aminonitriles in high yield and excellent 
enantioselectivity. In 2000 Vachal and Jacobsen extended the use of catalyst 72 from 
aldimines to ketimines.45
Intrigued by the increased activation of substrate provided by catalyst 72, Vachal and 
Jacobsen studied the effect of structural changes on 72 in 2002.46 Their investigation 
revealed that the thiourea moiety played a large role in substrate binding and thus 
activation. After modifying the catalyst design based on their mechanistic insights, 
catalyst 74 was identified as “the most enantioselective Strecker catalyst prepared to 
date” (Figure 6). 
 
Figure 6. Jacobsen’s Improved Thiourea Catalyst 
 
 
                                                 
43 Corey, E. J.; Grogan, M. J. Org. Lett. 1999, 1, 157. 
44 (a) Sigman, M. S.; Jacobsen, E. N. J. Am. Chem. Soc. 1998, 120, 4901. (b) Sigman, M.S.; Vachal, P.; 
Jacobsen, E. N. Angew. Chem. Int. Ed. 2000, 39, 1279. 
45 Vachal, P.; Jacobsen, E. N. Org. Lett. 2000, 2, 867. 
46 Vachal, P.; Jacobsen, E. N. J. Am. Chem. Soc. 2002, 124, 10012. 
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With only minor structural changes, Jacobsen has continued to use the thiourea motif 
of catalyst 74 to adapt this organocatalyst to a number of asymmetric reactions (Scheme 
7).47  
 
Scheme 7. Asymmetric Reactions Catalyzed by Jacobsen’s Thiourea Derivatives 
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47 (a) Wenzel, A. G.; Jacobsen, E. N. J. Am. Chem. Soc. 2002, 124, 12964. (b) Wenzel, A. G.; Lalonde, M. 
P.; Jacobsen, E. N. Synlett 2003, 12, 1919. (c) Joly, G. D.; Jacobsen, E. N. J. Am. Chem. Soc. 2004, 126, 
4102. (d) Taylor, M. S.; Jacobsen, E. N. J. Am. Chem. Soc. 2004, 126, 10558. 
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In only a few years, Jacobsen has shown that these chiral thioureas can efficiently 
accelerate and enantioselectively direct a variety of reactions to produce enantiomerically 
enriched amines (eq 18 – 26). Recently, Jacobsen reported the enantioselective catalytic 
acyl-Pictet-Spengler reaction using modified thiourea catalyst 84. In a one-pot reaction, 
18 
he was able to convert indole 82 to tetrahydro-β-carboline 83 in good yield with high 
enantioselectivity (eq 20). 
Shortly after Jacobsen’s initial reports using thioureas in asymmetric catalysis, 
Takemoto et al. described a new achiral thiourea 107, which they used to catalyze the 
addition of cyanide to nitrones (eq 27).48
 
This thiourea was converted into chiral bifunctional catalyst 111 and used in the Michael 
addition of malonates to nitroolefins (eq 28).49 They achieved high enantioselectivity in 
good yields for a broad range of substrates. 
 
The same catalyst 111 was used in a 2004 report by Takemoto et al. on the aza-Henry 
reaction.50 Again they believed that the catalyst had a bifunctional role, activating both 
the electrophile and nucleophile. This reaction will be further discussed in Section 2.1.  
Recently, Schaus has reported that a hydroquinine derived thiourea was a very 
effective general catalyst for the addition of stabilized nucleophiles to acyl imines. The 
nucleophiles studied included nitromethane, nitroethane and dimethyl malonate (eq 29).51
                                                 
48 Okino, T.; Hoashi, Y.; Takemoto, Y. Tetrahedron Lett. 2003, 44, 2817. 
49 Okino, T.; Hoashi, Y.; Takemoto, Y. J. Am. Chem. Soc. 2003, 125, 12672. 
50 Okino, T.; Nakamura, S.; Furukawa, T.; Takemoto, Y. Org. Lett. 2004, 6, 625. 
51 Bode, C. M.; Ting, A.; Schaus, S. E. Tetrahedron 2006, 62, 11499. 
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 1.3. Polar Ionic Hydrogen Bonds 
As discussed in Section 1.1.2, hydrogen bonding has recently witnessed great success 
in the area of asymmetric catalysis. These so-called organocatalysts have received special 
recognition in recent years. Although these catalysts have already been shown to 
accelerate reactions with high enantioselectivity, improvements can still be made. In 
order to advance upon the chiral non-metal catalysts that are already available, we noted 
the potential differences between polar covalent and polar ionic hydrogen bonds (Figure 
7). 
 
Figure 7. A Comparison of Polar Covalent and Polar Ionic Hydrogen Bond Solvation 
 
 
Specifically, the former employs a chiral anion, whereas the latter makes use of an 
uncharged chiral ligand for the proton. In essence, the requirement is a chiral solvating 
agent. It is for this reason that bulk solvation effects are a critical consideration in the 
proposal below. 
The same advantages that polar covalent hydrogen bonds have over traditional Lewis 
acid catalysts exist for polar ionic hydrogen bonds as well. We hypothesize that the 
benefits of using a polar ionic hydrogen bond over a polar covalent hydrogen bond are 
increased activation as well as increased turnover. This increase in activation will be 
discussed in more detail in Section 2.1.3. 
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Experimentally, it is easier to purify a neutral organic product from a salt than it is 
from a neutral catalyst, by column chromatography or aqueous extraction. Furthermore, 
the salts that are formed upon protonation by strong acid are more likely to be crystalline 
compounds that are bench stable. In order to utilize polar ionic hydrogen bonding in 
asymmetric catalysis, we began with the straightforward premise that a new ligand must 
be designed to both hold the proton throughout a reaction as well as impose its chirality 
onto the substrate.  
1.3.1. BAM Ligands 
The premise that a ligand must bind a proton and effectively transfer asymmetry to 
the substrate led to several key design elements. First, and perhaps most important, the 
ligand must be sufficiently Brønsted basic such that the proton will remain bound at all 
times and not transferred to achiral solvent, substrate, or product. Second, the ligand must 
provide a chiral environment while binding to the proton complex, presenting only one 
prochiral face of the substrate to the nucleophile. Third, the ligand should be readily 
available in enantiopure form and should be easily modified to allow a library of diverse 
structures to be created. Finally, we hypothesized that a bidentate ligand may prove more 
effective than a monodentate ligand. These principles of design led us to target 115 
(Figure 8). 
 
Figure 8. Chiral Ligand Designed For A Proton 
 
 
The design of 115 is similar to the N,N’-bis-(2-pyridyl-methyl)-N,N’-dimethyl-1,2-
cyclohexanediamine 116 (BPMCN) ligand that Que and coworkers described in 2001.52 
A crystal structure of this ligand bound to Fe(II) revealed a bidentate binding mode where 
                                                 
52 Costas, M.; Tipton, A. K.; Chen K.; Jo, D.; Que, L. J. Am. Chem. Soc. 2001, 123, 6722-6723. 
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the two pyridine rings were trans to each other (Figure 9). It should be noted that the 
complex is C2-symmetric with the pyridyl rings twisting out of planarity. 
 
Figure 9. ORTEP Plot for Que’s BPMCN·Fe(ClO4)2
 
 
When the 6-Me2-BPMCN ligand (117) was used, which placed methyls at the 6-position 
of the pyridyl ring, the pyridine rings were no longer trans to one another. This simple 
modification provided an unexpectedly large change in conformation and coordination 
geometry (Figure 10).  
 
Figure 10. ORTEP Plot for Que’s 6-Me2-BPMCN 
 
 
This change in conformation had a large impact in the cis-dihydroxylation of olefins, 
where the ee rose from 29% using BPMCN to 82% using 6-Me2-BPMCN. The change in 
conformation also increased the ratio of diol to epoxide formation as well. 
22 
In proposing 115, the lower homolog of Que’s BPMCN, a potentially more 
conformationally rigid ligand should result, as well as a Brønsted base whose strength 
approximates that of DMAP. Utilizing 1,2-(R,R)-trans-diaminocyclohexane as a 
backbone combined with substituted pyridines reveals the BisAMidine (BAM) moiety 
(eq 30).53 It should be noted that many BAM ligands that have been synthesized, as well 
as their triflic acid salts, are bench stable, crystalline solids. 
 
The basicity of the BAM was initially estimated by comparison to the pKa of 
dimethylaminopyridine (DMAP), which has been measured at 9.5.54 The BAM can be 
viewed as a chiral ortho-DMAP derivative and thus the pKa should be similar; however, 
this does not take into consideration the bidentate nature of the ligand which may have an 
increasing effect on the pKa of the protonated species. For comparison, the pKa of 
pyridinium has been measured at 5.2. Given the basicity of the BAM ligand, many strong 
acids can be used to form the protonated complex, 118 (eq 31). 
 
A naming system was adopted to more easily communicate structural differences in 
the BAM ligand motif. Using the numbering system below (Chart 5) for the R2 pyridine 
substituent, in conjuction with R1 as the cyclohexane diamine substituent, 115a would be 
called H,3Me-BAM, while 115k would be called Me,6Me-BAM. 
  
  
  
                                                 
53 Nugent, B. N.; Yoder, R. A.; Johnston, J. N. J. Am. Chem. Soc. 2004, 126, 3418. 
54 Perrin, D. D. Dissociation Constants of Organic Bases in Aqueous Solution; Butterworths: London, 
1965. 
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Chart 5. Shorthand Notation for BAM ligands. 
 
 
A complete list of all BAM ligands and their abbreviations can be found in Appendix 1. 
Modeling studies were used to determine the lowest energy conformations of the 
protonated complex. These studies were performed using PCModel; however, PCModel 
forces a proton onto one atom prior to minimization. By doing this, it was not possible to 
generate the desired C2-symmetric complex for some ligands. The views below were 
obtained by fixing the angle of the N-H-N of the protonated pyridine system at 180º. The 
models below used the 5,6-disubstituted (quinoline) BAM proton complex, which was 
minimized with only the restriction mentioned above. 
 
Figure 11. 3D Views of BAM-Proton Complex Generated by PCModel 
 
 
This low energy conformation is the expected C2-symmetric conformation of the active 
complex (Figure 11). From the modeling studies, it appeared that the 6-position on the 
pyridine ring would be most beneficial in terms of distinguishing faces of attack by the 
nucleophile. 
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Two crystal structures were obtained of the protonated BAM complexes. The first 
was using H,6Me-BAM (Figure 12). N-H bond distances are included, but the triflate 
counterion is omitted for clarity. 
 
Figure 12. X-ray Crystal Structure of H,6Me-BAM·HOTf complex 
N
N
H
H
N
N
Me
Me
H
0.803Å
0.838Å
0.700Å
118c
 
 
The complex appears to prefer a ‘swung-out’ conformation in the solid state in which no 
intramolecular hydrogen bonding is present. Also, notice that the cyclohexyldiamine 
chair is in a diaxial conformation. A possible reason for these deviations from the 
expected conformation is the stabilization of intermolecular hydrogen bonding in the 
solid state structure. Indeed, there are multiple intermolecular hydrogen bonds to bridging 
triflates.  
A second crystal structure was obtained using H,Quin-BAM·HOTf (Figure 13).  
 
Figure 13. X-ray Crystal Structure of H,Quin-BAM·HOTf complex 
N
H
H
N
H
NH
N
H
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0.905Å
N-H---N 1.818Å
118e
 
 
This X-ray showed an internal hydrogen bond between the N-H of the cyclohexyl 
diamine and the opposing quinoline N. Again the appropriate N-H bond lengths are 
displayed and it should be noted that the N-H---N distance is indicative of a medium-
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strong H-bond,55 at 1.82 Å. This can be compared to the crystal structure of the chiral 
(racemic) proton sponge obtained by Lloyd-Jones in 1998 which showed the N-H---N 
bond distance to be 1.72 Å (Figure 14).56  
 
Figure 14. X-ray Crystal Structure of Lloyd-Jones’ Chiral Proton Sponge 
 
 
The H,Quin-BAM X-ray does in fact show that the cyclohexyl diamine chair is in the 
di-equatorial position as expected. The deviation in this X-ray from the expected C2-
symmetric complex described above can again be attributed to the intermolecular 
hydrogen bonds which are present throughout the crystal lattice. The direct relevance of 
these solid state structures to their solution chemistry remains a question. 
1.3.2. Reaction Development 
The basis for developing a variety of chiral proton-catalyzed enantioselective 
reactions began from the general catalyst-substrate complex 120b (Figure 15).  
  
  
  
  
  
  
  
                                                 
55 Jeffrey, G. A. An Introduction to Hydrogen Bonding; Oxford University: New York, 1997. 
56 Charmant, Jonathan P. H.; Lloyd-Jones, Guy C.; Peakman, Torren M.; Woodward, Robert L. 
Tetrahedron Lett. 1998, 39, 4733. 
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Figure 15. Binding of Imine to Bidentate Proton Complex 
 
 
Although carbonyl compounds are attractive electrophiles, the basicity of the carbonyl 
oxygen is low57 and as such may lead to a long O---H*L bond in the transition state. The 
more basic imine58 might lead to a tighter bound electrophile in the transition state, 
hopefully leading to higher stereoselection. As our model advanced it became clear that 
stereochemical induction may be more difficult using a monodentate catalyst (Figure 16). 
The undefined coordination geometry of the proton allows for a multitude of binding 
modes. 
 
Figure 16. Binding of Imine to Monodentate Proton Complex 
 
 
We hypothesized that a bidentate ligand would force the substrate into a more defined 
position in the chiral proton complex (Figure 15). We turned to modeling to better 
rationalize how the ligand might shield one face of the substrate from attack, thereby 
leading to enantioselection. Chem 3D was used to dock a representative imine into the 
PCModel minimized protonated BAM, ultimately arriving at the complex shown below 
                                                 
57 pKa has been determined several times, with values ranging from -4 to -8 (see: Arnett, E. M.; Quirk, R. 
P.; Larsen, J. W. J. Am. Chem. Soc. 1970, 92, 3977.) 
58 pKa (N-benzylidenebenzylamine) ~ 7 (see: Koehler, K.; Sandstrom, W.; Cordes, E. H. J. Am. Chem. Soc. 
1964, 86, 2413. Cordes, E. H.; Jencks, W. P. J. Am. Chem. Soc. 1963, 85, 2843.) 
27 
(Figure 17). An imine bound in this way would only be accessible to attack from one 
face, leading to high enantioselection. 
 
Figure 17. Proposed Catalyst - Substrate Complex 
 
 
The diagram above suggests that an imine bound to the chiral proton complex will 
react with a nucleophile stereoselectively. To avoid the possibility of a strong nucleophile 
simply getting protonated by the catalyst, we hypothesized that neutral nucleophiles 
would provide a better starting point. Silyl nitronates are readily available neutral 
nucleophiles which could be used to test this hypothesis. 
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Chapter 2. Chiral Proton Catalyzed Additions to Imines: 
Silyl Nitronate and Nitronic Acid Nucleophiles 
2.1. Determination of the BAM Acidity Constant 
2.1.1. Background on pKa Values 
When talking about chiral Brønsted acids, it is useful to be able to compare their 
relative acidities. When the acid dissociation constant for an acid and its conjugate base 
(Ka) is known, this equilibrium constant can be converted to a pKa, where pKa = -log10Ka. 
Taking the logarithim to base 10 of the value creates a convenient scale for comparing 
relative acidities over a much smaller range since Ka varies over many degrees of 
magnitude. Chemists use this absolute scale for acidity as a tool for both comparing two 
compounds with known acidity constants as well as for predicting the pKa for a 
compound in which the acid dissociation constant is unknown.  
 
For polar covalent H-bonds, the acidity constant for a compound is a reflection of that 
compound’s ability to stabilize the resulting negative charge upon deprotonation (eq 32). 
The more stable a polar-covalent H-bond is upon loss of that proton, the lower the pKa 
value is for that compound. It then follows that HCl has a pKa of -6 compared to H2O 
which has a value of 15. The rationale is that the more electronegative chloride can better 
stabilize the resulting negative charge than hydroxide can. 
 
The corresponding acidity constant for a compound which has a polar ionic H-bond is 
a reflection of that compound’s inability to stabilize the resulting positive charge upon 
protonation (eq 33). Stabilization of the resulting positive charge causes an increase in the 
pKa, thus making the protonated complex a weaker acid. By way of example, the pKa for 
an ammonium ion is approximately 10. However, the addition of a phenyl group, to make 
the correspoinding anilinium ion, drops the pKa to 5. The anilinium is more acidic 
because of the electron withdrawing effect of the phenyl group. 
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There are two main influences that contribute to an acid-ionization constant. First 
there is a resonance effect (also known as the mesomeric effect, M), which describes the 
electron withdrawing (-M) or electron donating (+M) properties of the corresponding 
functional group based on the relevant resonance structures. Acetyl, phenyl, and nitro are 
examples of electron withdrawing groups (-M), while alcohols and amines are examples 
of electron donating groups (+M). 
The second major contributor to the overall electron flow to or from a substituent is 
the inductive effect. The inductive effect is based soley on the electronegativity of the 
individual atoms and their structural connectivity. The electron cloud that forms the bond 
between two atoms with different electronegativities is not uniform and as a result 
chemists describe the more electronegative element as having a partial negative (δ-) 
charge and the other atom as having a partial positive charge (δ+).  
 
Figure 18. Example of Inductive Effect on the Acidity Constant 
 
 
Although the inductive effect is strongest when the electronegative atom is directly 
connected to the functional group in question, it can be transferred through a chain of 
atoms. However, since the induced polarity through the chain is less than the original 
bond polarity and decreases with each bond, the inductive effect is only significant over 
short distances. Using acetic acid as an example, substitution of a trifluoromethyl group 
in place of the methyl group drops the pKa by 4.5 units due to the increased stabilization 
of the resulting anion provided by the electronegative fluorides (Figure 18). However 
replacement of the methyl by trifluoroethyl or trifluoropropyl groups only drops the pKa 
by 1.7 units and 0.6 units respectively. This demonstrates how significantly the bond 
polarization decreases over short distances. 
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Figure 19. Acidity Constants of Methoxy-Substituted Pyridines 
 
 
Although it is typical for a resonance donating effect (+M) to outweigh an inductive 
decreasing effect (-I) in cases where orbital overlap is good for pi-bonding, in large part 
due to the decreasing effect over short distances mentioned above, it is important to note 
that there are examples where the inductive effect overrides the resonance effect. One 
such example can be found in the chemistry of protonated methoxy-substituted pyridines 
(Figure 19). As mentioned above, oxygen can have a +M effect as a substituent, but due 
to its high electronegativity, it also has a significant –I contribution as well. When 
substituted at the 4-position of the pyridine ring, the inductive effect is minimized and a 
1.4 unit increase in pKa is observed over unsubstituted pyridine. However, when the 
methoxy is moved to the 2-position, the inductive effect is at its strongest. The resonance 
contribution (+M) has not changed, but the large decrease in I causes a net decrease in 
pKa by nearly 2 full units.  
 
Figure 20. Acidity Constants of Amino-Substituted Pyridines 
 
 
Since our efforts are primarily concerned with amino-substituted pyridines, it should 
be mentioned that a similar effect has been observed as in the methoxy-substituted 
pyridines. The large increase of almost 4 pKa units between pyridine and 4-amino 
pyridine can be attributed to the expected large M contribution (Figure 20). However, 
this effect is suppressed to some degree when the amino group is moved to the 2-position. 
This follows from a more pronounced decreasing contribution to the acidity constant 
from I. It should be noted that this I contribution does not cause a net decrease in pKa 
between pyridine and 2-aminopyridine as in the 2-methoxypyridine case above. This can 
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be rationalized from the decreased electronegativity of nitrogen relative to oxygen. As a 
result, amino substituents have larger M contributions and smaller I contributions as 
compared to their oxygen counterparts. Hence, protonated 2-aminopyridine has a lower 
pKa than that of protonated 4-aminopyridine resulting from an increase in the -I 
contribution, but is still greater than that of unsubstituted pyridine. 
2.1.2. Determining pKa Values For Protonated BAM Complexes 
In hopes of unraveling some of the mechanistic complexity associated with the chiral 
proton catalyzed aza-Henry reaction discussed below in Section 2.2.3, we set out to 
determine the pKa of the H,Quin-BAM·HOTf complex. Perrin has developed a titration 
procedure which utilizes the change in chemical shifts when titrating two bases with a 
Brønsted acid in a deuterated solvent. The result of Perrin’s method is the difference in 
pKa between two (or more) compounds as well as which compound is the most basic. 
This method would allow us to answer one question that arose early in the design stage of 
the BAM ligands. Does the bidentate nature of the catalyst have a base-strengthening 
effect similar to that of proton sponge (Figure 21)? 
 
Figure 21. Comparison of BAM and Proton Sponge Salts 
 
 
Although we initially had hoped to obtain the pKa in H2O, poor solubility of the free 
ligand (115e) forced us to use another solvent. We chose DMSO in part because it has 
been used as a solvent for the determination of many pKa values spanning a vast library 
of compounds. Furthermore, all protonation states of catalyst 115e have been shown to be 
soluble in DMSO which also makes it an operationally suitable choice. We found that 
when using Perrin’s method, it is advisable to choose an appropriate base such that the 
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difference in pKa is not greater than 2 units. We narrowed our window to range from 2-
aminopyridine to proton sponge (Figure 22).59
 
Figure 22. Acidity Constants for Protonated Compounds in DMSO 
 
 
Given that the base-strengthening effect of proton sponge over its functional 
component dimethyl aniline is over 5 units, we expected the pKa of H,Quin-BAM·HOTf 
(118e) to be between 6 and 11 in DMSO. Titration of H,Quin-BAM with 2-
aminopyridine determined that the ∆pKa was 0.34 with 2-aminopyridine being the more 
basic compound of the pair. This gave a pKa value of 5.78 for H,Quin-BAM·HOTf (118e) 
in DMSO. This shows that there is in fact no base-strengthening effect as observed in 
proton sponge. This is most likely due to the flexibility of the ligand in solution to change 
conformations where proton sponge is constrained in such a way as to force both lone 
pairs from nitrogen to participate in hydrogen bonds.  
 
We were also interested in determining the pKa of the diprotonated salt, which is 
inactive in the aza-Henry reaction as mentioned in Section 2.2.3. We were able to obtain 
the acidity constant by comparing it to two different bases, pyridine and lutidine. When 
the pKa was measured in a competition with pyridine, the value was determined to be 4.2. 
In a competition with picoline, a pKa of 4.4 was determined, emphasizing the importance 
of the accuracy of the absolute pKa chosen as a comparison. As expected, the inductive 
                                                 
59 Hess, A. S.; Yoder, R. A.; Johnston, J. N. SynLett 2006, 1, 147. 
33 
effect produced by having a protonated quinoline ring in close proximity to the second 
basic site, caused a decrease in pKa of 137 by 1.4-1.6 units.  
Finally, we confirmed that there was in fact no base increasing effect from the fact 
that 115e was a bidentate ligand. The pKa of 136 was determined to be 5.93, which 
clearly demonstrates that 118e does not possess any special base-strengthening 
properties. Although the bidentate nature is still believed to play a role in the 
stereochemical determining step in the aza-Henry reaction, this kinetic property does not 
translate to the thermodynamic acidity constant. Thus it appears that proton sponge is 
unique in its base-strengthening effect over its component functionality. 
2.2. Enantioselective Aza-Henry Reaction 
2.2.1. Background 
The aza-Henry reaction is a powerful C-C bond forming reaction in which a 
nitroalkane is added to an imine, typically using an acid or base catalyst (eq 34). 
 
The direct products of the reaction are α-nitro amines (141), and these products can be 
transformed into a number of synthetically useful intermediates such as vicinal diamines 
(143) or α-amino acids (142) (eq 35). 
R1
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Historically, the aza-Henry can be traced back to Henry who discovered the first example 
of a nitroalkane addition to an aldehyde in 1896.60,61 In that same work, Henry also 
described what could be considered the first example of an aza-Henry by using a 
nitroalkane and two equivalents of a hemi-aminal (eq 36). 
                                                 
60 Henry, L. Chem. Ber. 1905, 38, 2027. 
61 Henry, L. Bull. Acad. Roy. Belg. 1896, 32, 33. 
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This transformation is a traditional Mannich reaction using a nitroalkane as the 
nucleophile and as such has been referred to as a nitro-Mannich reaction. Although other 
examples of the aza-Henry emerged,62 it wasn’t until 1937 that Cerf extended the scope 
of the reaction.63 However, Cerf made claims that only two equivalents of 144 will react 
with nitromethane and only one equivalent of 144 will react with any other nitroalkane. 
This led to Senkus64 publishing work to the contrary in 1946 using primary amines and 
formaldehyde and Johnson65 in the same issue using seconday amine formation of the 
hemiaminal precursors. The work of Senkus was the first example of a nitro-Mannich 
using primary amines. 
Much of this work was left undeveloped for several years until mechanistic studies 
into the Mannich reaction were investigated in the late 1950’s and early 1960’s. Butler 
speculated that prior to attack by the nitroalkane, the hemiaminal actually formed the 
gem-diamine 147 (eq 37).66
 
This was followed by Fernandez who put forth that the aci-nitroalkane, which is similar 
to the enol tautomer of a ketone and now more commonly called nitronic acid, was the 
active form involved in the transition state (eq 38).67,68
N
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The aza-Henry as it is thought of today was not attempted using a traditional imine 
and nitroalkane until 1950.69 Hurd and Strong published the addition of nitromethane into 
N-phenylbenzylimine affording the aza-Henry product in 65% yield. The authors also 
                                                 
62 Duden; Bock; Reid, Ber. 1905, 38, 2036.  
63 Cerf de Mauney, H. Bull. Soc. Chim. France 1937, 4, 1451. 
64 Senkus, M. J. Am. Chem. Soc. 1946, 68, 10. 
65 Johnson, H. J. Am. Chem. Soc. 1946, 68, 12. 
66 Butler, G. J. Am. Chem. Soc. 1955, 78, 482. 
67 Fernandez, J. E.; Fowler, J. S. J. Am. Chem. Soc. 1964, 29, 402. 
68 Fernandez, J. E.; Fowler, J. S.; Glaros, S. J. J. Am. Chem. Soc. 1965, 30, 2787. 
69 Hurd, C. D.; Strong, J. S. J. Am. Chem. Soc. 1950, 72, 4813. 
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used nitroethane achieving a 35% yield, but there was no comment on 
diastereoselectivity.70 Similarly, Kozlov and Fink used nitropropane with the very same 
imine to also yield the α-nitro amine product in a 35% yield, again without comment on 
diastereoselectivity.71
In 1998 Anderson et al. revisited the aza-Henry reaction as a viable way to 
stereoselectively make vicinal diamines.72 Their investigations led them to a variety of 
vic-diamines (151) in high yields with diastereoselection as high as 15:1 (eq 39). 
 
Anderson continued this work and in 2001 published a catalytic variant using 
Sc(OTf)3 as the Lewis acid catalyst. To improve the rate of the reaction, they employed 
silyl-nitronates, similar to silyl enol ethers.73 In their best example, they were able to 
achieve a 99% yield after 2 hours at 0 ºC, with a 9:1 diatereomeric ratio. 
The following year, Qian, Gao, and Chen showed that TiCl4 alone or KOiPr alone did 
not catalyze the addition of nitromethane into N-tosyl imines.74 However, a mixture of 
the two gave a 34% yield of product. This led them to survey lanthanide alkoxides to see 
if the direct aza-Henry could be performed without an additional base. This screen 
revealed that Yb(OiPr)3 could in fact catalyze the aza-Henry reaction with excellent 
yields using as little as 1 mol% of the Lewis acid. 
A significant advancement in this area came in 1999, prior to the Chen work, when 
Shibasaki reported the first catalytic enantioselective aza-Henry reaction.75 Using a 
heterobimetallic complex prepared from Yb(OiPr)3, KOtBu, and (R)-binaphthol, the 
reaction was catalyzed with enantioselection as high as 91% ee (eq 40). 
 
                                                 
70 Our own work in this area has shown that these products undergo the retro process on the GC, making it 
difficult to assay the diastereoselectivity without NMR. 
71 Kozlov, L. M.; Fink, E. F. Trudy Kazan. Khim. Tekhnol. Inst. Im. S. M. Kirova 1956, 21, 163. 
72 Adams, H.; Anderson, J. C.; Peace, S.; Pennell, A. M. K. J. Org. Chem. 1998, 63, 9932. 
73 Anderson, J. C.; Peace, S.; Pih, S. Synlett 2000, 6, 850. 
74 Qian, C.; Gao, F.; Chen, R. Tetrahedron Lett. 2001, 42, 4673. 
75 Yamada, K.; Harwood, S. J.; Gröger, H.; Shibasaki, M. Angew. Chem. Int. Ed. 1999, 38, 3504. 
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This was followed in 2001 by the first example of an enantioselective and 
diastereoselective catalytic nitro-Mannich reaction, again by Shibasaki.76,77 This time the 
catalyst had to be modified to what he called a second-generation heterobimetallic 
complex. This is because the YbKH2[(R)-binaphthoxide]3 catalyst, which catalyzed the 
addition of nitromethane, did not catalyze the addition of nitroethane into the imine. By 
changing to an AlLi[(R)-binaphthoxide]2 complex, the reaction was efficient with 10 
mol%, giving high yields with enantioselection as high as 83% ee and a 7:1 
diastereomeric ratio. In 2002, two biologically active compounds, ICI-199441 (154) and 
CP-99994 (155), were synthesized using this methodology.78 Previously these 
compounds were only made using readily available chiral compounds such as amino 
acids, followed by functional group transformation to afford the vicinal diamine. 
Asymmetric catalysis provided a more straightforward and flexible approach to these 
targets and derivatives thereof (Chart 6). 
 
Chart 6. Biologically Active Compounds Containing 1,2-Diamines 
 
 
Jørgensen et al. published the first catalytic asymmetric aza-Henry reaction of silyl 
nitronates with α-imino esters in 2001 (eq 41).79
 
                                                 
76 Yamada, K.; Moll, G.; Shibasaki, M. Synlett 2001, SI, 980. 
77 Shibasaki, M.; Kanai, M. Chem. Pharm. Bull. 2001, 49, 511. 
78 Tsuritani, N.; Yamada, K.; Yoshikawa, N.; Shibasaki, M. Chemistry Letters 2002, 3, 276. 
79 Knudsen, K. R.; Risgaard, T.; Nishiwaki, N.; Gothelf, K. V.; Jørgensen, K. A. J. Am. Chem. Soc. 2001, 
123, 5843. 
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The reaction proceeds well using a variety of Cu(II) Box salts, affording the products in 
high yields, excellent enantioselectivities, and very good diastereomeric ratios. The 
stereoselection was surprisingly insensitive to differences in the chiral ligand as well as 
different counterions. Shortly after this publication, Jørgensen published a direct variant 
in which an external base was used in addition to the chiral Cu(II) Box catalyst (eq 42).80
 
The additional base allowed direct addition of nitroalkane, rather than preformation of the 
nucleophile as was done previously. Again, the stereoselection was excellent and the 
conversion was high using 20 mol% of catalyst. 
Early in 2004, concurrent with the work in our group, Takemoto et al. published an 
enantioselective aza-Henry reaction catalyzed by a bifunctional organocatalyst. The 
reaction proceeded to good conversion, with the enantioselectivity reaching as high as 
76% ee. Only one diastereoselective example was reported, with a ratio of 3:1. As 
mentioned in Section 1.1.2, the catalyst employed was thiourea 111, similar to Jacobsen’s 
hydrogen-bonding catalyst 74 (Chart 7).  
 
Chart 7. Jacobsen and Takemoto’s Thiourea Catalysts 
 
 
                                                 
80 Nishiwaki, N.; Knudsen, K. R.; Gothelf, K. V.; Jørgensen, K. A. Angew. Chem. Int. Ed 2001, 40, 2992. 
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The authors suggest possible bifunctionality stemming from the basic site of the 
dimethylamine allowing for deprotonation of the nucleophile while the thiourea can 
activate through hydrogen bonding. 
Although the aza-Henry reaction has been increasingly active in recent years,81 many 
opportunities for development remain. In particular, reported methods for high 
enantioselection in the nitro-Mannich involve organometallic complexes. Furthermore, 
readily available imines and nitroalkanes provide a good starting point for the 
development of a new asymmetric Brønsted acid catalyst.  
2.2.2. Silyl Nitronate Additions 
As discussed in Section 2.2.1, the aza-Henry reaction is a C-C bond forming reaction 
that yields vic-diamine products. 
 
This reaction is both acid and base catalyzed, and can also be a reversible process (eq 43). 
As discussed previously, the enantioselective reaction has been catalyzed using chiral 
Lewis acids by Shibasaki and Jørgensen. Following the plan outlined in Section 1.3.2, an 
imine will be activated by the chiral proton complex to render it more electrophilic, and 
therefore more reactive toward addition by a neutral nucleophile to afford the aza-Henry 
product (eq 44). 
 
The aza-Henry reaction provided an opportunity to test several of the hypotheses 
about chiral proton catalysis. First and foremost, we expected the chiral proton to effect 
rate-acceleration of the reaction, the hallmark of catalysis. We were pleased to discover 
that reactions with catalyst were in fact faster than the background rate of the reaction 
(without catalyst). For example, after 70 h the protonated H,6Me-BAM complex 
furnished the product in 47% conversion compared to just 22% for the uncatalyzed 
                                                 
81 Westermann, B. Angew. Chem. Int. Ed. 2003, 42, 151. 
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reaction.82 This indicates that the chiral proton is activating the electrophile (a Boc-imine) 
for attack by the nucleophile (a silyl-nitronate). Our second hypothesis was that the chiral 
proton could effectively shield one face of the substrate from attack by the nucleophile, 
assuming that the binding pocket would be formed by the two quinoline rings binding 
simultaneously to the proton. To test this hypothesis, we varied the position of methyl 
substitution on the pyridine ring of the BAM complex (Table 1).83
 
       Table 1. Effect of Stereoelectronics of BAM Ligand on the Chiral  
       Proton-Catalyzed Silyl Nitronate Addition to Azomethinea
 
 
 For example, substitution at the six-position of the pyridine ring proved vital for 
stereoselectivity (entry 3), while enantioselectivity dropped as substution moved to the 
five (entry 2) and three positions (entry 1). This behavior is consistent with azomethine 
binding to the proton proximal to the 6-position of each pyridine ring. 
  
  
  
  
  
  
  
  
  
  
  
  
  
                                                 
82 Percent conversion determined by GC analysis. 
83 With Ben Nugent. 
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      Table 2. Effect of Stereoelectronics of BAM Ligand on the Chiral  
       Proton-Catalyzed Silyl Nitronate Addition to Azomethinea
 
 
Using the basic assumption that bidentate ligand binding to the proton our stereochemical 
model to guide catalyst design, H,Quin-BAM (118e), was synthesized from 2-
chloroquinoline. We hypothesized that this ligand could provide even greater facial 
discrimination than H,6Me-BAM due to the greater shielding capability of the extension 
of the 5 and 6 positions outward. We were pleased to see that H,Quin-BAM·HOTf 
exhibited a significant increase in both enantioselectivity and diastereoselectivity (Table 
2, entry 1). 
The isoquinoline, which substitutes only the 3 and 4 positions of the pyridine ring, 
again saw a dramatic loss in enantioselectivity (entry 3). This data was consistent with 
our hypothesis that the 6-position of the pyridine ring was critical for enantioselection 
(Figure 23). The 4-methyl substituted quinoline, or lepidine (118f), was also synthesized. 
This supported the notion that the distal carbons of the pyridine ring (positions 3 and 4) 
were not important to the stereoselective pathway as no change in ee was observed (entry 
2). This also suggests that the 4-position could be substituted with both electron donating 
as well as electron withdrawing groups to probe electronic effects of the BAM ligands 
without additional steric complications. 
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Figure 23. Proposed Catalyst-Substrate Complex 
 
 
The importance of the 6-position of the pyridine ring is clearly shown in the above 
model. This model was created by minimizing the protonated catalyst using PC Model. In 
order to provide a C2-symmetric representation of the catalyst, the N-H-N bond angle was 
fixed at 180 degrees. The Boc-imine was then docked into the model to provide the 
proposed complex above. The conformation of the complex provides significant 
obstruction from the re face to the approaching nucleophile. 
Structurally, a very interesting change in enantioselectivity was observed when the 
cyclohexane diamine was tri-substitiuted (Table 3). 
 
    Table 3. Effect of Cyclohexane Diamine Substitution on the 
    Chiral Proton-Catalyzed Silyl Nitronate Addition to Azomethinea
 
 
Tetra-substitution of the diamine unexpectedly afforded racemic product (entry 3). With 
the importance of the N-H bond in question, the unsymmetrical BAM 118i was 
synthesized. Surprisingly, this afforded some enantioselection, above that of 118k, but 
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below that of 118c (entry 2). Changes in the overall conformation of the catalyst were 
expected to lead to changes in stereoselection. However, the role of the N-H in the 
asymmetric pathway is still not clearly understood. Further experiments are needed to 
probe the possible importance of the additional hydrogen bond donors. 
Perhaps even more striking is the drop in enantiomeric excess from 44% with 118i 
(entry 2) to 3% with 118j (entry 4). The substitution of the diamine backbone in each 
case is similar; however, the electron-withdrawing effect that the Bz group has on 118j 
appears to cause the significant decrease in ee. However, we cannot rule out the 
possibility that this is at least partially the result of a change in conformation. 
 
    Table 4. Electronic Effect of BAM Ligand on the Chiral 
    Proton-Catalyzed Silyl Nitronate Addition to Azomethinea
N
H
Boc HN
Boc
CH3
NO2
entry % ee
toluene, -20 °C
dr% yield
MeO2C MeO2C
NH3C O
OTMS
(10 equiv)
R2
(45)
aDiastereomeric ratios determined by GC. Enantiomeric excess determined by HPLC
using a chiral stationary phase. Isolated yield af ter chromatography.
1
2
3
6-Me (118c)
6-OMe (118h)
6-Me (118j)
56
12
65
12:1
5:1
5:1
70
4
3
100 mol% 118
R1
H
H
H,COPh
time (h)
163
192
70
N N
N
R1 R1
H H
HN
-OTf
c, R1=H, R2=6-Me; h, R1=H, R2=6-OMe;
j, R1=H,COPh, R2=6-Me
R2 R2
118
 
 
This electron-withdrawing effect led us to a survey of electronic effects of the BAM 
ligands on enantioselection in the aza-Henry reaction (Table 4). The H,6MeO-BAM 
(118h) was expected to have similar enantiomeric excess to the H,6Me-BAM (118c) 
based on sterics, but have an additional electon-donating effect on the BAM ligand. It 
wasn’t until much later that we discovered that 2-methoxypyridine actually has a lower 
pKa than pyridine. This is discussed in more detail in Section 2.1.1. Although the 
products afforded were racemic, it is interesting to note the significant drop in the rate of 
this reaction (entry 2). Not surprisingly, the aza-Henry is sensitive to the electronics of 
the BAM ligand and adjustments in either direction have an effect on enantioselectivity. 
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    Table 5. Effect of Additional Basic Sites on the BAM Ligand on the 
    Chiral Proton-Catalyzed Silyl Nitronate Addition to Azomethinea
N
H
Boc HN
Boc
CH3
NO2
entry % ee
toluene, -20 °C
dr% yield
MeO2C MeO2C
NH3C O
OTMS
(10 equiv)
R
(45)
aDiastereomeric ratios determined by GC. Enantiomeric excess determined by HPLC
using a chiral stationary phase. Isolated yield af ter chromatography.
1
2
3
4
5
quinoline (118e)
pyrazine (118l)
pyrimidine (118m)
quinoxaline (118n)
quin, naph (118o)
99
66
70
63
68
14:1
4:1
4:1
4:1
5:1
86
2
7
1
3
N N
N R2
H H
H H
HR2 R1
-OTf
100 mol% 118
118
time (h)
48
24
120
24
68
e, R1=N, R2=CH; n, R1=N, R2=N;
o, R1=CH, R2=CH
 
 
In order to investigate the importance of the Lewis basic pyridine nitrogen, several 
ligands were made containing two nitrogens per pyridine ring (Table 5). In all cases a 
substantial decrease in enantioselection was observed (entries 2, 3, and 4). Similarly, the 
removal of a basic site in the case of the unsymmetrical 118o led to the formation of 
racemic product. This implies that the second quinoline is not merely shielding one face 
of the substrate from attack; rather the quinoline nitrogen is a prerequisite for the 
asymmetric pathway. There are two explanations for this unusual result. First, both 
quinoline nitrogens are bound to the proton in the transition state along with the substrate. 
The finding that H,Quin(2Nap)-BAM leads to racemic product supports this notion, and 
at a minimum suggests that the conformation of the second cyclohexane diamine 
substituent is important for enantioselection, regardless of whether it is ligated to the 
proton in the transition state. Second, there is also the possibility that the quinoline 
nitrogen is directing the nucleophile to the substrate in the transition state. Both of these 
stereochemical models will be further evaluated in Section 2.2.3. 
Regardless of how the H,Quin(2Nap)-BAM is affecting the transition state, it is likely 
that there has been a change in the overall conformation of the chiral proton complex. As 
discussed in Section 1.3.2, changes to the conformation could have drastic effects on the 
stereoselection of the chiral proton catalyzed aza-Henry reaction. These changes in the 
chiral pocket or cavity of the BAM ligand are most striking in the H,2Quin(3Quin)-BAM 
(118q) catalyzed reaction (Table 6). 
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    Table 6. Effect of Cavity Shape in the BAM Ligand on the 
    Chiral Proton-Catalyzed Silyl Nitronate Addition to Azomethinea
 
 
3-Chloroquinoline was used to make H,3Quin-BAM and it was evaluated in the aza-
Henry reaction. The enantiomeric excess was found to be 5% which is not surprising 
considering the extreme change in catalyst structure (entry 2). However, when 
unsymmetrical BAM 118q is used, the opposite enantiomer is formed with nearly the 
same enantioselection as 118e. It is reasonable to conclude that this catalyst is either a 
simple chiral amidinium ion complex 165 in which the 3-quinoline ring acts soley as a 
steric force, or that the cyclohexane diamine nitrogen becomes the second donor ligand, 
resulting in a chiral complex with the Schiff-base that exposes the opposite prochiral face 
relative to complex 165 (Figure 24).  
 
Figure 24. Visualization for Catalyst Binding Site 
 
 
Given the weak Brønsted basicity of a naphthyl amino nitrogen, we favor the first of the 
possibilities, and rationalize the difference between naphtholine and quinoline as a 
conformational preference by the latter to minimize dipoles. 
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2.2.3. Development of a Chiral Proton Catalyzed Direct Aza-Henry 
Reaction 
The chiral proton-catalyzed silyl nitronate additions to imines a simplified picture of 
the BAM ligand and chiral proton complex in which Lewis acidity is clearly identified as 
the activation means. And within this context, variations in structure were evaluated by 
their effect on enantioselection to arrive at a stereochemical model for asymmetric 
induction. Silyl nitronate additions, however, are not ideal in that the nucleophile must be 
preformed. A more attractive approach would involve addition of a nitroalkane to an 
imine mediated by a catalyst that can in some way activate both the electrophile (as 
before) and the nucleophile, while maintaining enantiocontrol. However, this would be a 
greater challenge due to the loss in activation of the nitroalkane nucleophile. Although 
nitromethane is in equilibrium with its more reactive tautomer, the equilibrium constant 
is only 1.1×10-7 (eq 46). 84
 
The equilibrium constant Ki reflects the degree of tautomerization for nitromethane from 
166 to aci-166. This rate appears to be too small to account for an appreciable formation 
of the active nucleophile, which in turn could lead to product. Under our standard 
reaction conditions, using 0.4 mL of CH3NO2, there would only be 0.044 nL (less than 
0.01 equivalents) of aci-166 at equilibrium. A mechanism in which the rate determining 
step, the tautomerization of the nitroalkane, happens prior to attack of the activated 
electrophile is proposed below (Scheme 8). 
  
  
  
  
  
  
  
                                                 
84 Turnbull, D.; Maron, S. H. J. Am. Chem. Soc. 1943, 65, 212. 
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Scheme 8. Chiral Proton Catalyzed Aza-Henry Mechanism Using aci-nitromethane Tautomer 
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The stoichiometry of conversion alone suggests that the reaction could be catalytic in the 
chiral proton complex. In order for this to be true, the catalyst must have one of two roles. 
First the ligand could hold onto the same proton throughout the course of the reaction 
serving just as an activator, similar to a traditional Lewis acid complex. Another 
possibility is that the proton which activates the substrate is released during the C-C bond 
forming step to the product. In turn the enolized proton from the nitroalkane would be 
returned to the free ligand resulting in formation of the neutral product and regeneration 
of the catalyst (Scheme 8).  
Our hypothesis was that the direct aza-Henry would be comparable to the indirect 
variant in terms of enantioselectivity, but slower due to the loss of activation in the 
electrophile. There is an added benefit to this loss in activation of the nucleophile, i.e. a 
slower background rate and therefore a greater possibility to employ substoichiometric 
amounts of the chiral proton promoter. In order to test our hypothesis, a Boc-imine was 
added to a solution of catalyst 118e in nitromethane (Table 7). 
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                      Table 7. Effect of Catalyst Loading on the Chiral Proton- 
                Catalyzed Direct Nitromethane Addition to Azomethinea
 
 
The reaction with a full equivalent of promoter proceeded rapidly at room temperature 
and with good enantiomeric excess. Gratifyingly, the stereoselection was maintained with 
as little as 1 mol% of catalyst (entry 5). The observation that ee translates well between 
the silyl nitronate additions and nitronic acid additions suggests a common model for 
enantioselection. Although it was shown that the catalyst loading could be as low as 1 
mol%, in order to minimize reaction times 10 mol% would be used as the standard 
catalyst loading. 
 
                     Table 8. Effect of Nitroalkane on the Chiral Proton- 
                Catalyzed Direct Nitroalkane Addition to Azomethinea
 
 
To study the effect of substitution on the nucleophile in the direct aza-Henry reaction, 
a variety of nitroalkanes were surveyed (Table 8). Cooling to -20 ºC allowed for higher 
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enantioselectivities than had previously been obtained, reaching as high as 95% ee (entry 
1). The use of nitroethane led to product with good diastereoselectivity and high 
enantioselectivity (entry 2). Although larger nitroalkanes such as nitropropane and 
nitrobutane were equally selective, the rate of the reaction was slower (entries 3 and 4), 
leading to 34% and 18% yields of nitroethane and nitropropane adducts, respectively, 
after 37 days. Disubstituted nitroalkanes such as 2-nitropropane, nitrocyclohexane, and 
nitrocyclopentane did not form any product after several weeks even at room 
temperature. 
 
                            Table 9. Chiral Proton-Catalyzed Direct Nitromethane 
                   Addition to Azomethinea
Ar
N
H
Boc
Ar
HN
Boc
NO2
entry % ee
CH3NO2, -20 °C
% yieldAr
(49)
aDiastereomeric ratios determined by GC. Enantiomeric excess
determined by HPLC using a chiral stationary phase. Isolated yield af ter
chromatography.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
p -CH3OC6H4 (167a)
p -CH3C6H4 (167b)
2-naphthyl (167c)
1-naphthyl (167d)
C6H5 (167e)
p -ClC6H4 (167f)
p -AcOC6H4 (167g)
p -CF3OC6H4 (167h)
2-NO2-5-ClC6H3 (167i)
3,4-Cl2C6H3 (167j)
3,4-F2C6H3 (167k)
p -CF3C6H4 (167l)
m-CF3C6H4 (167m)
o-CF3C6H4 (167n)
p -MeO2CC6H4 (167o)
o-NO2C6H4 (167p)
m-NO2C6H4 (167q)
p -NO2C6H4 (167r)
64
49
60
73
57
52
46
42
46
47
80
60
66
90
62
57
65
61
25
50
42
64
60
79
65
67
61
76
84
78
71
73
80
70
95
82
10 mol%
H,Quin-BAM•HOTf
167 168
prod
168a
168b
168c
168d
168e
168f
168g
168h
168i
168j
168k
168l
168m
168n
168o
168p
168q
168r
 
 
The substrate scope was examined first using nitromethane and a variety of Boc-
imines under the aforementioned optimized conditions (Table 9). The stereoselectivity of 
the aza-Henry appears to be sensitive to the electronics of the Schiff base. In the case of 
the p-MeOPh imine, the enantioselectivity was very poor at 25% ee (entry 1). 
Furthermore, the amine derived from p-tolyl imine was produced with 40% ee, 
suggesting the need for electron withdrawing groups on the Schiff base to achieve high 
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enantioselectivity. Yields were as high as 90% for the o-CF3Ph imine (entry 14). 
Excellent enantioselection was achieved in the m-NO2Ph imine, reaching 95% ee (entry 
17). 
 
                            Table 10. Chiral Proton- Catalyzed Direct Nitroethane 
                   Addition to Azomethinea
 
 
Nitroethane was also screened as the nucleophile against a variety of Boc-imines 
using the optimal conditions (Table 10). The p-AcOPh had the highest yield at 95% of 
any direct aza-Henry (entry 5). The diastereoselection was typically greater than 10:1, 
reaching as high as 19:1 in the p-CF3Ph imine (entry 6). Enantioselection was very high 
on average, with p-NO2Ph attaining a 90% ee (entry 14). The stereoselection was 
expected to increase in the nitroethane reactions with the additional methyl substituent 
able to provide additional gauche interactions in the transition state to limit the number of 
low energy transition states. 
In an effort to increase the rate of the reaction without sacrifice of enantioselection, 
several counterions were screened in the aza-Henry reaction (Table 11). 
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Table 11. Effect of Counterion on Conversion and  
Enantioselectivity of the Chiral Proton-Catalyzed Direct  
Nitromethane Addition to Azomethinea
 
 
The trifluoromethanesulfonate appears to be the best counterion in terms of both 
reactivity and stereoselectivity (entry 5). The data suggests that the weakly-coordinating, 
dissociative counterions are better for enantioselection in the chiral proton catalyzed aza-
Henry than the more associative counterions such as acetate (entry 1). 
Since it appears that the best counterion was already chosen with triflate, several 
additives were employed to see if the nitroalkane could be activated either by a base 
through deprotonation, or by an acid that might increase the concentration of nitronic acid 
(Table 12). 
 
                        Table 12. Effect of Additive on the Chiral Proton-Catalyzed 
                 Direct Nitromethane Addition to Azomethinea
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The addition of a base whose pKa was similar to or higher than our catalyst gave a faster, 
base-catalyzed reaction, but afforded racemic product (entries 2, 3, and 5). The addition 
of pyridine, which has a pKa of 5.2, lower than that of our catalyst, had no effect on the 
rate of the reaction (entry 4). Finally, the addition of a hydrogen bond donor had a 
negative effect on the rate of reaction, completely inhibiting it (entries 6 and 7). This 
could be due to the fact that the BAM·HOTf complex is now inhibited by the additive. 
However, this is not likely because the phenol is much less nucleophilic than pyridine 
which had no effect on the reaction. More likely, the acidic proton is being at least 
partially transferred to the free quinoline on the BAM ligand. 
If the transfer of a proton to the free quinoline of the complex is shutting down the 
reaction, then the quinoline must be playing an important role not only in the asymmetric 
step, but also in the activation. This data lends itself to a new mechanistic picture than the 
one previously described in which the rate determining step is no longer simply self- 
tautomerization of nitromethane, but rather an assisted deprotonation of nitromethane by 
the free quinoline of the catalyst (Scheme 9). 
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Scheme 9. Chiral Proton Catalyzed Aza-Henry Mechanism Using Bifunctional Catalyst 
 
 
This data suggests the chiral proton complex is bifunctional in the aza-Henry reaction, i.e. 
it activates the electrophile and also activates the nucleophile. Although it was not our 
intent to gather direct mechanistic evidence in the investigation as to what may improve 
the rate of the reaction, it was discovered that a second equivalent of triflic acid shuts 
down product formation. This also supports the theory that the catalyst is bifunctional in 
the aza-Henry reaction. 
There is one piece of data that does not fit into the mechanistic picture depicted in 
Scheme 9. The products obtained from the indirect (I) aza-Henry show the same level 
and direction of stereochemical induction as the products from the direct (D) aza-Henry 
(Table 13).85 Using the same substrate in each reaction produces similar levels of 
enantioselection (Table 13, entries 6 and 7). While this finding may be coincidental, an 
unavoidable possibility is that both variants share a stereochemical model in the 
enantioselectivity-determining step.  
                                                 
85 With Anand Singh. 
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Table 13. Comparison of Enantioselection in Direct and Indirect aza-Henry Reaction. 
 
 
Since the stereochemical determining step in the indirect aza-Henry reaction can only be 
through Lewis acid activation of the electrophile (the nucleophile is preformed), we again 
revised the mechanistic picture to that proposed below (Figure 25). Figure 25 represents 
two possible scenarios in which catalyst 118e can activate both the electrophile and the 
pronucleophile. Activation of both the electrophile and pronucleophile by a single 
catalyst is depicted on the right side of Figure 25 and was also depicted in Scheme 9. 
Another possibility is depicted on the left side of Figure 25, whereby both the 
electrophile and pronucleophile are activated simultaneously, but by two catalysts. This 
mechanism best fits all of the data that we currently have regarding the mechanism. We 
know that the activation of the electrophile is the stereochemical determining step and 
that the stereochemical step must be conserved between the indirect and direct 
mechanisms. However, we also needed to account for the rate limiting step being the 
deprotonation of the nitroalkane by the catalyst. This is best explained by a second 
molecule of catalyst being involved in the deprotonation step. 
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Figure 25. Two Possible Activation Scenarios for Bifunctional Catalysis 
 
 
Further clarification of the mechanism turned us to an investigation of non-Boc Schiff 
bases to examine the effect of the Boc group on the rate as well as on the enantioselection 
of the direct aza-Henry reaction (Table 14). 
 
Table 14. Chiral Proton-Catalyzed Direct Nitromethane 
      Addition to Azomethinea
entry % ee% conv
1
2
3
4
5
6
7
8
9
10
11
12
13
14
95
95
100
-
-
-
25
50
80
50
100
100
100
100
11
22
25
-
-
-
29
54
14
48
11
11
4
6
R1
Ph
p -(NO2)Ph
2-pyridyl
2-pyridyl
p -(NO2)Ph
p -ClPh
Ph
p -ClPh
Ph
p -ClPh
Ph
2-pyridyl
2-pyridyl
2-pyridyl
time (h)
14
36
2.5
no rxn
no rxn
no rxn
48
84
96
60
8
1
1
1
R1
N
H
R2
R1
HN
R2
NO2CH3NO2, 23 °C
(53)
10 mol%
H,Quin-BAM•HOTf
aEnantiomeric excess determined by HPLC using a chiral stationary
phase.
R2
2-pyridyl
2-pyridyl
DPM
CPh3
CPh3
CPh3
BOC
BOC
CBz
CBz
p -(OCH3)Ph
p -(OCH3)Ph
m-(OCH3)Ph
o-(OCH3)Ph
 
 
The Boc and CBz protected imines were the least reactive, but afforded the highest 
enantiomeric excess (entries 7-10). This seems to indicate an importance of the Boc 
group in the stereochemical determing step. The Boc group does allow for a bidentate 
mode of binding, but that may not be the only factor which leads to high enantioselection 
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for these substrates. The diphenylmetyhl (DPM) imines appeared to be the next most 
promising in terms of fastest conversion and highest enantioselectivity (entry 3). In order 
to evaluate the effect that the DPM group has on the aza-Henry reaction, a series of DPM 
imines were screened for enantiomeric excess (Table 15). 
 
Table 15. Chiral Proton-Catalyzed Direct Nitromethane 
      Addition to Azomethinea
entry % ee% conv
1
2
3
4
5
6
7
8
9
10
11
100
85
>50
35
25
25
95
0
50
75
85
25
10
2
6
<10
7
30-35
-
4
9
0
R
2-pyridyl
Ph
C6H11tBu
o-(OCH3)Ph
p -(OCH3)Ph
3-pyridyl
4-pyridyl
p -(NO2)Ph
o-BrPh
p -ClPh
time (h)
2.5
14
24
72
8
8
8
60
36
24
24
R
N
H
DPM
R
HN
DPM
NO2CH3NO2, 23 °C
(54)
10 mol%
H,Quin-BAM•HOTf
aEnantiomeric excess determined by HPLC using a chiral stationary
phase.  
 
The 2-pyridyl was considerably faster than any other DPM imine, affording the product 
in 25% ee (entry 1). This substrate again has the possibility for a bidentate mode of 
coordination to the catalyst. However, it was discovered that over time, the DPM 
products would undergo complete racemization. For example, a sample of the 
enantioenriched product would be racemized to 0% ee within 18-24 hours in ethanol or in 
72 hours in dichloromethane. This is presumably due to the retro-process forming the 
iminium ion and nitronate, which in turn recombine nonselectively to afford the racemic 
product (eq 55).  
 
Perhaps this is one reason the Boc-imines are so much more stereoselective than other 
imines screened in the aza-Henry reaction. The carbamate functionality withdraws the 
lone pair of electrons on the nitrogen such that they become less nucleophilic toward 
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regeneration of the iminium ion. Due to this electron withdrawing effect of the 
carbamate, no racemization was ever observed in any Boc-protected products. 
There are many additional factors that may contribue to the high stereoselection of 
the Boc-imines, not the least of which is their possibility for bidentate coordination 
mentioned above. In order to maintain the high enantioselectivity as well as increase the 
rate of the reaction, we reexamined our bifunctional mechanism hypothesis (Figure 25). 
If the rate-limiting step of the reaction is in fact the deprotonation of the nitroalkane by 
the free quinoline of the BAM ligand, then the rate would be substantially higher by 
dropping the pKa of the pronucleophile’s proton. With this in mind, ethyl nitroacetate was 
combined with the Boc-imine and BAM·HOTf complex to yield the new aza-Henry 
product 175 (eq 56). 
 
For the first time, only one equivalent of the nucleophile was necessary as opposed to its 
use as solvent in the previous cases. This is attributed to the dramatic increase in the rate 
of the reaction due to the more acidic proton as previously mentioned. The enantiomeric 
excess of 175 can be compared to the nitromethane and nitroethane enantioselectivities 
using the same substrate. When nitromethane was used as solvent, the product was 
afforded in 52% yield and 79% ee (Table 9 entry 6). When nitroethane was the 
nucleophile, the product was afforded in 59% yield, 17:1 diastereomeric ratio, and 82% 
ee (Table 10 entry 4). These can now be compared directly to ethyl nitroacetate which 
was obtained in 75% yield using only one equivalent and in a fraction of the time. The 
diastereomeric ratio was found to be 1:1 by HPLC; GC could not be used in this case as 
the product appeared to undergo the retro process on the column. HPLC separation of 
175, gratifyingly showed an enantiomeric excess of 80% for both diastereomers. Thus it 
appears not only that the rate greatly improved, but the enantioselection was at least 
maintained if not enhanced. However, the low diastereoselection would need to be 
addressed before nitroacetates could be used effectively in a new methodology. This will 
be addressed in greater detail in Section 2.3.1. 
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2.3. Application of the Asymmetric Aza-Henry Reaction to the 
Synthesis of Enantioenriched α-Amino Acids 
The enantioselective synthesis of α-amino acids is an actively pursued area of 
asymmetric catalysis.86 At the forefront of this field is the phase-transfer catalysis 
pioneered by O’Donnell (eq 57).87
 
As his source of asymmetry, O’Donnell used the cinchonidine-derived phase-transfer 
catalysts of type 178 (Chart 8). In 1994, they improved the enantioselectivity by using 
second generation catalysts of type 179. In 1997, Lygo88 and Corey89 independently 
developed the so-called third generation cinchona-derived phase-trnasfer catalysts of type 
180. 
 
Chart 8. First, Second, and Third Generation Cinchonidine-Derived Phase Transfer Catalysts 
 
 
Nitroacetic acid derivatives have also been used as masked amino acids in a variety of 
transformations,90 but their use in enantioselective transformations is presently limited to 
only three recent cases91 that produce non-epimerizable nitroacetate derivatives. At the 
end of Section 2.2.3, it was shown that chiral proton catalyst 118e could successfully 
                                                 
86 For a recent review, see: O’Donnell, M. J. Acc. Chem. Res. 2004, 37, 506 and references therein. 
87 O’Donnell, M. J.; Eckrich, T. M. Tetrahedron Lett. 1978, 4625. 
88 Lygo, B.; Wainwright, P.G. Tetrahedron Lett. 1997, 38, 8595. 
89 Corey, E. J.; Xu, F.; Noe, M. C. J. Am. Chem. Soc. 1997, 119, 12414. 
90 (a) Shipchandler, M. T. Synthesis 1979, 666. (b) Rosini, G.; Ballini, R. Synthesis 1988, 833. (c) Charette, 
A. B.; Wurz, R. P.; Ollevier, T. Helv. Chim. Acta 2002, 85, 4468. (d) Fornicola, R. S.; Oblinger, E.; 
Montgomery, J. J. Org. Chem. 1998, 63, 3528. 
91 (a) Li, H.; Wang, Y.; Tang, L.; Wu, F.; Liu, X.; Guo, C.; Foxman, B. M.; Deng, L. Angew. Chem. Int. 
Ed. 2005, 44, 105. (b) Knudsen, K. R.; Jorgensen, K. A. Org. Biomol. Chem. 2005, 3, 1362. (c) Charette: 
Moreau, B.; Charette, A. B. J. Am. Chem. Soc. 2005, 127, 18014. 
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catalyze the addition of ethyl nitroacetate into Boc-imines with good enantioselection (eq 
56). We hypothesized that nitroacetate 185 could be converted to enantiomerically 
enriched α-amino acids 186 (eq 59). A side by side comparison of the Brønsted base and 
Brønsted acid approaches to the synthesis of enantioenriched α-amino acids is provided 
in Scheme 10.  
 
        Scheme 10. Brønsted Base and Brønsted Acid Approaches to  
        the Synthesis of Enantioenriched α-Amino Acids 
 
 
The addition of nitroacetates into N-Boc-imines, which was demonstrated in Section 
2.2.3, produces α,β-diamino acids which are protected orthogonally, allowing the 
underlying amino acid to be revealed with a high degree of chemoselectivity.92  
 
2.3.1. Enantioselective Synthesis of Anti-α,β-diamino Acids 
Although high enantioselectivity had been observed in our initial addition of ethyl 
nitroacetate to an N-Boc imine, we set out to optimize this procedure for the large-scale 
synthesis of these α,β-diamino acids. Among our initial goals was to use an easily 
removable protecting group on the ester functionality that masked the carboxylic acid. 
We thought benzyl and tert-butyl would both be beneficial to others interested in this 
methodology. Screening the ester substituent also provided us with a good starting point 
for the optimization of yield, enantioselection, and diastereoselection (Table 16). 
 
                                                 
92 Viso, A.; de la Pradilla, R. F.; Garcia, A.; Flores, A. Chem. Rev. 2005, 105, 3167. 
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Table 16. Effect of Nitroacetate Ester Substitution on Stereoselection 
 
 
The rate was unaffected by the change in substituent and only small changes were 
observed in enantioselection. We chose tert-butyl nitroacetate as the optimal nucleophile 
for this reaction because of its high enantioselectivity as well as the ease with which it 
can be cleaved (entry 4). The low diastereoselection observed was unexpected in light of 
nitroethane products that resulted in diastereomeric ratios of >20:1 (Section 2.2.3). 
Initially it was believed that a change in catalyst structure could provide an increase in 
diastereoselection. As a result, several BAM ligands were surveyed in this reaction as 
well as similar motifs that lack the Bis-Amidine core (Chart 9). 
 
Chart 9. Structural Variations on Bis-Amidine Motif (without the bis-amidine) 
 
 
The triflic acid complexes of ligands 188, 189, and 190 did not catalyze the reaction. 
In 188 and 189, the pyridines are less basic than the corresponding bis-amidines. Ligand 
190 has an alkyl amine which is more basic than the bis-amidines, but is expected to be 
very different conformationally. 
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The same trends found in the ligand screen with silyl nitronates were consistent in the 
screen with nitroacetates. First, the position of substitution on the pyridine ring proved to 
be critical to enantioselection (Table 17 entries 1, 3, and 4). 
 
Table 17. Effect of Pyridine Substitution on Nitroacetate Additions 
 
 
The more acidic H,6MeO-BAM did not catalyze the reaction (entry 2); however, the 
larger H,6(Ph2COH)-BAM provided low enantiomeric excess for the opposite enantiomer 
(entry 5). 
The quinoline derived bis-amidines proved to have various effects on the 
enantioselection (Table 18). H,Quin-BAM and H,Lep-BAM again proved to be the most 
selective affording 83% and 87% ee respectively (entries 1 and 6). As expected, 
H,Isoquin-BAM afforded racemic product due to lack of substitution at the 5 or 6 
position (entry 5). 
 
Table 18. Effect of Ligand Conformation of Enantioselection 
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The enantioselection was again reversed with H,2Quin(3Quin)-BAM (entry 3). 
Interestingly, H,3Quin was found to provide some enantioselection, but also for the 
opposite enantiomer (entry 2). H,Quinox-BAM did not afford any product, which is 
consistent with the trend of more acidic ligands not catalyzing the reaction (entry 7). 
Anand Singh identified unsymmetrical H,Quin(6(9Anth)2Pyr)-BAM complex 118oo 
as a catalyst for the highly anti-diastereoselective and enantioselective nitroacetate 
additions. In order to isolate the aza-Henry adduct with high diastereoselection, the 
product needed to be reduced before warming to room temperature. It was observed that 
these adducts would epimerize on warming to room temperature, which will be discussed 
in more detail in Section 2.3.2. To avoid any loss in diastereoselection, Bo Shen 
developed a method for the cold reduction of the nitro group following a Ganem 
protocol.93 Table 19 summarizes their work. 
 
Table 19. Chiral Proton Catalyzed Additions of α-Nitroesters to Azomethines: Scopea
entry
1
2
3
4
5
6
7
8
9
10
11
12
13
aAll reactions were 0.30 M in substrate and proceeded to complete conversion.
bDiastereomer ratios were measured by 1H NMR (a reliable measurement was
not possible for the addition product for entries 7-8). Enantiomer ratios were
measured using chiral stationary phase HPLC. cIsolated yield (two steps).
dMeasured by GC.
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%eeb
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85
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67
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toluene, -78 °CN
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-
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2Np
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1:2
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1:1
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7:1
6:1
6:1
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8:1
(6) (6)
1.
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80
81
83
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a
a
b
b
c
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d
d
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g
h
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118oo
118oo
118oo
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H,Quin-BAM (118e)
N N
N
H H
H H
N
N N
N
H H
H H
N
H,Quin(6(9Anth)2Pyr)-BAM (118oo)
 
 
With a reliable two step procedure in hand, we surveyed a variety of N-Boc imines 
with catalyst 118oo (Table 19).94 Use of sodium borohydride/cobalt(II) chloride allows 
                                                 
93 Satoh, T.; Suzuki, S.; Suzuki, Y.; Miyaji, Y.; Imai, Z. Tet. Lett. 1969, 4555. Heinzman, S. W.; Ganem, B. 
J. Am. Chem. Soc. 1982, 104, 6801. 
94 Singh, A.; Yoder, R. A.; Shen, B.; Johnston, J. N. J. Am. Chem. Soc. 2007, 129, 3466. 
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for an effective reduction of the adducts without epimerization at the α-position. 
Alternatives that were investigated resulted in either lowering of the diastereomeric ratio, 
or reduction of halogenated adducts.95 These issues are cleanly avoided in the protocol 
described here, and over two steps, high yields are consistently observed. It is also 
important to note that using catalyst 118oo with nitroacetates, we did not observe any 
effect on enantioselection from the substituent on the aromatic ring of the imine as was 
observed in the addition of nitroalkanes (see Section 2.2.3). Excellent enantioselection 
and high diastereoselection were demonstrated for a variety of substrates isolated in good 
yield after two steps.  
 
It was estabilished that the anti diastereoselection represents a kinetic selectivity by 
subjecting the product to conditions that favor epimerization (eq 63).85 It was observed 
that a 5:1 (anti:syn) mixture resulted in a 1:2 (anti:syn) mixture after warming and 
filtering the reaction mixture through silica gel.96 This post addition epimerization also 
highlights the fact that this catalyst can selectively deprotonate 191 in a mixture of 191 
and 193. We hypothesized that this post addition epimerization could allow access to 
enantioenriched syn-α,β-diamino acids. 
 
2.3.2. Enantioselective Synthesis of Syn-α,β-diamino Acids 
As mentioned in the previous section, it was discovered that the products obtained 
from nitroacetate addition into N-Boc imines would epimerize upon warming to room 
temperature (eq 63). Initial experiments were carried out examining the degree to which 
this thermodynamic epimerization could be used to increase diastereoselection favoring 
the syn product (Table 20). 
 
                                                 
95 Shen, B.; Johnston, J. N. unpublished results. 
96 Note: Silica gel is not necessary for the epimerization but it accelerates the process. 
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Table 20. Effect of Time and Temperature on Diastereoselection 
 
 
Monitoring the reaction of ethyl nitroacetate by NMR showed an increase in 
diastereoselection to 3:1 (entry 7). The same experiment was conducted with methyl 
nitroacetate, but the diastereoselection only increased to 1.5:1. Since it appears to be a 
thermodynamically driven isomerization, tert-butyl nitroacetate was expected to give the 
highest diastereselection. In fact, after stirring for 6 days at room temperature, the 
diastereoselection rose to 4:1. Since the enantioselection is conserved as these changes in 
diastereomeric ratios were observed, we can rule out a retro-aza-Henry mechanism 
leading to the observed epimerization. Therefore, the increased acidity of the hydrogen 
atom on the nitroacetate could be used as a tool in selective epimerization leading to the 
syn-diastereomers. 
 
These experiments suggested that catalyst-mediated epimerization led to a 
thermodynamic ratio of 3-4:1 syn:anti-α,β-diamines. An alternative rationale for the ratio 
involves a stereoselective reprotonation mediated by the chiral catalyst. We therefore 
examined whether the catalyst could enantioselectively protonate a similar compound 
(195). Since no enantioselection was observed under these conditions, it is unlikely that 
the catalyst is deprotonating and diastereoselectively reprotonating the product with facial 
selectivity. More likely, the catalyst is serving as a general base allowing for the 
epimerization of the kinetic (anti) product to the thermodynamically favored syn product. 
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In fact, it was found that the purified nitro compound would isomerize upon standing at 
room temperature and that silica gel catalyzes that process. 
 
Scheme 11. Syn Selective Synthesis of Nitroacetate adducts using Recrystallization 
 
 
We thought that recrystallization could be used as a means to obtain highly syn-
enriched product. As illustrated in Scheme 11, it was possible to get material with high 
optical purity but it turned out that the recrystallization was exceedingly difficult to 
reproduce.97 It should be noted that this highly syn-enriched material was also found to 
epimerize over time, eventually resulting in a 4:1 mixture of diastereomers (syn:anti). 
However, it was possible to obtain material consistently in 60-70% yield and 7:1 dr using 
the recrystallization process. An X-Ray crystal structure of syn-193a was obtained which 
showed a hydrogen bond between the NH of the Boc-amine and the nitro group (Figure 
26). 
 
Figure 26. X-Ray Crystal Structure of syn-193a 
 
 
Our initial efforts in optimizing a protocol for a highly enantioselective and 
diastereoselective nitroacetate addition to yield syn-enriched products began with 
H,Quin-BAM·HOTf (118e). 
                                                 
97 With Bo Shen. 
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Table 21. Substrate Scope of 118e Catalyzed Nitroacetate Additions to N-Boc Imines 
aAll reactions were 0.30 M in substrate and proceeded to complete conversion. bDiastereomer and
enantiomer ratios were measured using chiral stationary phase HPLC. cIsolated yield after two step.
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The results of a substrate screen using H,Quin-BAM·HOTf as the catalyst were 
somewhat surprising (Table 21). Although enantioselection was good for several 
substrates (entries 1-3), they were uncharacteristically low for several other substrates 
(entries 6-8). The ligand screen reported in Section 2.3.1 demonstrated that 
H,Quin(6(9Anth)2Pyr)-BAM provided the α,β-diamino acid products with higher 
enantioselection.  
 
Table 22. Substrate Scope of 118oo Catalyzed Nitroacetate Additions to N-Boc Imines 
 
 
By comparison, we were pleased to discover that the reactions catalyzed by 118oo 
gave consistently higher enantioselectivities for all substrates (Table 22). Excellent 
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enantioselectivities were obtained for a variety of substrates (entries 1-6). Product 192g 
was obtained with 93% ee, 26% higher than the analogous reaction catalyzed by H,Quin-
BAM·HOTf (entry 6). Recrystallization of these adducts could provide access to highly 
enantioenriched syn-α,β-diamino acids. 
 
Table 23. Substrate Scope of 118oo Catalyzed Nitroacetate Additions to N-Boc Imines 
 
 
Recrystallization of the products before reduction allows for a substantial increase in 
diastereoselection for most substrates (Table 23).95 These numbers now approach the 
desired level of stereoselection necessary for this to be a useful methodology to access 
the syn-α,β-diamino acids. Therefore, using the same reaction and the same catalyst, both 
syn- and anti-α,β-diamino acids can be obtained with very good stereoselection and in 
good yield. The key difference being allowing the initial nitroacetate adduct to warm to 
room temperature and recrystallized before employing the reduction procedure. 
 
2.3.3. Rationale for Stereoselection of the Nitroacetates 
Variations to each component of a highly stereoselective chiral proton catalyzed 
reaction provide insight into our evolving stereochemical model. The proposed 
stereochemical model was first introduced in Figure 17 in Section 1.3.2. Support for this 
model was obtained when an increase in rate was observed with the catalyst in the silyl-
nitronate addition to imines in Section 2.2.2. Furthermore, the importance of substitution 
at the six-position of the pyridine ring was verified in that section. The importance of the 
Boc group of the N-Boc imines was shown in Section 2.2.3. In addition, experiments 
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suggest that the direct aza-Henry reaction proceeds via bifunctional catalysis even though 
the activation of the electrophile and the nucleophile are not believed to occur 
simultaneously. Just as each of these examples helped evolve the stereochemical model, 
using nitroacetates as nucleophiles has also provided additional information which can 
contribute to the overall picture of the stereochemical model. 
One key difference in the addition of nitroacetates was the discovery that catalyst 
118oo achieved better enantioselection and diastereoselection than H,Quin-BAM·HOTf 
(118e). Because the structure of the unsymmetrical 118oo is significantly different from 
that of the symmetrical 118e, it is remarkable that the catalyst provided an increase in 
enantioselection. Furthermore, the fact that the products produced by these two catalysts 
have the same sense of stereoinduction lends further support to the stereochemical 
model’s proposal of bidentate chelation by the ligand.  
 
Figure 27. One Alternative to the Proposed Stereochemical Model 
 
 
One alternative to the proposed stereochemical model is binding of the N-Boc imine 
to a monodentate amidinium ion as depicted in 196a (Figure 27). The implications of this 
transition state in the enantiodetermining step are very different for the symmetrical 118e 
and the unsymmetrical 118oo. H,Quin-BAMHOTf (118e) offers equivalent binding sites 
to the substrate whereas H,Quin(6(9Anth)2Pyr)-BAM (118oo) provides competing 
recognition motifs. The fact that there is a shared sense of stereoinduction between these 
two very different catalysts lends support to the bidentate nature of the catalyst in the 
enantiomer-determining step. 
Catalysts 118e and 118oo also have the unique ability of providing highly 
diastereoselective reactions, both yielding the anti diastereomer as their respective kinetic 
products (nitroalkanes for 118e and nitroacetates for 118oo). This indicates that the 
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catalyst plays an important role in determining the diastereoselection of the products. 
Furthermore, although catalyst 118e can effect high diastereoselectivity for nitroalkanes, 
it produces 1:1 mixtures of syn and anti when nitroacetates are used. Therefore, catalyst 
118oo must be perturbing the transition state to regain the preferential selectivity for the 
anti diastereomer. 
 
Figure 28. Newman Projections for Nitroalkane and Nitroacetate Additions to N-Boc Imines 
 
 
A closer examination of the diastereoselection in these reactions led to the Newman 
projections depicted above (Figure 28). These pictures can be simplified by the 
assumption that the nitro group is influenced in some way by the catalyst, perhaps in a 
secondary hydrogen bonding interaction. Fixing the nitro group to that quadrant only 
gives the R group two options. First, the methyl could be up (leading to the syn product), 
but in this orientation there is repulsion from the Boc group. Alternatively and more 
likely, the R group could be pointed down, thus minimizing the steric repulsion while still 
allowing for the secondary control element that holds the nitro near the catalyst. Although 
this clearly explains why the anti diastereomer is favored in both reactions, it does not 
account for the dramatic decrease in dr when catalyst 118e is used with nitroacetates. 
 
Figure 29. Alternative Newman Projection Leading to syn Product 
 
 
In order to provide a unified rationale for observed diastereoselection in all highly 
selective chiral proton catalyzed aza-Henry variants, two main issues must be addressed. 
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First, the loss of diastereoselection when using H,Quin-BAM·HOTf (118e) with 
nitroacetates as opposed to nitroalkanes must be explained. Also the recovery of 
diastereoselection with nitroacetates when catalyst 118oo was used instead of 118e must 
be addressed by the same model. This data can best be explained by an alternative 
transition state only accessible to the nitroacetates and not the nitroalkanes (Figure 29). 
The ester group of the nitroacetates has the ability to interact with the catalyst as a Lewis 
base (hydrogen bond acceptor) in the same manner invoked for the nitro group. This in 
turn allows for alternate Newman projection C2, which accounts for the drop in 
diastereoselection by catalyst 118e when going from nitroalkanes to nitroacetates. 
Furthermore, changes in the ligand could allow for better discrimination between the 
ester group and the nitro group of the nitroacetates. In this way, it is believed that catalyst 
118oo causes a steric repulsion with the tert-butyl ester group and disfavors transition 
state C2. This would select for formation of the anti diastereomer through transition state 
arrangement C1 and effectively recover the high diastereoselection observed in the 
nitroalkane chemistry with 118e. 
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Chapter 3. Chiral Proton Catalyzed Diels-Alder 
Reactions 
3.1. Brevianamide 
3.1.1. Background 
The brevianamide class of natural products possess a structurally unique 
diazabicyclo[2.2.2] octane core which has stimulated interest in its proposed biosynthesis 
as well as in its laboratory synthesis. Birch and Wright first isolated brevianamide A in 
1969 from the culture extracts of the fungus Penicillium brevicompactum.98 Structure 
elucidation by spectroscopic methods (UV, IR, 1H NMR, MS), and derivative studies, 
revealed a diketopiperazine bicyclic core and a spiro-indoxyl center (Figure 30). X-ray 
analysis of a single crystal of the semisynthetic derivative 5-bromo-brevianamide A by 
Coetzer in 1974 confirmed the proposed structure and at the same time established the 
relative and absolute stereochemistry of brevianamide A.99 Since its initial isolation in 
1969, brevianamide A has also been isolated from Penicillium viridicatum100 and 
Penicillium ochraceum.101  
 
Figure 30. Stucture of Brevianamide A 
 
 
Minor metabolites were also isolated from the extracts of Penicillium 
brevicompactum and were subsequently named brevianamides B-F (Chart 10).102 It was 
later discovered that irradiation of brevianamide A with white light produced 
                                                 
98 (a)Birch, A. J.; Wright, J. J. Chem. Soc. Chem. Comm. 1969, 644-645. (b) Birch, A. J.; Wright, J. 
Tetrahedron 1970, 26, 2329. (c) Birch, A. J. J. Agr. Food Chem. 1971, 19, 1088-1092. 
99 Coetzer, J. Acta Cryst. 1974,  B30, 2254.
100 Wilson, B. J.; Yang, D. T.; Harris, T. M. Appl. Microbiol. 1973, 26, 633. 
101 Robbers, J. E.; Straus, J. W.; Tuite, J. Lloydia 1975, 38, 355. 
102 Birch, A. J.; Russell, R. A. Tetrahedron 1972, 28, 2999. 
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brevianamides C and D and thus their isolation was concluded to be an artifact of culture 
conditions. The relative and absolute stereochemistry of the proposed structure 201 for 
brevianamide E was later confirmed by total synthesis. Brevianamide F (202) was 
determined to be cyclo(L-tryptophyl-L-proline), which was later determined to be a 
biosynthetic precursor of brevianamide A using feeding experiments. 
 
Chart 10. The Brevianamide Family of Natural Products 
 
 
Upon the initial isolation of brevianamide B, the structure was hypothesized to be 
epimeric to that of brevianamide A at the indoxyl spirocyclic center (C2). The rationale 
for this assignment was that brevianamide B could be made from brevianamide A via a 
three-step reduction/oxidation sequence (Scheme 12), a procedure that proved useful in 
obtaining sufficient quantities of this minor metabolite for studies. However, in 1988 
Williams and coworkers completed the total synthesis of brevianamide B which revealed 
its true absolute stereochemistry (Chart 10).103 Surprisingly, the structures for naturally 
occurring brevianamides A and B were found to be enantiomorphic with respect to their 
diazabicyclo[2.2.2] octane core and possess identical configuration at the C2 spiroindoxyl 
center. This discovery had major implications on the ensuing debate over the biosynthesis 
                                                 
103 (a) Williams, R. M.; Glinka, T.; Kwast, E. J. Am. Chem. Soc. 1988, 110, 5927. (b) Williams, R. M.; 
Glinka, T.; Kwast, E.; Coffman, H.; Stille, J. K. J. Am. Chem. Soc. 1990, 112, 808. (c) Williams, R. M.; 
Glinka, T. Tetrahedron Lett. 1986, 27, 3581. 
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of brevianamides A and B. These implications will be the focus of the following 
discussion. 
 
Scheme 12. Three-Step Synthesis of Brevianamide B from Brevianamide A 
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A great deal of interest has been generated by the possible biosynthetic origin of the 
bicyclo[2.2.2] pyrazinedione core, which in large part has fueled studies on this family of 
natural products.104 Shortly after the structure of brevianamide A was published, Sammes 
put forth a provocative hypothesis for the formation of the bicyclo[2.2.2] pyrazinedione 
core, suggesting it could arise from an intramolecular [4+2] cycloaddition reaction of a 
hydroxypyrazinone moiety and the tethered prenyl alkene (Figure 31).105 At the time, 
Diels-Alder reactions on these systems were unknown; however, Sammes supported this 
proposal with experimental results on model pyrazine systems (vide infra). 
 
Figure 31. Proposed Biological Diels-Alder Reaction 
 
 
By proposing a biological Diels-Alder reaction for the formation of the brevianamide 
bicyclic core, Sammes was able to account for the formation of both enantiomorphic 
forms embodied by brevianamides A and B. Approach of the prenyl alkene dienophile 
from one face of the relatively planar prochiral hydroxypyrazinone diene would produce 
                                                 
104 For reviews, see (a) Williams, R. M.; Cox, R. J. Acc. Chem. Res. 2003, 36, 127. (b) Williams, R. M 
Chem. Pharm. Bull. 2002, 50, 711. 
105 Porter, A. E. A; Sammes, P. G. Chemical Communications 1970, 1103. 
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the bicyclic core of brevianamide A, while approach from the opposite face would 
produce the core of brevianamide B (Figure 32).  
 
Figure 32. Diels-Alder Reaction Leading to Brevianamides A and B 
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Combining the elucidation of the absolute stereochemistry of brevianamide B with 
Sammes hypothesized hetero-Diels-Alder reaction, Williams developed a more detailed 
biosynthetic proposal (Scheme 13).106 In this pathway, two electron oxidation of the 
known biological precursor brevianamide F forms the achiral hydroxypyrazinone 206, 
which serves as the azadiene for the intramolecular hetero-Diels-Alder reaction. As 
mentioned above, approach of the prenyl alkene (dienophile) from either face of the 2-
hydroxypyrazinone (diene) would furnish adducts 207 or 208. Oxidation at the 3-position 
of the indole would produce hydroxylindolenines 209 and 210, which could then undergo 
a well-precedented stereospecific Pinicol rearrangement to furnish both naturally 
occurring Brevianamides A and B. 
 
                                                 
106 Williams, R. M.; Kwast, E.; Coffman, H.; Glinka, T.; J. Am. Chem. Soc. 1989, 111, 3064. 
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Scheme 13. Proposed Biosynthesis of Brevianamides A and B via Enantioselective [4+2] Cycloaddition 
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The above biosynthetic proposal outlined by Williams has several major implications. 
First, since brevianamide A is produced naturally in a greater quantity than brevianamide 
B (~20:1), either (1) the Diels-Alder reaction produces adducts 207 and 208 in unequal, 
nonracemic form favoring 207, or (2) a kinetic resolution takes place in the oxidation of 
racemic 207. If the former were true, intervention of an enzyme capable of 
stereoselectively effecting a [4+2] cycloaddition reaction (the so-called Diels-Alderase) 
would be necessary. Moreover, the involvement of a Diels-Alderase would explain the 
complete diastereoselectivity observed in the biosynthesis, which only produces the anti-
C-19 configuration, a diastereomer that is not favored in the thermal Diels-Alder reaction 
of 206 (vide infra).  
Second, since both brevianamides A and B share the same stereochemistry at the 
indoxyl spirocenter (R), the oxidation of 208 would take place from the less hindered face 
for brevianamide B (198) and the more hindered face for brevianamide A (197). As was 
shown above, the preferred facial selectivity of this oxidation has been established 
experimentally in the semisynthesis of brevianamide B from A (Scheme 12). An (R)-
selective indole oxidase was proposed to explain the diastereoselectivity of the oxidation 
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step by recognizing the binding orientation of the indole moiety. However, no enzyme 
responsible for mediating the Diels-Alder or indole oxidation has been characterized for 
Penicillium brevicompactum. 
On the contrary, feeding experiments of radio-labeled d,l-[8-13C]-202 into cultures of 
Penicillium brevicompactum resulted in no observable incorporation into brevianamides 
A or B, which would have been expected based on the above proposal.107 As a result, 
Williams proposed a revised biosynthetic pathway shown below (Scheme 14).108 In this 
pathway, deoxybrevianamide E is first diastereoselectively oxidized by an (R)-selective 
indole oxidase, producing hydroxyindolenine 211. This intermediate can then undergo 
nucleophilic addition from the pyrazinedione nitrogen to form brevianamide E, or a 
stereospecific pinacol rearrangement could take place to form 212. Indoline 212 must 
then undergo a 2 electron oxidation to give the putative hydroxypyrazinone which can 
then undergo the hetero-Diels-Alder reaction. 
 
Scheme 14. Proposed Biosynthesis of Brevianamides A and B via Diastereoselective [4+2] Cycloaddition 
N
N
O
OH
NH CH3
CH3
O
N
N
O
O H
HNH3C
H3C
O
(+)-brevianamide B (198)
(+)-brevianamide A (197)
N
HN
O
O
H
nucleophilic
[4+2]
R-selective
oxidase
N
H
N
N
O
O
H
H
HO
Me
Me
brevianamide E (201)
addition
(irreversible)
N
H
N
HN
O
O
H
Me
H
O
2 e- oxidation
tautomerization
N
H
Me
Me
N
HN
O
O
H
N
Me
Me
HO
Me
N
H
N
N
OH
OMe
O
Me
pinacol
rearrangement
deoxybrevianamide E (205) 211
212 213
 
 
                                                 
107 Sanz-Cervera, J. F.; Glinka, T.; Williams, R. M. Tetrahedron 1993, 49, 8471. 
108 Sanz-Cervera, J. F.; Glinka, T.; Williams, R. M. J. Am. Chem. Soc. 1993, 115, 347. 
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Feeding experiments were again conducted in an effort to test the revised proposal for 
the biosynthesis of the brevianamides. These results indicated significant incorporation of 
[8-3H]-deoxybrevianamide E into brevianamides A (7.8%), B (0.9%) and E (24.9%). 
However, no incorporation was observed when [8-3H]-brevianamide E was used in the 
feeding experiments.107 Furthermore, it was shown that brevianamide E could be made 
directly from photooxidation of deoxybrevianamide E. This led Williams to conclude that 
brevianamide E is a shunt metabolite that is not an intermediate in the biosynthesis of 
brevianamides A or B. Unfortunately, attempts to synthesize 211 for feeding experiments 
to validate this pathway have been unsuccessful. 
 
3.1.2. Previous Total Syntheses of the Brevianamides 
In 1988, Williams completed the first total synthesis of (-)-Brevianamide B (Scheme 
15).103 Starting from known pivaldehyde acetal 214, amide 215 was formed after opening 
the lactone functionality with lithium p-methoxybenzylamide salt. Acylation of the 
proline nitrogen with bromoacetylbromide, followed by alkylative ring closure formed 
pyrazinedione 216. 217 was then formed by ozonolysis of the terminal olefin, Wittig 
olefination of the resulting aldehyde and alkylation of the pyrazinedione with gramine. 
Formation of the bicyclo[2.2.2]diazaoctane ring of the natural product was accomplished 
in the key step using a stereoselective SN2’ cyclization. Optimization of the solvent and 
as well as of an additive for the cyclization revealed that the addition of several 
equivalents of 18-crown-6 to a reaction of 217 with sodium hydride in THF gave the 
desired diastereomer 219 in a 4.9:1 ratio. Williams’ proposed that association of the 
crown ether with the sodium cation generated a sterically demanding environment around 
the enolate oxygen, which in turn favored transition state 218, with the allylic chloride 
facing away from the enolate. Ring closure and Boc deprotection was achieved by 
treatment of 219 with aqueous HCl to give 220. Oxidation of 220 gave a single 
diastereomer of hydroxyindolenine 221. This was then treated with NaOMe in methanol 
to effect the stereospecific pinacol rearrangement to (-)-brevianamide B. X-ray 
crystallographic analysis was obtained to confirm the relative stereochemistry of the 
synthetic product. 
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Scheme 15. Williams’ Total Synthesis of (-)-Brevianamide B 
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Ten years after his initial synthesis of (-)-brevianamide B, Williams employed an 
intramolecular hetero-Diels-Alder reaction in the racemic synthesis of C-19-epi-
brevianamide A and brevianamide B (Scheme 16).109 Beginning with epi-
deoxybrevianamide E as reported by Kametani (vide infra), treatment with Me3OBF4 
furnished the amidate 222. 222 was then oxidized with DDQ to afford 223, which upon 
treatment with methanolic KOH produced the desired Diels-Alder precursor, achiral 
azadiene 224. 224 could not be purified due to spontaneous [4+2] cyclization at room 
temperature, producing 225 in a 2:1 ratio respectively. The major diastereomer, which 
possessed the incorrect syn stereochemistry at C-19, was carried on to the nonnatural C-
19-epi-brevianamide A as described earlier. In the same way, the minor diastereomer was 
used to form brevianamide B (not shown). With this study, Williams effectively 
demonstrated the viability of an intramolecular Diels-Alder reaction of a 
                                                 
109 (a) Williams, R. M.; Sanz-Cervera, J. F.; Sancenon, F.; Marco, J. A.; Halligan, D. J. Am. Chem. Soc. 
1998, 120, 1090. (b) Williams, R. M.; Sanz-Cervera, J. F.; Sancenon, F.; Marco, J. A.; Halligan, D. Bioorg. 
Med. Chem. 1998, 120, 1233. 
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hydroxypyrazinone intermediate in the biosynthesis of the bicyclo[2.2.2]diazaoctane core 
of the brevianamides. 
 
Scheme 16. Williams’ Total Synthesis of C-19-epi-Brevianamide E 
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In 1988, Dunkerton and co-workers reported efforts toward the synthesis of 
brevianamides A and B (Scheme 17).110 His synthetic approach utilized an Ireland ester 
enolate Claisen rearrangement of indole 227 to reverse-prenylated indoline 230. After 
transforming 230 to aldehyde 231, condensation with N-para-methoxybenzyl-protected 
cyclo-Gly-L-Pro gave 233. Unfortunately, there were no reports on an attempted hetero-
Diels-Alder reaction with compound 233. 
 
                                                 
110 Dunkerton, L. V.; Chen, H.; Mc Killican, B. P. Tetrahedron Lett. 1988, 29, 2539. 
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Scheme 17. Dunkerton’s Partial Synthesis of the Brevianamides 
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In 1980, Kametani completed the first total synthesis of (-)-brevianamide E.111 Amide 
235 was formed by Schotten-Baumann reaction of the acid chloride of CBz-protected 
proline with dimethyl aminomalonate (Scheme 18). Hydrogenation to remove the CBz 
protecting group, followed by hydroxypyridine catalyzed cyclization, produced 
diketopiperazine 236. Condensation of 236 with gramine 237 afforded 238, which after 
saponification and decarboxyation gave deoxybrevianamide E. Oxidation of 205 by 
irradiation in the presence of O2 and Rose Bengal in MeOH followed by treatment with 
dimethyl sulfide furnished (-)-brevianamide E and its isomer in a 2:1 ratio. 
 
Scheme 18. Kametani’s Synthesis of (-)-Brevianamide E 
 
                                                 
111 (a) Kametani, T.; Kanaya, N.; Ihara, M. J. Am. Chem. Soc 1980, 102(11), 3974. (b) Kametani, T.; 
Kanaya, N.i; Ihra, M. J.C.S. Perkin I 1981, 959. 
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 In 1999, Danishefsky accomplished the most concise and efficient synthesis of 
deoxybrevianamide E and brevianamide E.112 During the course of his total synthesis of 
gypsetin, Danishefsky developed a novel methodology to reverse prenylate the 2-position 
of indoles (Scheme 19). This had an obvious application to the synthesis of brevianamide 
E and as such it served as the key step. Starting with N-phthaloyltryptophan methyl ester, 
treatment with tert-butylhypochlorite gave the unstable 3-chloroindolenine which was 
immediately reacted with prenyl-9-BBN to give 241 in 95% yield over the two steps. 
Deprotection of the phthaloyl nitrogen with hydrazine followed by coupling with N-Boc-
protected L-proline furnished amide 242. Nitrogen deprotection and cyclization afforded 
deoxybrevianamide E. In contrast to Kametani’s oxidation of 205 with O2 above, 
treatment of 205 with dimethyldioxirane actually favored the undesired, nonnatural bis-
epi-brevianamide to brevianamide E (~5:1). 
 
Scheme 19. Danishefsky’s Synthesis of Deoxybrevianamide E and Brevianamide E 
 
                                                 
112 Schkeryantz, J. M.; Woo, J. C. G.; Siliphaivanh, P.; Depew, K. M.; Danishefsky, S. J. J. Am. Chem. Soc. 
1999, 121, 11964. 
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3.1.3. Chiral Proton Catalyzed Hetero-Diels-Alder Reaction 
The success of the chiral proton catalyst in the enantioselective aza-Henry reaction 
led us to consider other reactions for its application. One such reaction was the hetero-
Diels-Alder reaction, specifically the intramolecular variant that forms the 
bicyclo[2.2.2]diazaoctane core of the brevianamides as discussed above. The recent 
success of organocatalysts to promote a variety of transformations suggests that small 
molecules may be able to approach the selectivity and efficiency of their much larger 
enzymatic counterparts. Our efforts in this pseudo-biomimetic total synthesis could lend 
support to the notion that an enzyme is involved in the biosynthetic cycloaddition 
reaction that forms the bicyclo[2.2.2]diazaoctane core of the brevianamides. However, it 
is not suggested that disclosure of a chiral proton catalyzed [4+2] reaction of the 
brevianamide putative intermediate would unequivocally prove the existence of a Diels-
Alderase in Penicillium brevicompactum. Rather, such a discovery would add to the 
growing amount of experimental evidence supporting the intervention of such an enzyme 
and shed additional light onto the biosynthesis of this fascinating family of alkaloids. 
Based on information learned in developing the aza-Henry reaction, the brevianamide 
Diels-Alder precursor 206 appears to be a suitable candidate for catalysis with chiral 
proton complexes. The relative planarity of the 2-hydroxypyrazinone moiety, analogous 
to the Boc Schiff bases, should allow binding in the sterically demanding BAM chiral 
pocket. Furthermore, the additional Lewis basic sites offered by 206 are also encouring as 
that was a key feature in achieving high enantioselectivity in the aza-Henry reaction 
(Figure 33). In addition, Brønsted acids have already been shown to activate identical 
azadiene systems by lowering the LUMO-HOMO energy gap for the corresponding 
[4+2] cycloaddition.113
 
                                                 
113 (a) Domingo, L. R.; Sanz-Cervera, J. F.; Williams, R. M.; Picher, M. T.; Marco, J. A. J. Org. Chem. 
1997, 62, 1662. (b) Jin, S.; Wessig, P.; Liebscher, J. Eur. J. Org. Chem. 2000, 1993. (c) Shangde, J.; 
Wessig, P.; Liebscher, J. J. Org. Chem. 2001, 66, 3984-3997. 
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Figure 33. Comparison of 2-Hydroxypyrazinone and Boc Shiff Base Coordination 
 
 
In order to efficiently synthesize the brevianamide core, the chiral proton catalyst 
must be able to direct both enantio- and diastereocontrol of the hetero-Diels-Alder 
reaction. A simplified depiction of the azadiene intermediate 206 bound to H,Quin-
BAM⋅HX is shown below with the indole omitted for clarity (Figure 34). This figure is 
only intended to show the anticipated substrate coordination sites and the approach of the 
dieonophile necessary for obtaining each product enantiomer. This figure is not intended 
as a predictive tool for enantioselection in the [4+2] cycloaddition. Chelation of the 
pyrazinone amidate to the BAM-protic acid complex is envisioned to occur in a bidentate 
manner, analogous to the stereochemical model developed for N-Boc imines that was 
adopted for the aza-Henry reaction (Figure 17). The BAM ligand must effectively 
destabilize the transition state formed by approach of the tethered dieneophile from one 
face of the 2-hydroxypyrazinone relative to the opposite face in order to achieve 
enantioselection. If facial discrimination is accomplished, then use of the opposite 
enantiomer of the BAM catalyst (S,S-BAM) would also furnish the opposite enantiomer 
of the Diels-Alder adduct, thus providing access to cores of both brevianamide A and B. 
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Figure 34. H,Quin-BAM·HX Azadiene Complex 
 
 
The diastereoselectivity of the hetero-Diels-Alder reaction is determined by the 
intrinsic preference for endo or exo orientation of the prenyl olefin in the transition state 
(Figure 35). As discussed in Section 3.1.2, the endo transition state is favored in the 
thermal Diels-Alder reaction of 206, which produces the syn configuration at C19.109 
Therefore, the catalyst will be required to not enhance, but completely reverse the 
endo:exo selectivity of the Diels-Alder reaction with respect to the thermal process. This 
will be critical to allow access to the brevianamide core. 
 
Figure 35. Endo vs Exo Selectivity 
 
 
For the initial synthesis of the Diels-Alder precursor in our labs, Ben Nugent used a 
combination of Williams’ and Kametani’s total syntheses described above.114 As 
discussed earlier, Williams had previously synthesized the achiral Diels-Alder precursor 
                                                 
114 Nugent, B. M. PhD Dissertation, October 2005. 
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(224) from epi-deoxybrevianamide E (205). Kametani’s convergent synthesis of 
intermediate 205 was adopted, which involves the coupling of reverse-prenylated indole 
237 and pyrazinedione 236 (Scheme 20). 
 
Scheme 20. Retrosynthetic Analysis of Achiral Diels-Alder Precursor 
 
 
Reverse-prenylated indole 237 was synthesized in three steps starting from indole and 
known sulfide 245, which is made from the corresponding allyl chloride (Scheme 21).115 
Warming a solution of indole and sulfide 245 with NCS generated the thio-Claisen 
product 247, albeit in low yield. Strictly following the literature procedure proved to be 
extremely problematic for this reverse-prenylation process, resulting in yields ranging 
from 1-9%. However, Nugent found that yields could be significantly improved by 
cooling the solution of NCS to -40 °C before adding the sulfide (245) and indole.  Using 
this protocol, higher yields were achieved reproducibly, however; the reaction was still 
difficult to scale-up, losing significant yield on 10 g scale and even 5 g scale. Heating an 
acetic acid solution of 247 with zinc powder effected the removal of the sulfide group 
and gave reverse-prenylated indole 248. This was followed by subsequent Mannich 
alkylation with dimethylamine/formaldehyde under acidic conditions furnishing gramine 
237 in good yield. 
 
                                                 
115 Tomita, K.; Terada, A.; Tachikawa, R. Heterocycles, 1976, 4, 733-737. 
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Scheme 21. Synthesis of Intermediate 237 from Indole 
 
 
In an attempt to optimize the reverse-prenylation protocol outlined by Nugent above, 
several temperatures were surveyed for this reaction (Table 24). It should be noted that -
40 °C does in fact appear to be the optimal temperature for this reaction, with cooling an 
additional 10 °C adversely affecting the yield. The sensitivity to temperature was 
surprising and may explain, at least partially, the difficulty of this reaction to effectively 
produce 247 on larger scale. 
 
Table 24. Effect of Scale and Temperature on Reverse-Prenylation 
scale (g of indole)entry
T °C 35 °C
% yieldT (°C)
(70)
1
2
3
4
5
6
7
-50
-45
-40
-35
-30
-40
-40
1.00
1.00
1.00
1.00
1.00
5.00
10.00
21
32
34
25
18
14
6
NCS, CH2Cl2
N
H N
H
SEt
MeMe
MeMe
SEt
 
 
Pyrazinedione 236 was synthesized in three steps from L-proline (Scheme 22). The 
proline nitrogen was protected with a benzyloxycarbonyl (CBz) group followed by 
coupling with dimethylaminomalonate using EDC and DMAP to produce diester 250. 
Removal of the CBz protecting group under hydrogenation conditions was immediately 
followed by thermal cyclization to form pyrazinedione 236. 
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Scheme 22. Synthesis of Intermediate 236 from Proline 
 
 
The desired coupled product 251 was produced from fragments 236 and 237 using tri-
n-butylphosphine, but again in low yield (Scheme 23). Saponification of the methyl ester 
followed by decarboxylation gave epi-deoxybrevianamide E (205) as the major 
diastereomer (9:1 ratio). Using Williams’ protocol for alkylation of the amide oxygen 
with Me3OBF4 produced 222, which was then oxidized with DDQ to provide azadiene 
223, albeit in low yield. 
 
Scheme 23. Synthesis of Azadiene Precursor 223 via Coupling of 236 and 237 
 
 
The problematic step in the above synthetic route has always been the reverse 
prenylation of the indole ring (Scheme 21). Although some optimization, such as a lower 
temperature (-40 °C instead of -30 °C), was found to increase yield, scale-up attempts 
were still coupled with significantly decreased yields. Furthermore, this problem was 
coupled with additional key steps, such as the convergent coupling, also producing very 
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low yields. These synthetic challenges proved to be too large of an obstacle to overcome 
with brute force and as a result a new pathway was desired.  
As discussed in Section 3.1.2, the most concise and efficient synthesis of 
deoxybrevianamide E (205) has been accomplished by Danishefsky. Starting from L-
Tryptophan, the synthesis is six steps, of which four are protections/deprotections and 
one is a routine peptide coupling. The only step which caused concern at the outset was 
the reverse prenylation using prenyl 9-BBN (Scheme 24). After synthesizing N-
phthaloyltryptophan methyl ester (239), the Danishefsky protocol was tested. The 
reaction proceeded exactly as reported and provided the desired reverse prennylation 
product (241) in 65% yield. The scale of this reaction did not provide any additional 
issues; reaction of 57.5 g of substrate produced the desired product in 57% yield. The 
effectiveness of this procedure to produce the desired product provided access to 223 in 
much greater amounts than achieved previously. 
 
Scheme 24. Danishefsky’s Reverse-Prenylation of N-Protected L-Tryptophan Methyl Ester 
 
 
241 is only three steps from deoxybrevianamide E (205) as reported by Danishefsky 
(Scheme 25). The phthalimide deprotection proceeds smoothly, however, the purification 
is complicated by the extreme polarity of the primary amine on standard silica gel. 
Danishefsky reported the use of silica gel pretreated with HMDS, but a MeOH/ CH2Cl2 
column on standard silica gel was also effective. Further optimization of this reaction was 
attempted by increasing the temperature to 60 °C for several hours. Unfortunately, the 
crude NMR showed complete loss of the methyl ester, presumably from dimerization of 
the desired product to form the dipeptide.  
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Scheme 25. Final Steps of Danshefsky’s Synthesis of Deoxybrevianamide E 
 
 
The remaining steps from 252 to deoxybrevianamide E (205) are done sequentially 
without purification of the intermediates. After workup of the peptide coupling reaction, 
the crude product is dissolved in dichloromethane and an excess of trifluoroacetic acid is 
added. After stirring at room temperature, a 7M solution of NH3 in MeOH is added and 
the solution is allowed to continue stirring until cyclization appeared complete. After 
purification, this afforded deoxybrevianamide E (205) in a 45% yield over the final three 
steps. 
From deoxybrevianamide E (205), there are two remaining steps before reaching the 
Diels-Alder precursor (Scheme 26). Formation of the lactim ether was performed using 
Me3OBF4 as reported by Williams and described above. Lactim ether (222) was 
converted to azadiene (223) using DDQ, also as reported by Williams and described 
above. The yield over these two steps is typically around 15-20% due to the low yielding 
DDQ reaction. This product is stored and only deprotonated with KOH to reveal the 
Diels-Alder precursor (224) when performing the enantioselective Diels-Alder reaction. 
 
Scheme 26. Synthesis of Azadiene Precursor 223 from Deoxybrevianamide E (205) 
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The Meerwein salt reaction proved to be very sensitive to the reagent itself. Several 
attempts were made to scale-up this reaction, but regardless of how many equivalents of 
the oxonium salt were used, the reaction would not proceed in any appreciable yield. 
Finally, fresh salt was ordered and tested and the reaction proceeded to approx. 4:1 
conversion by NMR. This reaction was further optimized by changing the order of 
addition. When 205 was cooled to -78 °C and added to the Meerwein salt, the reaction 
proceeded to complete conversion by NMR. Since it was suspected that some yield may 
have been lost during purification, and having pushed the reaction to complete 
conversion, the crude material was taken on without further purification to the final 
oxidation step. 
The DDQ reaction, which is unfortunately the last step of the synthesis of the 
azadiene precursor, has proven to be the most difficult. The reaction is carefully 
controlled from the point of addition at -78 °C, allowed to stir for 8 hours, then warmed 
to room temperature overnight, then heated to reflux for approx. 3 hours or until starting 
material is completely consumed. Unfortunately the crude NMR shows a 1:1 ratio of 
product to byproduct which leads to a 31% yield of the desired product after isolation. 
Optimization of the potassium hydroxide catalyzed isomerization of azadiene 223 to 
form Diels-Alder precursor 224 was performed (Table 25). Previously, entry 1 was used 
as the standard conditions in which the diene was formed prior to addition of catalyst. 
This consistently left 30-40% of azadiene precursor 223 unreacted. Varying the reaction 
time at 0 °C, followed by warming to room temp, again for a controlled period of time, 
led to the optimal results in entry 2. Diels-Alder product was avoided which is essential 
to obtain an accurate picture of the catalyst’s effect on the reaction. Furthermore, the 
conversion of 223 to 224 has been increased to 90% which allows for greater amount of 
Diels-Alder product to be formed after being treated with BAM·HOTf catalysts. 
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Table 25. Optimization of Base Catalyzed Isomerization 
 
 
The [4+2] cycloaddition was found by Williams to occur spontaneously in the 
absence of solvent which was confirmed in our hands. Unfortunately the hetero-Diels-
Alder reaction was not catalyzed by H,Quin-BAM·HOTf in solvent, however; Nugent 
found that the reaction was catalyzed with a small degree of stereoselection when 
performed neat. Expanding on this initial result, Nugent performed a ligand screen which 
is summarized below (Table 26).11  Enantioselectivity was generally minimal with the 
exception of one ligand, H,
4
3Quin-BAM·HOTf (118p), which afforded an appreciable 
increase to 35% ee (entry 4). The structurally similar H,Quinox-BAM·HOTf also gave 
similar enantioselection with a small increase in de (entry 12). 
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Table 26. Nugent Ligand Screen on Hetero-Diels-Alder Reaction of 224 
N
N
O
OMe
H
N Me
Me
neat, 25 °C
aReactions carried out to complete conversion. bDiastereomeric excess determined by 1H NMR.
cEnantiomeric excess determined by HPLC using OD-H column.
N
N
OMe
O
N
H
Me
Me
224 225
(72)
100 mol%
cataylst
entry
1
2
3
4
5
6
7
8
9
10
11
12
13
1
14
35
5
0
11
5
2
6
12
35
% eectime(h)a
21
24
42
48
48
48
48
48
48
42
48
48
47
41
20
36
13
37
13
33
46
49
49
56
%de (dr)b
H,Quin-BAM·HOTf (118e)
H,6Me-BAM·HOTf (118a)
H,Isoquin-BAM·HOTf (118d)
H,3Quin-BAM·HOTf (118p)
H,5Me-BAM·HOTf (118b)
H, 2Quin, Napth-BAM·HOTf (118o)
H,5CF3-BAM·HOTf (118cc)
H,6MeO-BAM·HOTf (118h)
H,Me-6Me-BAM·HOTf (118i)
H,2,3Quin-BAM·HOTf (118q)
H,3Quin,Phen-BAM·HOTf (118xx)
H,Quinox-BAM·HOTf (118n)
catalyst
118p, R1=N, R2,R4=CH, R3=H;
118xx, R1,R4=CH, R2,R3=benzo
118n, R1,R2,R4=N, R3=H
N
R4
N
R2
R1
H H
H H
N
-OTf
H
R3
 
 
The H,3Quin-BAM·HOTf result was followed up by Nugent with two important 
experiments. First, the enantioselection was verified by reaction of (S,S)-H,3Quin-
BAM·HOTf producing the opposite enantiomer of the product with 25% ee. Second, the 
importance of the proton was established by demonstrating that free H,3Quin-BAM 
ligand alone catalyzed the addition with -9% ee. This provided preliminary circumstantial 
evidence for the proton as a primary stereocontrol element. 
After modifying the synthetic route to the Diels-Alder precursor, the goal was to 
expand upon these initial results in hopes of identifying a more selective chiral proton 
catalyst (Table 27). Regrettably there was no increase in enantioselection for those 
ligands that afforded the cycloaddition product. Many of these ligands were complicated 
by hydrolysis of the product to form the amide byproduct. In some cases this side 
reaction prevented the determination of enantioselection with that catalyst. In the cases of 
entries 6-8, it appeared that some other side-reaction may have taken place. The resulting 
crude NMR spectra did not have any major identifiable peaks. This is similar to the 
reaction observed by Nugent using IAN-amines in that both examples do not posess the 
bis-amidine motif that has successfully catalyzed the reaction. 
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Table 27. Ligand Screen on Hetero-Diels-Alder Reaction of 224 
entry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
aReactions carried out to complete conversion. bDiastereomeric excess determined by 1H NMR.
cEnantiomeric excess determined by HPLC using an OD-H column.dComplex mixture resulted;
unable to determine.
35
-d
8
12
2
-d
-d
-d
-2
-d
15
7
0
-d
-d
% eectime(h)a
48
24
36
48
48
96
96
96
48
48
48
36
72
36
48
36
49
45
51
39
-
-
-
17
53
45
32
35
-
-
%de (dr)b
H,3-Quin-BAM (118p)
H,8Me3Quin-BAM (118t)
H,Quinox(2Quin)-BAM (118v)
H,3,6Me22Pyrimidine-BAM (118w)
H,4,6Me2Pyrazine-BAM (118aa)
2-Quin-Trost (189)
2-Quin-Jacobson (188)
2-Quin-Que (190)
H,6Ph-BAM (118x)
H,Quin(6Ph)-BAM (118z)
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Although the synthetic route to the Diels-Alder precursor (224) was improved, no 
ligands were identified that could improve the overall selectivity of the [4+2] 
cycloaddition. The difficulties associated with the development of an enantioselective 
reaction in which the substrate requires over ten steps to produce proved to be too great 
of a challenge to be done in a time efficient manner. In order to optimize the 
enantioselective hetero-Diels-Alder reaction, smaller model cases will be used by Anand 
Singh before returning to the pseudo-biomimetic substrate. 
3.2. Tamiflu 
3.2.1. Background 
While it is likely that influenza has been a serious disease to mankind for thousands 
of years, the first well-documented report of a worldwide influenza pandemic was in 
1580.116 After originating in Asia, the virus was able to spread to Africa and then Europe 
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before finally reaching America.117 Since then, influenza pandemics have occurred at 
varying intervals with unpredictable degrees of severity. Perhaps the most famous global 
outbreak of influenza occurred during the fall and winter of 1918-1919. An exceptionally 
virulent form of influenza, the so-called Spanish influenza, spread globally killing at least 
20 million and possibly more than 40 million people worldwide.118 At the time, the cause 
of the disease was unknown and there were no effective preventive or curative measures 
available that had scientific evidence to support such claims. The virus caused epidemics 
again in 1957 and 1968, foreshadowing the high risk for future epidemics as well as 
pandemics. Today, influenza is responsible for the deaths of 20,000 to 40,000 Americans 
each year.119 However, the lethality of this disease historically increases the likelihood of 
influenza becoming a pandemic once again. Fortunately, science has begun to make 
significant progress towards combatting the next influenza outbreak with respect to a 
century ago.120
Although isolated over half a century earlier, the fowl plague virus was not identified 
to be an influenza virus until 1955. This led many to believe that the first influenza virus 
isolated was a swine influenza virus in 1931.121 This was follwed in 1933 by the first 
isolation of the human influenza virus by Smith and coworkers.122 Interestingly, another 
human influenza virus was isolated in 1940 and found to be completely unrelated, 
serologically, to the known human influenza virus.123 In order to distinguish these 
viruses, they were labeled Type A and for the new strain Type B. It should be noted that 
both influenza A and B viruses are RNA viruses. Using subtypes based on the structure 
of the two surface proteins, the influenza A virus can be classified as haemagglutinin (H) 
and neuraminidase (N). Furthermore, the influenza A virus is unique in that it contains 
the M2 protein, which has been found to act as a proton channel. This M2 protein is not 
                                                 
117 Pyle, G.F. The Diffusion of Influenza: Patterns and Paradigms; Rowan and Littlefield: New Jersey, 
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118 Taubenberger, J. K.; Reid, A. H.; Fanning, T. G. Virology 2000, 274, 241. 
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present in the type B virus, but another protein called BM2, may function as an ion 
channel.124
Once the human influenza virus had been isolated, it did not take long to prove that it 
was antigenically unstable.125 Several years later, this discovery was confirmed 
mercilessly by the infamous epidemic of 1946-47 in which people immunized with the 
then available flu vaccine were not protected at all against the new strain. Since then 
science has shown that the virus continues to change gradually and continually, 
commonly referred to as antigenic drift. However, the virus has also undergone sudden 
and complete changes known as major antigenic shifts. Although there are believed to 
have been many of these major antigenic shifts in the long history of the influenza virus, 
there are three recorded occurrences which happened at irregular intervals over the last 
50 years. In 1957, the circulating H1N1 strains, which were related to the type A virus 
originally isolated in 1933, were replaced by a never before isolated H2N2 strain. 
Similarly, in 1968 H3N2 replaced the aforementioned H2N2 strains and in 1977 the 
H1N1 subtype from 1950 reappeared. 
Since vaccinations were developed by the United States military in the 1940s, 
immunization has been an invaluable tool to battle the constant threat of flu epidemics. 
However, constant and unpredictable antigenic variation in the human influenza viruses 
caused by error-prone RNA replication has made vaccine production difficult. 
Vaccination against influenza virus is complicated by a reduced effectiveness due to the 
constant antigenic variation, which as a result requires continuous updates of vaccines. 
Since vaccines against a new pandemic strain would almost certainly take 6 months to a 
year before becoming available to the public, small-molecule antiviral agents offer a 
novel alternative for effective prevention and therapy of the influenza viruses. It is no 
wonder that with the widespread commonality and ability to cause worldwide human 
affliction influenza is among the best studied of all the viruses. However, it is surprising 
that despite the fact that no reliable vaccine exists and despite the pharmaceutical 
industries best efforts in the combinatorial screening of many thousands of compounds 
for anti influenza activity, there has only very recently been anti-viral drugs discovered 
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which were effective against all strains of influenza, including both Type A and Type 
B.116 
One potential therapeutic method for treating influenza was developed in the 1960s, 
which targeted the M2 protein of the Type A influenza viruses. The M2 protein spans the 
lipid bilary and functions as an ion channel, allowing the entry of H+ into the virus. The 
inhibitors of this M2 proton pump have been known for decades since their discovery in 
1964.126 Amantadine, and its derivative, rimantadine, the two marketed, clinically 
effective inhibitors, have been used therapeutically against Type A influenza. However, 
these drugs are useless against Type B influenza, which is a serious limitation.127 This is 
because they function by blocking the M2 ion channel which is not present in the Type B 
viruses.128 Furthermore, these drugs have been plagued by the emergence of drug 
resistant strains as well as by toxic side effects. Until very recently, however, amantadine 
and rimantadine were the only drugs which had been approved for worldwide use against 
influenza. 
In the 1940s, a series of key discoveries ranging from the observation that influenza 
virus appeared to have an enzyme which destroyed receptors for the virus on red blood 
cells,129 to the identification by Alfred Gottschalk and others that this enzyme was a 
sialidase or neuraminidase. This in turn led to the realization by McFarlane Burnet in 
1948, long before anything was known about the molecular biology of the influenza 
viruses, that inhibitors of the recently discovered and isolated neuraminidase enzyme 
might be useful as anti-viral therapies. “An effective competitive poison for the virus 
enzyme might be administered which, when deposited on the mucous film lining the 
respiratory tract would render this an effective barrier against infection, both initial 
infection from without and the spreading surface infection of the mucosa which follows 
the initiation of infection.”130
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The function of this neuraminidase was determined in 1966 by Seto and Rott to be the 
release of virus particles from infected cells.131 By directing an antibody exclusively 
against the neuraminidase, it was fount that the virus, while not prevented from infecting 
cells, was prevented from releasing newly formed virus particles.132 This determination 
of how the neuraminidase works is critical to understanding in what capacity inhibitors of 
the viral enzyme may be able to function as therapeutic agents. Clearly, an inhibitor will 
be most effective when administered as close as possible to the onset of the infection. 
It should also be emphasized that neuraminidase is an essential enzyme for viral 
replication in all classes of influenza. By solving the X-ray crystal structure for this 
enzyme, it was learned that the enzyme is a tetramer made up of identical subunits. 
Furthermore this enyme has also been characterized crystallographically as a complex 
with sialic acid.133 This complexation helped identify the active site, which turns out to be 
highly conserved across all strains of the influenza A and B viruses. This suggests that 
the neuramidase enzyme could make a very attractive target for inhibiting all strains of 
the influenza viruses with one drug. The structural data that has been obtained about the 
active site has, in turn, stimulated the proposal of potent inhibitors.11  Two of these 
inhibitors have already reached the market, while two others, developed by Biocryst and 
Abbott, have not yet been approved for use in humans.
9
                                                
134 The first of the two 
aforementioned neuramidase inhibitors to reach the market was zanamivir (253), 
marketed by GSK as Relenza and released in July 1999. Unforunately, Relenza is not 
capapble of being submitted orally to the patient. Instead it is administered as a powder 
which is puffed into the lungs by inhalation, which can cause problems in patients with 
underlying respiratory disease. Obviously the attractiveness of an orally bioavailable drug 
left something to be desired. 
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Figure 36. Structures of Relenza (253) and Tamiflu (254). 
 
 
In October 1999, oseltamivir phosphate (254) was released to the market as Tamiflu, 
developed by Gilead Sciences and also marketed by Roche. Tamiflu was in fact orally 
bioavailable, stemming from the carboxylic acid moiety which is revealed after 
hydrolysis of the ethyl ester pro-drug by the liver.135 Both Tamiflu as well as Relenza 
were successful in Phase 1, 2 and 3 clinical trials and are currently being administered for 
the treatment of influenza world-wide. While their success in preventing death in cases of 
severe influenza has not yet been determined, anecdotal evidence suggests that this could 
very well be an important property of these drugs. Identifying these effective therapeutic 
agents was a spectacular scientific breakthrough. The challenge now is to develop a low-
cost and readily scalable synthesis for the orally bioavailable Tamiflu, the best protection 
that humankind has against an influenza pandemic. 
3.2.2. Synthesis 
The intial total synthesis developed by Roche and Gilead Sciences for the prodrug 
tamiflu used shikimic acid as a precursor (Scheme 27). Unfortunately, this precursor has 
limited the largescale production of the prodrug due to its scarcity, for the most part 
obtained from the extraction of plants. Shikimic acid (256) is an intermediate in the 
biosynthetic pathways leading to essential aromatic amino acids. In plants, it is also a 
precursor to lignins and phenols136 and is accumulated to some extent, especially in 
gymnosperms and woody dicotyledons. 
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Scheme 27. Retro-synthetic route of 254 starting from shikimic acid (256). 
 
 
The most abundant source of shikimic acid is in the Illicium family, which is a small 
tree or shrub of known herbal value. Although shikimic acid was first isolated from a 
member of this family, I. religiosum in 1885,137 star anise (I. verum), which is found in 
four provinces of Southern China, was found to be a rich natural source for shikimic acid. 
Starting from 30 kg of dried plant, approximately 1 kg of shikimic acid can be 
produced.138 This fact alone causes concern to the US government’s goal of storing 300 
million doses of Tamiflu, each dose being approximately 75 mg. This would require 23 
tons of the prodrug substance and assuming a yield of 35% from shikimic acid to 
oseltamivir phosphate, the amount of shikimic acid needed would require about 840 tons 
of star anise.138 An alternative source of shikimic acid has been driven by the demand 
from the United States alone. One possible solution to this problem was reported by Frost 
and co-workers at Michigan State University. Using genetically modified E. coli, they 
were able to produce shikimic acid by recombinant microbial biocatalysis.139 Currently, 
this fermentation approach supplies approximately 30% of the present requirements.13   8
                                                
Although scientists at Roche were able to improve the yield of the synthesis from 
epoxide 255 to Tamiflu (254) by over 30%, the improved synthetic route still relied on 
shikimic acid.140 The desire for an alternative approach to Tamiflu, which does not rely 
on the relatively scarce shikimic acid, has stimulated interest throughout the synthetic 
community. 
Scientists at Roche did make an effort to move away from shikimic acid as a raw 
material, which proved to be more challenging, but attempts to this end can be found in 
 
137 Jiang, S.; Singh, G. Tetrahedron 1998, 54, 4697; this review also describes approaches to shikimic acid 
by total chemical synthesis. 
138 Flores, G. The Scientist, Published online: January 4, 2006. 
139 Draths, K. M.; Knop, D. R.; Frost, J. W. J. Am. Chem. Soc. 1999, 121, 1603. 
140 (a) Karpf, M.; Trussardi, R. J. Org. Chem. 2001, 66, 2044. (b) Harrington, P. J.; Brown, J. D.; Foderaro, 
T.; Hughes, R. C. Org. Process Res. Dev. 2004, 8, 86. 
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the patent literature. The first of which utilized a Lewis acid activated Diels–Alder 
reaction of ethyl acrylate and furan as the first step of the synthesis (Scheme 28).141 This 
reaction resulted in a 9:1 mixture of racemic exo/endo adducts. This racemic adduct (258) 
underwent an effective resolution using an esterase (Chirazyme L-2). After the [4+2] 
cycloaddition, the resulting was combined with phosphoryl azide to give two 
regioisomeric [3+2] exo products, which were found to decompose thermally to aziridine 
259. This intermediate underwent transesterification with ethanol and base elimination to 
give 260, which is a key precursor to 254.142
 
Scheme 28. Diels-Alder Approach to Tamiflu (254) Avoiding Shikimic Acid 
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There were several flaws in this initial attempt to eliminate shikimic acid from the 
Tamiflu synthesis. First and perhaps most adverse to product throughput is the fact that 
several steps required high dilution. Also, the resolution of the cycloaddition product 
catalyzed by Chirazyme L-2 was not efficient, with a yield of only 20%. This led to a 
revised synthesis by the scientists at Roche in which they utilized a very inexpensive 
starting material, 1,6-dimethoxyphenol (261) (Scheme 29).143 The key hydrogenation to 
give an all-cis diether was catalyzed by Ruthenium, and was followed by deprotection of 
the methyl ethers using in situ generated trimethylsilyl iodide. The resulting dihydroxy 
diester 263 was desymmetrized by using inexpensive pig-liver esterase to give 264 in 
very high yield (96%) as well as excellent enantiomeric excess (96–98% ee). 264 was 
then subjected to a Yamada–Curtius degradation using diphenylphosphoryl azide, which 
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produced oxazolidinone 265. Reaction with NaN3 gave the 266, which was transformed 
into 254 in four additional steps with good overall yield (30%).  
 
Scheme 29. Desymmetrization Approach to Tamiflu (254) Starting From Phenol 261. 
 
 
This approach avoids the use of shikimic acid while still maintaining high throughput 
and good yields as compared to the manufacturing process. On the downside, the 
synthesis still requires sodium azide late in the process, which from a reaction safety 
standpoint is undesirable. More recently, the demand for Tamiflu has attracted the 
attention of academic chemists, who have reported several new approaches.  
In 2006 Corey reported a twelve step synthesis of oseltamivir phosphate (Tamiflu) 
which began with the enantioselective Diels-Alder reaction of 1,3-butadiene and 
trifluoroethyl acrylate (Scheme 30).144 After conversion to amide 271, bicyclic copound 
272 was formed in 84% yield. Protection of the amide with Boc was followed by 
elimination of the iodine to form compound 274. After bromination and alkene 
isomerization, the lactam was opened with Cs2CO3 and EtOH to form diene 276. Acyl 
aziridine 278 was formed in two steps and was opened under Lewis Acidic conditions 
with 3-pentanol to reveal compound 279. Subjecting this compound to H3PO4 in EtOH 
served to both deprotect the Boc group as well as form the desired phosphate salt (254). 
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Scheme 30. Corey’s Synthesis of oseltamivir phosphate (Tamiflu). 
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Concurrent with Corey’s report, Shibasaki also published a synthesis of Tamiflu in 
2006.145 Shibasaki’s synthesis utilized an enantioselective ring-opening of meso-aziridine 
280 with TMSN3. The resulting diamine 282 is obtained in 96% yield with 91% ee, but 
can be recrystallized from iPrOH to >99% ee in 72% yield. 
 
 
 
Transformation of azide 282 to the bis-Boc protected diaminocyclohexene (284) was 
performed in four steps (Scheme 31). Conversion of the alkene to the enone, followed by 
Michael addition of a cyano group afforded compound 286 in four steps. This was then 
reduced to the allylic alcohol using LiAlH(OtBu)3 in 20:1 dr favoring the desired product 
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287. Conversion to the aziridine followed by BF3·OEt2 catalyzed ring-opening with 3-
pentanol afforded 288 in good yield with a net retention of stereochemistry. Protecting 
group manipulation followed by conversion of the nitrile to the ethyl ester afforded 
compound 279 in four steps. This intermediate is converted directly to Tamiflu upon 
addition of H3PO4. 
 
Scheme 31. Shibasaki’s synthesis of oseltamivir phosphate (Tamiflu). 
 
 
Also in 2006, Yao reported his synthesis of the active pharmaceutical ingredient 
(279) which utilized a ring-closing methathesis as the key transformation (Scheme 32).146 
Starting from L-serine, an inexpensive commercially available chiral starting material, 
they were able to form intermediate 290 in short order using known chemistry.147 This 
intermediate was able to be converted into the metathesis precursor (297) in good yield, 
albeit low diastereoselectivity (3:1). The key ring-closing metathesis step gave the 
desired product 298 in a remarkable 98% yield. Deprotection to reveal the primary 
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alcohol (299), followed by oxidation and esterification gave intermediate 300. Finally, 
protecting group removal afforded the active pharmaceutical ingredient 279 in good 
yield. The synthesis was completed in 18 steps from intermediate 290 with an overall 
yield of 16.5%.  
 
Scheme 32. Yao’s Synthesis of 279 Starting From L-Serine-derived 290. 
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In 2007, Shibasaki and coworkers reported an improved synthesis of Tamiflu (254) 
(Scheme 33),148 building off of their previous work (vide supra). Intermediate 283 was 
again synthesized using their previously reported catalytic enantioselective meso-
aziridine desymmetrization methodology. However, rather than forming symmetrical 
cyclohexene 284 as previously reported, they instead converted intermediate 283 into 
carbamate 302. After conversion to enone 304, a cyanophosphorylation was used to 
generate intermediate 305 with excellent diastereoselection. The key allylic 
rearrangement produced 306 in 78% yield over two steps. Although more direct routes 
were attempted, the authors found the conversion of 306 to 308 to be most effective using 
a series of Mitsunobu reaction, aziridination formation, and aziridine opening with 3-
pentanol. This intermediate was then converted to Tamiflu (254) in 60% yield over two 
steps. This second-generation synthesis is only 15 steps from aziridine 280, in part due to 
the elimination of protecting group shuffling at the beginning of the synthesis.  
 
Scheme 33. Shibasaki’s Second-Generation of Tamiflu (254). 
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 Also in 2007, concurrent with our work, Shibasaki reported his third-generation 
synthesis of Tamiflu (254) in Tetrahedron Letters.149 This time he chose to abandon the 
catalytic enantioselective meso-aziridine desymmetrization methodology. His synthetic 
strategy was obviously inspired by intermediate 307 in his second-generation synthesis. 
Arguably, the most concise method to reach intermediate 307 would utilize a Diels-Alder 
reaction to build the cyclohexene ring. Shibasaki found that diene 309 and dienophile 310 
successfully underwent a [4+2] cycloaddition to give the desired product in 55% yield 
after the removal of the TMS protecting group. The free hydroxyl group underwent the 
designed reaction with the intermediate isocyanate formed during the Curtius 
rearrangement to give intermediate 312. Once converted to cyclohexenone 314, the 
racemic material was resolved using chiral HPLC. The enantiomerically enriched 
material was taken forward first undergoing a 1,4-addition of TMSCN to give 
intermediate 315, followed by reduction of the ketone with LiAl(OtBu)3H to give the 
desired diastereomer of 307 in 44% yield over 3 steps. Shibasaki used the same 
procedure to convert 307 to Tamiflu (254) here as in his second-generation synthesis, 
although with an improved yield. Utilizing a Diels-Alder reaction followed by a Curtius 
rearrangement allowed for rapid access to Tamiflu (254), 12 steps in 4% overall yield. 
 
                                                 
149 Yamatsugu, K.; Kamijo, S.; Suto, Y.; Kanai, M.; Shibasaki, M. Tetrahedron Lett. 2007, 48, 1403. 
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Scheme 34. Shibasaki’s Third-Generation Synthesis of Tamiflu (254). 
 
 
3.2.3. Retro-synthetic Analysis of Tamiflu 
The proposed retro-synthesis of oseltamivir phosphate (Tamiflu), 254, is shown 
below (Scheme 35). The key step is a Diels-Alder reaction which in one step generates all 
three stereocenters with proper relative configuration. The starting materials are cheap 
and available in large quantities and the overall synthesis is highly atom economic. 
However, neither the diene nor the dienophile have been previously synthesized, let alone 
used in a [4+2] cycloaddition reaction. 
 
Scheme 35. Retro-synthetic analysis of oseltamivir phosphate (Tamiflu). 
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After formation of the novel diene and dienophile, the remaining steps in the 
proposed synthesis consist of the key Diels-Alder step mentioned above as well as 
functional group transformation of the nitro to the acylated amine present in 254 (Scheme 
36). 
 
Scheme 36. Proposed End Game for synthesis of oseltamivir phosphate (Tamiflu). 
 
 
Our group has experience in reducing the nitro group chemoselectively in the presence of 
other functionality. The final two steps have been previously reported to proceed in high 
yield, acylation and Boc deprotection concurrent with forming the phosphate salt 254. 
Therefore the only questionable step of the synthesis appears to be the Diels-Alder 
reaction. Further investigation into the literature has shown that there are very few 
examples using either a diene or dienophile of the types described here. However, there 
are three precedents which lend a great deal of support to the proposed reaction. 
First the only example of an N-acyl,N-Boc-diaminoethylene (321) in a Diels-Alder 
reaction was reported in 1999 by chemists at Gilead Sciences Inc. and Roche Discovery 
Welwyn.150 This Diels-Alder reaction was used to generate a new series of potential 
influenza neuramidase inhibitors with a Tamiflu like structure. However, the synthesis of 
the dienophile proved to be inefficient, yielding only 8% over two steps. Furthermore, the 
regioselectivity of the Diels-Alder reaction favored the undesired isomer in a 3:1 ratio. 
Although the synthesis was not efficient, it did show that a Diels-Alder using dienophile 
321 could be performed in 87% yield (Scheme 37). 
 
                                                 
150 Zhang, L.; Williams, M. A.; Mendel, D. B.; Escarpe, P. A.; Chen, X.; Wang, K-Y.; Graves, B. J.; 
Lawton, G.; Kim, C. U. Bioorg. Med. Chem. Lett. 1999, 9, 1751. 
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Scheme 37. Diels-Alder reaction of 321 to make Tamiflu-like compounds. 
 
 
Kraus reported a Diels-Alder reaction using unsaturated benzoyloxy, nitro compound 
324 in 1988.151 The products were found to give endo/exo ratios of 1:1 to 6:1 depending 
on the R group of the diene (eq 73). However, the paper does not mention how the 
endo/exo ratio was determined and there is no experimental section. Furthermore, rapid 
decomposition of the Diels-Alder products to the aromatic nitrobenzenes was found to 
occur in the presence of a slight excess of base. 
 
 
 
In 1996 Node and coworkers published an interesting exo selective Diels-Alder 
reaction using nitroolefins and Danishefsky’s diene.152 Using various substituents on the 
nitroolefin, they found the cyclohexenes generated from reaction with Danishefsky’s 
diene consistently favored the exo product in ratios from 2:1 to 10:1 (eq 74). 
 
 
 
The authors did suggest a possible explanation for the unusual exo stereoselectivity that 
resulted. There are two interactions, one electrostatic and one steric, which could favor 
either the exo or endo transition state respectively (Figure 37). 
                                                 
151 Kraus, G. A.; Thurston, J.; Thomas, P. J. Tetrahedron Lett. 1988, 29, 1879. 
152 Node, M.; Nishide, K.; Imazato, H.; Kurosaki, R.; Inoue, T.; Ikariya, T. Chem. Commun. 1996, 2559. 
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Figure 37. Rationale for observed exo selectivity in the Diels-Alder reaction. 
 
 
 
Extrapolating this to the expected outcome of the proposed Diels-Alder reaction, it is 
hypothesized that the ethyl ester group can cause an electrostatic repulsion in the same 
way as the OTMS does in Danishefsky’s diene (Figure 38). This repulsion in turn should 
provide high exo selectivity if the group on the nitroolefin does not cause too much of a 
steric repulsion with the ester group on the diene (or OTMS as shown in Figure 37). 
 
Figure 38. Proposed exo and endo transition states. 
RO
O
OR
N
HN
RO O
N
HN
RO O
OR
O
OR
O
O
O
O
A exo B endo
 
 
110 
3.2.4. Synthetic Studies toward Tamiflu 
At first glance, the synthesis of the diene appeared to be straight forward starting 
from commercially available dimethoxyacetaldehyde (332) and commercially available 
triethyl 2-phosphonopropionate (333). Using a Horner-Emmons reaction as reported by 
Pfander in 1999, unsaturated aldehyde 334 was isolated in 78% yield (Scheme 38).153 
The next step to make the acetal proceeds smoothly with 10 equivalents of 3-pentanol in 
toluene over 4 Å molecular sieves at 60 °C. However, attempts to eliminate the resulting 
acetal that forms diene 317 were unsuccessful. Further research into the literature of 3-
ester-butadienes revealed that they are unstable even at cold temperatures and quickly 
dimerize or polymerize to produce complex mixtures. It was hypothesized that this diene 
may have potential if generated in situ with the dieneophile present so as to trap the diene 
in a [4+2] cycloaddition upon formation. 
 
Scheme 38. Synthesis of the diene precursor to oseltamivir phosphate (Tamiflu). 
 
 
Turning to the synthesis of the dienophile, commercially available N,N-dimethyl 
formamide dimethyl acetal (335) and commercially available tert-butyl carbamate (336) 
were initially chosen as starting materials (Scheme 39). Compound 337 was formed in 
88% yield using Lin’s general procedure154 as described by Helmchen.155 It was 
hypothesized that this intermediate could then be treated with nitromethane to form the 
desired product 318. 
 
Scheme 39. Synthesis of the dienophile precursor to oseltamivir phosphate (Tamiflu). 
 
 
                                                 
153 Häberli, A.; Pfander, H. Helv. Chim. Act. 1999, 82, 696. 
154 Lin, Y.; Lang, Jr., S. A. Synthesis 1980, 119. 
155 Weihofen, R.; Tverskoy, O.; Helmchen, G. Angew. Chem. Int. Ed. 2006, 45, 5546. 
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However, heating in nitromethane provided the over-addition product (338) in which a 
second equivalent of nitromethane was added to the desired product (Scheme 40). 
Intermediate 338 was refluxed in xylenes in the presence of DMAP, however; the 
additional nitromethane equivalent was unable to be removed. Formation of 338 goes 
through the desired product 318, but the addition of the second equivalent of 
nitromethane is faster than the addition of the first equivalent. Hence at various points 
during the course of the reaction, only starting material 337 and over-addition product 
338 could be observed. 
 
Scheme 40. Attempted Synthesis of Dienophile 318 from Amidine 337. 
 
 
Similarly, if acetic acid and water is used to make the Boc-protected formamide 
(337), the same over-addition product (338) is obtained after treatment with nitromethane 
(Scheme 41). Again it is presumed that the intermediate (318) in route to the over-
addition product is formed, but reacts faster with nitromethane than the starting Boc-
protected formamide (339). 
 
Scheme 41. Attempted Synthesis of Dienophile 318 from Formamide 339. 
 
 
Our next approach was to intercept methazonic acid, a precursor to nitroacetonitrile, 
which has been shown to react with aniline to form nitro-olefin 341 (Scheme 42). 
Unfortunately the analogous reaction using tert-butylcarbamate was unsuccessful. Gas 
evolution was observed during the reaction suggesting decarboxylation of the Boc 
preotecting group. 
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Scheme 42. Attempted Synthesis of Dienophile 318 from Methazonic Acid (340). 
 
 
Finally, we hypothesized that it might be possible to displace thiophenol in an 
analogous matter to what had been previously reported using N-methylaniline to form 
nitro-olefin 346 (Scheme 43).156 After forming the nitro-olefin (345) from intermediate 
344 using sulfuryl chloride,157 the desired reaction using tert-butylcarbamate did not 
proceed, presumably due to the lower nucleophilicity of the carbamate nitrogen. 
 
Scheme 43. Attempted Synthesis of Dienophile 318 from Nitroethanol 342. 
 
 
While work continued to generate the desired dienophile, we turned our attention to 
the possibility of using the commercially available nitro-olefin 347 and Danishefsky’s 
diene (329) to study the Diels-Alder reaction. Unfortunately no product was formed after 
refluxing in toluene for several days. Although no thermal reaction was observed, the 
possibility to catalyze the reaction with a Lewis acid still exists. Several Lewis acids were 
screened in dichloromethane at room temperature (eq 75). Regrettably, there was again 
no cycloaddition reaction observed eventually leading to decomposition of the diene in 
the cases of the stronger Lewis acids. Presumably, the captodative nature of the 
dienophile (347) is playing a large role in its poor reactivity. This problem is avoided in 
                                                 
156 Kamimura, A.; Ono, N. Synthesis 1988, 11, 921. 
157 Ono, N.; Kamimura, A.; Kaji, A. J. Org. Chem. 1986, 51, 2139. 
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the proposed dienophile (318) as the electron-withdrawing nature of the Boc protecting 
group should increase its reactivity. 
 
 
 
Turning to the literature, it was discovered that the Diels-Alder reaction could be 
examined using Danishefsky’s diene (329) and commercially available nitro-styrene 
(349).15  The goal of this model study was to better simulate this unique cycloaddition 
reaction with a dienophile more similar electronically to the proposed dienophile (318) 
than the above nitro-olefin (347). Using nitrostyrene, the thermal Diels-Alder reaction 
produced the product in 60% yield favoring the desired exo adduct in a 9:1 ratio over the 
endo isomer (eq 76).  
2
 
 
 
With this result in hand, we next investigated the effectiveness of a Lewis acid 
catalyzed cycloaddition. Since no reaction was observed at room temperature, our 
concern at the outset was to find a catalyst to improve the rate of the reaction at lower 
temperatures while not diminishing the already favorable exo selectivity. We were 
surprised to see that reaction with BF3·OEt2 at -78 °C in dichloromethane led to 
decomposition of Danishefsky’s diene before any reaction could take place (eq 77).  
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Suspecting that a weaker catalyst may be more effective at catalyzing the 
cycloaddition reaction without decomposing the starting diene, H,Quin-BAM·HOTf 
(118e) was examined. The reaction was found to proceed, albeit in very low conversion 
(<10%), at -20 °C in toluene (eq 78). The product was isolated in such a small amount 
that it is difficult to comment on the exo:endo ratio with a high degree of certainty. After 
purification, only peaks corresponding to the exo product were observed by NMR. This 
product was examined by HPLC to determine if there was any enantioselection, however; 
the product was racemic. Although there was no enantiomeric excess, this result does 
suggest that it may be possible to develop a catalyst for this cycloaddition reaction. 
 
 
 
In conclusion, although we were not able to demonstrate the capability of this method 
as a viable route to Tamiflu, we have determined several key factors that may one day 
lead to a powerful new synthetic route. First, the dienophile can not be so captodative so 
as to become unreactive. This can be accomplished by substituting the enamine nitrogen 
with an electron withdrawing protecting group such as Boc or CBz. Second, although the 
diene appears to be extremely reactive, so much so that it rapidly leads to dimerization 
and polymerization, it has the potential to be trapped given a sufficiently reactive 
dienophile. Finally, the proposed Diels-Alder reaction has been shown to produce the 
desired exo cyclohexene in useful ratios for model compounds. Furthermore, this reaction 
can be catalyzed using a Brønsted acid catalyst at low temperatures. This opens the door 
for enantioselective catalysts such as H,Quin-BAM·HOTf to be used in the 
enantioselective synthesis of Tamiflu. 
115 
Chapter 4. Experimental Section 
 Flame-dried (under vacuum) glassware was used for all reactions. All reagents 
and solvents were commercial grade and purified prior to use when necessary. Diethyl 
ether (Et2O), tetrahydrofuran (THF), dichloromethane (CH2Cl2), and benzene (C6H6) 
were dried by passage through a column of activated alumina as described by Grubbs.158 
Benzene was additionally passed through a column containing activated Q-5 reactant. 
Methanol was distilled from Mg under N2 immediately before use. The aldimines159 and 
Pd(dba)2160 were prepared as reported in literature. Palladium-mediated aryl amination 
was executed using a Buchwald protocol.161
 Thin layer chromatography (TLC) was performed using glass-backed silica gel (250 
µm) plates and flash chromatography utilized 230–400 mesh silica gel from Scientific 
Adsorbents. UV light, and/or the use of ceric ammonium molybdate and potassium 
iodoplatinate solutions to visualize products. 
 IR spectra were recorded on a Nicolet Avatar 360 spectrophotometer and are 
reported in wavenumbers (cm-1). Liquids and oils were analyzed as neat films on a NaCl 
plate (transmission), whereas solids were applied to a diamond plate (ATR). Nuclear 
magnetic resonance spectra (NMR) were acquired on either a Varian INOVA-400 (400 
MHz) or VXR-400 (400 MHz) instrument. Chemical shifts are measured relative to 
residual solvent peaks as an internal standard set to δ 7.26 and δ 77.1 (CDCl3) and δ 7.15 
and δ 128.1 (d6-benzene). Mass spectra were recorded on a Kratos MS-80 spectrometer 
by use of chemical ionization (CI). Atlantic Microlabs, GA, performed combustion 
analyses.  
 
                                                 
158 Pangborn, A. B.; Giardello, M.A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 
15, 1518-1520 
159 Kanazawa, A. M.; Denis, J.; Greene, A.E. J. Org. Chem. 1994, 59, 1238-1240. 
160 Rettig, M.F.; Maitlis, P.M. Inorg. Synth. 1992, 28, 110. 
161 Wagaw, S.; Rennels, R.; Buchwald, S. J. Am. Chem. Soc. 1997, 119, 8451-8458. 
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H,3Me-BAM (115a). Pd(dba)2 (14.4 mg, 50.0 µmol), BINAP (31.1 mg, 50.0 µmol), and 
NaOtBu (288.3 mg, 3.0 mmol) were combined in a round-bottomed flask in a glove box. 
Toluene (10 mL, 0.10 M) was added to the mixture, followed by 1,2-(R,R)-trans-
diaminocyclohexane (114.2 mg, 1.0 mmol), and 2-bromo-3-methylpyridine (344.1 mg, 
2.0 mmol) as a solution in toluene. The reaction was heated to 80 °C and stirred until 
TLC suggested complete conversion. The reaction was cooled to room temperature, 
concentrated, and purified by flash chromatography (SiO2, 25% ethyl acetate in hexanes) 
to afford the desired diamine as a white solid (120 mg, 40%); [α]D25 +186.7 (c 1.0, 
CHCl3); mp = 132-134 °C; Rf = 0.25 (20% EtOAc/hexanes); IR (neat) 3339, 2930, 2855, 
1603, 1505, 1418 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 3.9 Hz, 1H), 7.10 (d, J 
= 6.7 Hz, 1H), 6.43 (dd, J = 5.1, 1.9 Hz, 1H), 5.04 (d, J = 4.3 Hz, 1H), 4.07-4.04 (m, 1H), 
2.30 (d, J = 12.9 Hz, 1H), 1.87 (s, 3H), 1.81 (d, J = 6.7 Hz, 1H), 1.52-1.38 (m, 2H); 13C 
NMR (100 MHz, CDCl3) ppm 157.8, 145.4, 137.0, 116.9, 112.3, 56.6, 34.0, 25.7, 17.5; 
HRMS (EI) Exact mass calculated for C18H24N4 [M+H]+ 297.2074. Found 297.2074.  
 
H,5Me-BAM (115b). Pd(dba)2 (14.4 mg, 50.0 µmol), BINAP (31.1 mg, 50.0 µmol), and 
NaOtBu (288.3 mg, 3.0 mmol) were combined in a round-bottomed flask in a glove box. 
Toluene (10 mL, 0.10 M) was added to the mixture, followed by 1,2-(R,R)-trans-
diaminocyclohexane (114.2 mg, 1.0 mmol) and 2-bromo,5-methylpyridine (344.1 mg, 2.0 
mmol) as a solution in toluene. The reaction was stirred at 80 °C until TLC indicated 
complete conversion. The reaction was cooled to room temperature, concentrated, and 
purified by flash chromatography (SiO2, 25% ethyl acetate in hexanes) to provide the 
desired diamine as a white solid (70 mg, 24%); [α]D25 +593.0 (c 0.5, CHCl3); mp = 126-
128 °C; Rf = 0.33 (40% EtOAc/hexanes); IR (neat) 3283, 3006, 2928, 2858, 1616, 1500 
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cm-1; 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.07 (dd, J = 8.4, 2.0 Hz, 1H), 6.12 (d, 
J = 8.4 Hz, 1H), 4.89 (s, 1H), 3.69 (d, J = 3.3 Hz, 1H), 2.19 (d, J = 13.1 Hz, 1H), 2.10 (s, 
3H), 1.72 (dd, J = 3.5, 3.5 Hz, 1H), 1.41 (dd, J = 6.4, 3.5 Hz, 1H), 1.37-1.26 (m, 1H); 13C 
NMR (100 MHz, CDCl3) ppm 157.2, 147.2, 138.2, 121.0, 108.4, 56.3, 33.3, 25.1, 17.6; 
HRMS (EI): Exact mass calculated for C18H24N4 [M+H]+ 297.2074. Found 297.2079. 
 
H,6Me-BAM (115c). Pd(dba)2 (10.1 mg, 17.5 µmol), BINAP (21.8 mg, 35.0 µmol), and 
NaOtBu (286.4 mg, 2.98 mmol) were loaded into a round bottom flask in a glove box. 
Toluene (10 mL, 0.10M) was added to the mixture followed by the 1,2-(R,R)-trans-
diaminocyclohexane (100.0 mg, 876.0 µmol). 2-Bromo,6-methylpyridine (301.5 mg, 
1.75 mmol) was added as a solution in toluene. The reaction was allowed to stir at 80 °C 
and monitored by TLC. The reaction was then cooled to room temperature, concentrated, 
and purified by flash column chromatography on silica gel (5% Et3N, 10% EtOAc in 
hexanes) affording 115c as a white solid (200 mg, 77%); [α]D25 +111.1 (c 1.0, CHCl3); 
mp 126-128 °C; Rf =0.17 (5% Et3N, 10% EtOAc, 85% hexanes); IR (neat) 3256 3051 
2927 2855 1559 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.17 (dd, J = 8.2, 7.3 Hz, 1H), 6.33 
(d, J = 7.3 Hz, 1H), 6.09 (d, J = 8.2 Hz, 1H), 5.08 (m, 1H), 3.66 (dd, J = 7.3, 7.0 Hz, 1H), 
2.34 (s, 3H), 2.20 (dd, J = 10.7, 6.7 Hz, 1H), 1.70-1.72 (m, 1H), 1.23-1.43 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 158.4, 156.8, 137.5, 111.6, 104.6, 55.3, 32.3, 24.7, 24.5; 
HRMS (EI) Exact mass calculated for C18H24N4 [M]+ 296.2001, found 296.1994. 
 
H,Isoquin-BAM (115d). Pd(dba)2 (118.9 mg, 130.0 µmol), BINAP (161.9 mg, 260.0 
µmol), and NaOtBu (2.15 g, 22.3 mmol) were loaded into a round bottom flask in a glove 
box. Toluene (65 mL, 0.10M) was added to the mixture followed by the 1,2-(R,R)-trans-
diaminocyclohexane (750.0 mg, 6.6 mmol). 1-Chloroisoquinoline (2.1 g, 13.1 mmol) was 
118 
added as a solution in toluene. The reaction was allowed to stir at 80 °C and monitored 
by TLC. The reaction was then cooled to room temperature, concentrated, and purified by 
flash column chromatography on silica gel (5% Et2O in hexanes) affording 115d as a 
white solid (1.75 g, 60%). [α]D25 -240.0 (c 1.0, CHCl3); Mp 141-142 °C; IR (film) 3315, 
3048, 2931, 2855, 1594, 1522, 1427, 1409 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J 
= 5.8 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.45 (dd, J = 7.3, 6.7 
Hz, 1H), 7.32 (dd, J = 8.2, 7.9 Hz, 1H), 6.81 (d, J = 5.8 Hz, 1H), 6.50 (s, 1H), 4.26 (s, 
1H), 2.42 (d, J = 10.7 Hz, 1H), 1.85 (d, J = 6.7 Hz, 1H), 1.54-1.17 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 155.9, 141.1, 137.9, 137.2, 129.8, 127.0, 125.8, 122.2, 110.6, 56.8, 
33.3, 25.3; HRMS (EI): Exact mass calcd for C24H24N4 [M]+ 368.2001, found 368.2009.  
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H,Quin-BAM (115e). Pd(dba)2 (800.0 mg, 880.0 µmol), BINAP (1.1 g, 1.76 mmol), and 
NaOtBu (14.3 g, 148.9 mmol) were loaded into a round bottom flask in a glove box. 
Toluene (250 mL, 0.18M) was added to the mixture followed by the 1,2-(R,R)-trans-
diaminocyclohexane (5.0 g, 43.8 mmol). 2-Chloroquinoline (14.3 g, 87.6 mmol) was 
added as a solution in toluene. The reaction was allowed to stir at 80 °C and monitored 
by TLC. The reaction was then cooled to room temperature, concentrated, and purified by 
flash column chromatography on silica gel (5% Et2O in hexanes) affording 115e as a 
white solid (13.9 g, 86%); [α]D25 +686.2 (c 1.0, CHCl3); mp 156-158 °C; Rf =0.13 (20% 
EtOAc/hexanes); IR (neat) 3410, 3297, 2931, 1618, 1524, 1486, 1421, 1401, 817, 755 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.2 Hz, 1H), 7.55 (d, J = 8.9 Hz, 1H), 
7.47-7.51 (m, 2H), 7.14 (dd, J = 7.0, 7.9 Hz, 1H), 6.28 (d, J = 8.9 Hz, 1H), 5.86 (s, 1H), 
4.12 (s, 1H), 2.37 (d, J = 12.5 Hz, 1H), 1.81-1.83 (m, 1H), 1.40-1.52 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 169.9, 157.3, 136.9, 129.6, 127.6, 126.1, 123.5, 121.9, 113.2, 56.3, 
33.1, 25.1; HRMS (CI, CH4) Exact mass calculated for C24H24N4 [M]+ 368.2001, found 
368.1992.  
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H,Lep-BAM (115f). Pd(dba)2 (165.0 mg, 320.0 µmol), BINAP (39.9 mg, 640.0 µmol), 
and NaOtBu (3.69 g, 38.4 mmol) were combined in a round-bottomed flask in a glove 
box. Toluene (250 mL, 0.05 M) was added to the mixture, followed by 1,2-(R,R)-trans-
diaminocyclohexane (1.46 g, 12.8 mmol) and 2-chlorolepidine (4.54 g, 25.6 mmol) as a 
solution in toluene. The reaction was allowed to stir at 85 °C and monitored by TLC. The 
reaction was then cooled to room temperature, concentrated, and purified by flash 
chromatography (SiO2, 15% ether in hexanes) to afford the desired diamine as a white 
solid (3.90 g, 77%); [α]D25 +706.6 (c 1.0, CHCl3); mp = 168-170 °C; Rf = 0.19 (40% 
EtOAc/hexanes); IR (film) 3252, 3058, 2931, 2855, 1622, 1538, 1505, 1447, 1416 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.74-7.68 (m, 2H), 7.53 (dd, J = 14.0, 8.0 Hz, 1H), 7.21 
(dd, J = 8.0, 7.2 Hz, 1H), 6.13 (s, 1H), 5.73 (s, 1H), 4.14 (s, 1H), 2.35 (s, 3H), 1.85 (d, J 
= 7.6 Hz, 2H), 1.59-1.32 (m, 2H); 13C NMR (100 MHz, CDCl3) ppm 157.3, 148.2, 144.2, 
129.3, 126.5, 123.9, 123.7, 121.6, 113.4, 56.3, 33.2, 25.3, 18.6; HRMS (EI): Exact mass 
calcd for C26H28N4 [M+H]+ 396.2308. Found 396.2310. 
 
H,6OMe-BAM (115h). Pd(dba)2 (14.4 mg, 25.0 µmol), DPPF (27.7 mg, 50.0 µmol), and 
NaOtBu (288.3 mg, 3.0 mmol) were loaded into a round bottom flask in a glove box. 
Toluene (10 mL, 0.10M) was added to the mixture followed by the 1,2-(R,R)-trans-
diaminocyclohexane (114.2 mg, 1.0 mmol). 2-Bromo,6-methoxy-pyridine (376.0 mg, 2.0 
mmol) was added as a solution in toluene. The reaction was allowed to stir at 80 °C and 
monitored by TLC. The reaction was then cooled to room temperature, concentrated, and 
purified by flash column chromatography on silica gel (5% Et2O in hexanes) affording 
115h as a white solid (215 mg, 65%); Mp 70-72 °C; Rf = 0.33 (25% Et2O/hexanes). IR 
(film) 3389, 3325, 3051, 3002, 2936, 2855, 1615, 1505, 1456, 1425, 1405, 1332, 1248, 
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1147, 1059 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.25 (dd, J = 7.9, 7.9 Hz, 1H), 5.97 (d, J 
= 7.7 Hz, 1H), 5.84 (d, J = 7.9 Hz, 1H), 5.11 (d, J = 4.0 Hz, 1H), 3.91 (s, 3H), 3.70-3.66 
(m, 1H), 2.30 (d, J = 13.0 Hz, 1H), 1.81-1.79 (m, 1H), 1.44-1.30 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 163.8, 158.0, 140.0, 99.2, 96.6, 56.5, 53.4, 33.4, 25.2; HRMS (CI, CH4) 
Exact mass calculated for C18H24N4O2 [M]+ 329.1972, found 329.1973. 
 
Me,6Me-BAM (115k). To a solution of H,6Me-BAM (250.0 mg, 843.0 µmol) in THF (10 
mL, 0.08M) was added n-butyl lithium (697.0 µL, 2.42M in hexanes, 1.7 mmol) via 
syringe at 0 ºC. Methyl iodide (105.0 µL, 1.7 mmol) was added and the reaction was 
warmed to room temperature. The reaction was allowed to stir at room temperature and 
monitored by TLC. The reaction was then quenched with water, the organic phase 
separated and the aqueous phase back-extracted with EtOAc. The combined organic 
phases were dried over MgSO4, filtered, and concentrated. Purification by flash column 
chromatography on silica gel (5% Et2O in hexanes) afforded 115k as a white solid (210 
mg, 77%); Rf = 0.70 (20% EtOAc/hexanes). IR (film) 2927, 2851, 1589, 1481, 1428, 
1314, 772 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.21 (dd, J = 8.5, 7.3 Hz, 1H), 6.30 (d, J = 
7.0 Hz, 1H), 6.04 (d, J = 8.5 Hz, 1H), 4.98-4.96 (m, 1H), 2.62 (s, 3H), 2.35 (s, 3H), 1.81-
1.75 (m, 2H), 1.61-1.41 (m, 2H); 13C NMR (100 MHz, CDCl3) ppm 158.6, 156.3, 137.4, 
110.3, 102.4, 54.7, 30.3, 30.0, 25.9, 25.0; HRMS (EI): Exact mass calcd for C20H28N4 
[M]+ 324.2314, found 324.2286. 
Pd(dba)2
toluene, 75°C
(52%)
H2N NH2
N Cl
BINAP, NaOtBu
N NH H
H H
N
Br
 
H,Quin(2Nap)-BAM (115o). Pd(dba)2 (14.4 mg, 25.0 µmol), BINAP (31.1 mg, 50.0 
µmol), and NaOtBu (336.4 mg, 3.5 mmol) were loaded into a round bottom flask in a 
glove box. Toluene (20 mL, 0.05M) was added to the mixture followed by the 1,2-(R,R)-
121 
trans-diaminocyclohexane (114.2 mg, 1.0 mmol). 2-Chloroquinoline (163.6 mg, 1.0 
mmol) was added as a solution in toluene and monitored by TLC. 2-Bromonaphthalene 
(207.1 mg, 1.0 mmol) was added as a solution in toluene. The reaction was allowed to stir 
at 80 °C and monitored by TLC. The reaction was then cooled to room temperature, 
concentrated, and purified by flash column chromatography on silica gel (20% EtOAc in 
hexanes) affording 115o as a white solid (190 mg, 52%). [α]D25 +698.4 (c 1.0, CHCl3); 
Mp 124-126 °C; IR (film) 3406, 3280, 3051, 2932, 2848, 1627, 1524, 1486, 1401 cm-1 1H 
NMR (400 MHz, CDCl3) δ 7.85 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.65-7.54 
(m, 4H), 7.44 (d, J = 8.8 Hz, 1H), 7.34-7.27 (m, 2H), 7.13 (dd, J = 7.7, 7.1 Hz, 1H), 6.68 
(bs, 1H), 6.59 (d, J = 8.8 Hz, 1H), 6.47 (d, J = 9.0 Hz, 1H), 6.09 (bs, 1H), 4.55 (d, J = 7.0 
Hz, 1H), 4.36-4.31 (m 1H), 3.30-3.28 (m, 1H), 2.52 (d, J = 12.3 Hz, 1H), 2.22 (d, J = 9.2 
Hz, 1H), 1.88 (bs, 1H), 1.56-1.38 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 157.4, 147.8, 
146.3, 137.4, 135.6, 130.0, 129.0, 127.8 (2C), 127.1, 126.3, 126.2, 125.8, 123.8, 122.5, 
121.5, 118.6, 112.9, 103.0, 61.1, 54.1, 33.9, 32.6, 25.6, 24.7. HRMS (CI): Exact mass 
calcd for C25H25N3 [M]+ 368.2127, found 368.2123.  
 
H,3Quin-BAM (115p). Pd(dba)2 (14.4 mg, 25.0 µmol), BINAP (31.1 mg, 50.0 µmol), 
and NaOtBu (288.3 mg, 3.0 mmol) were loaded into a round bottom flask in a glove box. 
Toluene (10 mL, 0.10M) was added to the mixture followed by the 1,2-(R,R)-trans-
diaminocyclohexane (114.2 mg, 1.0 mmol). 3-Bromoquinoline (268.8 µL, 2.0 mmol) was 
added and the reaction was allowed to stir at 80 °C and monitored by TLC. The reaction 
was then cooled to room temperature, concentrated, and purified by flash column 
chromatography on silica gel (25% EtOAc in hexanes) affording 115p as a white solid 
(158 mg, 43%); Mp 128-130 °C; Rf = 0.15 (50% EtOAc/hexanes). IR (film) 3259, 3048, 
2935, 2851, 1608, 1538, 1487, 1392, 1221 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 
1H), 7.89 (d, J = 7.1 Hz, 1H), 7.43-7.38 (m, 3H), 6.61 (s, 1H), 4.99 (s, 1H), 3.15 (s, 1H), 
2.35 (d, J = 12.8 Hz, 1H), 1.82 (d, J = 6.8 Hz, 1H), 1.43 (dd, J = 9.5, 9.3 Hz, 1H), 1.28-
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1.24 (m, 1H); 13C NMR (100 MHz, CDCl3) ppm 143.9, 141.9, 141.2, 129.8, 129.0, 127.0, 
126.3, 124.9, 109.7, 56.4, 31.8, 24.8. 
 
H,2Quin(3Quin)--BAM (115q). Pd(dba)2 (14.4 mg, 25.0 µmol), BINAP (31.1 mg, 50.0 
µmol), and NaOtBu (288.3 mg, 3.0 mmol) were loaded into a round bottom flask in a 
glove box. Toluene (10 mL, 0.10M) was added to the mixture followed by the 1,2-(R,R)-
trans-diaminocyclohexane (114.2 mg, 1.0 mmol). 2-Chloroquinoline (163.6 mg, 1.0 
mmol) was added as a solution in toluene and monitored by TLC. 3-Bromoquinoline 
(134.4 µL, 1.0 mmol) was added and the reaction was allowed to stir at 80 °C and 
monitored by TLC. The reaction was then cooled to room temperature, concentrated, and 
purified by flash column chromatography on silica gel (25% EtOAc in hexanes) affording 
115q as a white solid (120mg, 33%); Mp 98-100 °C; Rf = 0.13 (50% EtOAc/hexanes). IR 
(film) 3410, 3255, 3048, 2932, 2855, 1609, 1522, 1484, 1420, 1401 cm-1; 1H NMR (400 
MHz, CDCl3) δ 8.08 (d, J = 2.7 Hz, 1H), 7.83 (dd, J = 8.2, 4.8 Hz, 1H), 7.80 (s, 1H), 7.72 
(d, J = 8.8 Hz, 1H), 7.63-7.58 (m, 2H), 7.52 (dd, J = 8.1, 8.1 Hz, 1H), 7.35 (ddd, J = 6.8, 
6.8, 1.1 Hz, 1H), 7.31-7.25 (m, 2H), 6.95 (bs, 1H), 6.83 (d, J = 2.6 Hz, 1H), 6.49 (d, J = 
8.8 Hz, 1H), 4.60 (d, J = 6.8 Hz, 1H), 4.37-4.30 (m 1H), 3.22-3.17 (m, 1H), 2.46 (m, 1H), 
2.18 (d, J = 10.4 Hz, 1H), 1.91-1.87 (m, 2H), 1.79 (bs, 1H), 1.55-1.50 (m, 4H); 13C NMR 
(100 MHz, CDCl3) ppm 157.3, 147.4, 144.2, 142.1, 141.5, 137.7, 130.3, 130.0, 129.1, 
127.8, 126.8, 126.0, 125.7, 124.1, 123.8, 122.8, 112.7, 108.1, 61.8, 54.0, 33.7, 32.2, 25.5, 
24.5. 
 
H,6-Me-BAM·HOTf (118c). To a solution of BAM in CH2Cl2 was added freshly 
distilled trifluoromethanesulfonic acid via syringe at room temperature. The reaction was 
allowed to stir for 20-30 minutes and was concentrated to afford 118c as a white solid. 
123 
[α]D25 -103.0 (c 1.0, CHCl3); mp 142-144°C; IR (neat) 3290, 3122, 2938, 2862, 1652, 
1602, 1516, 1464, 1283, 1243, 1225, 1163, 1029, 782 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 10.75 (bs, 1H), 7.53 (dd, J = 7.9, 7.9 Hz, 1H), 6.68-6.80 (m, 2H), 6.42 (d, J = 7.3 Hz, 
1H), 3.67 (m, 1H), 2.38 (s, 3H), 2.08 (d, J = 13.1 Hz, 1H), 1.79 (d, J = 6.1 Hz, 1H), 1.42-
1.50 (m, 2H); 13C NMR (100 MHz, CDCl3) δ156.6, 153.3, 139.9, 111.8, 106.1, 55.6, 
31.7, 24.1, 22.8; 19F NMR (376 MHz, CDCl3) δ −79.09; HRMS (FAB) Exact mass 
calculated for C19H25F3N4O3S [M]+ 297.2079, found 297.2072. 
 
H,Quin-BAM·HOTf (118e). To a solution of BAM in CH2Cl2 was added freshly 
distilled trifluoromethanesulfonic acid via syringe at room temperature. The reaction was 
allowed to stir for 20-30 minutes and was concentrated to afford 118e as a white solid; 
[α]D25 +450.7 (c 1.0, CHCl3); mp 134-136°C; IR (neat) 3276, 3164, 3069, 2942, 2866, 
1661, 1652, 1616, 1532 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.03 (bs, 1H), 7.81 (m, 2H), 
7.61 (dd, J = 7.0, 8.2 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.31 (dd, J = 7.6, 7.6 Hz, 1H), 
6.82 (bs, 1H), 4.19 (m, 1H), 2.18 (d, J = 13.4 Hz, 1H), 1.86 (d, J = 8.5 Hz, 1H) 1.72 (d, J 
= 9.8 Hz, 1H) 1.50-1.58 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 154.2, 141.4, 132.4, 
128.7, 124.9, 122.0, 120.6, 118.8, 113.2, 56.7, 31.8, 24.1; 19F NMR (376 MHz, CDCl3) 
δ −78.67; HRMS (FAB) Exact mass calculated for C25H25F3N4O3S [M]+ 369.2079, found 
369.2079. 
 
(E)-tert-butyl 4-chlorobenzylidenecarbamate (167f). Following the Greene protocol, 
the Schiff base was obtained as a white solid; Mp = 60-62 °C; IR (film) 2976, 1715, 
1268, 1154 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.85 (s, 1H), 7.87 (d, J = 8.5 Hz, 2H), 
7.47 (d, J = 8.5 Hz, 2H) 1.61 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 168.5, 162.6, 
124 
140.1, 132.8, 131.5, 129.5, 82.8, 28.2; HRMS (CI): Exact mass calcd for C12H14NO2Cl 
[M]+, 239.0713, found 239.0706. 
 
(E)-tert-butyl 5-chloro-2-nitrobenzylidenecarbamate (167i). Following the Greene 
protocol, the Schiff base was obtained as a white solid; IR (film) 2976, 1702, 1571, 1527, 
1369, 1337, 1179, 841 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.42 (s, 1H), 8.40 (d, J = 2.1 
Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H) 7.85 (dd, J = 8.7, 2.3 Hz, 1H) 1.80 (s, 9H); HRMS (CI): 
Exact mass calcd for C12H14ClN2O4 [M+H] +, 285.0642, found 285.0635. 
 
(E)-tert-butyl 3,4-dichlorobenzylidenecarbamate (167j). Following the Greene 
protocol, the Schiff base was obtained as a white solid; IR (film) 2982, 1680, 1397, 1364, 
1190 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.79 (s, 1H), 8.06 (d, J = 1.7 Hz, 1H), 7.74 (dd, 
J = 8.2, 1.7 Hz, 1H) 7.58 (d, J = 8.2, 1H) 1.61 (s, 9H); HRMS (CI): Exact mass calcd for 
C12H14NO2Cl2 [M+H] +, 274.0402, found 274.0397. 
 
(E)-tert-butyl 4-(trifluoromethyl)benzylidenecarbamate (167l). Following the Greene 
protocol, the Schiff base was obtained as a white solid; IR (film) 3325, 2982, 1696, 1500, 
1326, 1168 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.88 (s, 1H), 8.04 (d, J = 8.2 Hz, 2H), 
7.75 (d, J = 8.2 Hz, 2H) 1.62 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 167.7, 162.4, 
137.4, 134.8, 130.4, 126.9, 126.1, 83.1, 28.1; HRMS (CI): Exact mass calcd for 
C13H15F3NO2 [M+H] +, 274.1055, found 274.1060. 
 
 (E)-tert-butyl 4-(trifluoromethoxy)benzylidenecarbamate (167n). Following the 
Greene protocol, the Schiff base was obtained as a clear oil; IR (film) 3330, 2982, 1701, 
125 
1507, 1369, 1263, 1223, 1164, 1015 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 
7.98 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H) 1.61 (s, 9H); 13C NMR (100 MHz, 
CDCl3) ppm 167.9, 162.5, 153.1, 132.7, 132.0, 128.0, 121.0, 82.8, 28.1; HRMS (CI): 
Exact mass calcd for C13H15F3NO3 [M+H]+, 290.1004, found 290.1007. 
 
 (E)-tert-butyl 2-nitrobenzylidenecarbamate (167p). Following the Greene protocol, 
the Schiff base was obtained as a yellow oil; IR (film) 2981, 1721, 1635, 1530, 1369, 
1347, 1253, 1155 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 8.17 (d, J = 7.0 Hz, 
1H), 8.07 (dd, J = 7.6, 0.9 Hz, 1H) 7.71-7.67 (m, 2H) 1.57 (s, 9H); 13C NMR (100 MHz, 
CDCl3) ppm 164.4, 161.8, 150.1, 133.9, 133.2, 130.0, 129.4, 124.9, 83.3, 28.1; HRMS 
(CI): Exact mass calcd for C12H15N2O4 [M+H]+, 251.1032, found 251.1033. 
 
 (E)-tert-butyl 3-nitrobenzylidenecarbamate (167q). Following the Greene protocol, 
the Schiff base was obtained as a yellow oil; IR (film) 3083, 2978, 2928, 1717, 1533, 
1352, 1255, 1155 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.76 (s, 1H), 8.41 (d, 
J = 6.7 Hz, 1H) 8.25 (d, J = 7.7 Hz, 1H) 7.70 (dd, J = 7.9 Hz, 1H) 1.61 (s, 9H); 13C NMR 
(100 MHz, CDCl3) ppm 166.5, 162.0, 148.9, 136.0, 135.4, 130.3, 127.7, 124.8, 83.4, 
28.1; HRMS (CI): Exact mass calcd for C12H14N2O4 [M+H]+, 251.1032, found 251.1026. 
 
 (E)-tert-butyl 4-nitrobenzylidenecarbamate (167r). Following the Greene protocol, 
the Schiff base was obtained as a yellow solid; Mp = 102-105 °C; IR (film) 2976, 1707, 
1522, 1348, 1157, 852 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.34 (d, J = 8.7 
Hz, 2H), 8.10 (d, J = 8.9 Hz, 2H) 1.62 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 166.5, 
162.0, 139.6, 130.9, 124.3, 123.7, 83.5, 28.3; HRMS (CI): Exact mass calcd for 
C12H15N2O4 [M+H]+, 251.1032, found 251.1037. 
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(1-Naphthalen-2-yl-2-nitro-ethyl)-carbamic acid tert-butyl ester (168c). A solution of 
imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitromethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (Al2O3, 25% ethyl acetate in hexanes) to furnish the 
product as a white solid (19.0 mg, 60 %) and was determined to be 42% ee by chiral 
HPLC analysis (Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL/min, tr(major) = 15.0 min, 
tr(minor) = 18.1 min); Mp = 128-130 °C; Rf = 0.55 (50% EtOAc/hexanes); IR (film) 
3358, 3059, 2976, 2930, 1695, 1556, 1509, 1368, 1166 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.08-7.97 (m, 4H), 7.73-7.70 (m, 2H), 7.60 (dd, J = 8.4, 1.5 Hz, 1H), 5.76-5.72 
(m, 1H), 5.61 (d, J = 7.3 Hz, 1H), 5.13-4.97 (m, 2H), 1.66 (s, 9H); 13C NMR (100 MHz, 
CDCl3) ppm 155.2, 134.6, 133.7, 133.6, 129.7, 128.5, 128.2, 127.2, 127.1, 126.0, 124.2, 
79.3, 67.3, 53.8, 28.7; HRMS (EI): Exact mass calcd for C17H21N2O4 [M]+, 317.1501, 
found 317.1511. 
 
(1-Naphthalen-1-yl-2-nitro-ethyl)-carbamic acid tert-butyl ester (168d). A solution of 
imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitromethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (Al2O3, 25% ethyl acetate in hexanes) to furnish the 
product as a white solid (23.1 mg, 73 %) and was determined to be 64% ee by chiral 
HPLC analysis ([α]D25 -4.0 (c 1.0, CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 
mL/min, tr(major) = 13.7 min, tr(minor) = 19.7 min); Mp = 158-160 °C; Rf = 0.44 (50% 
EtOAc/hexanes); IR (film) 3357, 2980, 2360, 2342, 1685, 1542, 1526, 1167, 775 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 8.2 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.84-
7.82 (m, 1H), 7.59 (ddd, J = 8.2, 7.0, 1.5 Hz, 1H), 7.52 (dd, J = 7.0, 7.0 Hz, 1H), 7.42-
7.46 (m, 2H), 6.25 (d, J = 6.4 Hz, 1H), 5.30 (d, J = 7.0 Hz, 1H), 4.87 (bm, 2H), 1.41 (s, 
9H); 13C NMR (100 MHz, CDCl3) ppm 154.9, 134.3, 132.8, 130.5, 129.7, 129.5, 127.5, 
127 
126.5, 125.4, 123.4, 122.4, 81.0, 78.5, 49.5, 28.4; HRMS (EI): Exact mass calcd for 
C17H20N2O4 [M]+, 316.1423, found 316.1411. 
 
tert-butyl (R)-2-nitro-1-phenylethylcarbamate (168e). A solution of imine (100.0 mg, 
487.0 µmol) and H,Quin-BAM•TfOH (25.3 mg, 48.7 µmol) in CH3NO2 (0.4 mL, 0.25M) 
was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (Al2O3, 20% ethyl acetate in hexanes) to furnish the product as a white 
solid (74.0 mg, 57 %) which was determined to be 60% ee by chiral HPLC analysis 
(Chiralcel® AD, 95:5 hexanes:i-PrOH, 1 mL / min, tr(major) = 24.9 min, tr(minor) = 23.3 
min); Mp = 116-118 °C; Rf = 0.33 (30% EtOAc/hexanes); IR (film) 3331, 2984, 1682, 
1553 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.30-7.40 (m, 5H), 5.37 (m, 1H), 5.29 (bs, 1H), 
4.85 (m, 1H), 4.71 (dd, J = 12.4, 5.2 Hz, 1H), 1.44 (s, 1H); 13C NMR (100 MHz, CDCl3) 
ppm 154.9, 137.0, 129.4, 128.9, 126.5, 80.9, 79.1, 53.0, 28.4; HRMS (EI): Exact mass 
calcd for C13H19N2O4 [M+H] +, 267.1345, found 267.1343.  
 
tert-butyl (R)-1-(4-chlorophenyl)-2-nitroethylcarbamate (168f). A solution of imine 
(100.0 mg, 417.0 µmol) and H,Quin-BAM•TfOH (21.6 mg, 41.7 µmol) in CH3NO2 (0.4 
mL, 0.25M) was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (Al2O3, 20% ethyl acetate in hexanes) to furnish the product as a white 
solid (65.4 mg, 52 %) which was determined to be 79% ee by chiral HPLC analysis 
(Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 14.9 min, tr(minor) = 
11.8 min); Mp = 128-130 °C; Rf = 0.33 (30% EtOAc/hexanes); IR (film) 3330, 2977, 
2926, 1680, 1553 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.2 Hz, 2H), 7.25 (d, J 
= 8.2 Hz, 2H), 5.33 (m, 2H), 4.83 (m, 1H), 4.69 (dd, J = 12.5, 4.3 Hz, 1H), 1.44 (s, 1H); 
13C NMR (100 MHz, CDCl3) ppm 154.9, 135.7, 134.8, 129.6, 127.9, 81.1, 78.9, 52.4, 
28.4; HRMS (EI): Exact mass calcd for C13H17ClN2O4 [M+H]+, 301.0955, found 
301.0956.  
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Acetic acid 4-(1-tert-butoxycarbonylamino-2-nitro-ethyl)-phenyl ester (168g). A 
solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitromethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2 Al2O3, 25% ethyl acetate in hexanes) to furnish 
the product as a white solid (15.0 mg, 46 %) and was determined to be 65% ee by chiral 
HPLC analysis ([α]D -10.0 (c 1.0, CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 
mL/min, tr(major) = 17.6 min, tr(minor) = 21.7 min). Rf = 0.36 (50% EtOAc/hexanes); IR 
(film) 3367, 2985, 1747, 1678, 1551, 1522, 1511, 1368, 1217, 1161 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.30 (d, J = 8.2 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H), 5.36 (d, J = 5.8 Hz, 
1H), 5.22 (bm, 1H), 4.80 (bm, 1H), 4.67 (ddd, J = 12.5, 5.5, 5.5 Hz, 1H), 2.27 (s, 3H), 
1.41 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 169.4, 151.0, 134.7, 127.8, 122.6, 122.5, 
81.0, 78.9, 52.5, 28.5, 21.3; HRMS (CI): Exact mass calcd for C15H21N2O6 [M+H]+, 
325.1399, found 325.1388.  
 
tert-butyl (R)-2-nitro-1-(4-(trifluoromethoxy)phenyl)ethylcarbamate (168h). A 
solution of imine (100.0 mg, 345.7 µmol) and H,Quin-BAM•TfOH (57.0 mg, 34.6 µmol) 
in CH3NO2 (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (Al2O3, 40% ethyl acetate in hexanes) to furnish the 
product as a white solid (51.0 mg, 42 %) which was determined to be 67% ee by chiral 
HPLC analysis (Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 12.0 min, 
tr(minor) = 9.0 min); Mp = 104-107 °C; Rf = 0.25 (40% EtOAc/hexanes); IR (film) 3357, 
2981, 2935, 1684, 1537, 1511, 1267, 1214, 1164 cm-1; 19F NMR (376 MHz, CDCl3) δ -
58.3; 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 
5.40-5.48 (m, 2H) 4.86 (m, 1H) 4.72 (dd, J = 12.5, 4.2 Hz, 1H) 1.45 (s, 9H); 13C NMR 
(100 MHz, CDCl3) ppm 154.9, 149.5, 135.9, 128.2, 121.8, 119.3, 81.2, 79.9, 52.4, 28.5; 
HRMS (CI): Exact mass calcd for C14H18F3N2O5 [M+H] +, 351.1168, found 351.1157. 
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tert-butyl (R)-1-(5-chloro-2-nitrophenyl)-2-nitroethylcarbamate (168i). A solution of 
imine (28.5 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in CH3NO2 
(0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and purified by 
flash chromatography (Al2O3, 20% ethyl acetate in hexanes) to furnish the product as a 
white solid (16.0 mg, 46 %) which was determined to be 61% ee by chiral HPLC analysis 
(Chiralcel® OD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 13.8 min, tr(minor) = 
32.3 min); Rf = 0.14 (40% EtOAc/hexanes); IR (film) 3359, 2981, 1688, 1550, 1522, 
1374, 1341, 1171 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.5 Hz, 1H), 7.54 (d, J 
= 2.1 Hz, 1H), 7.46 (dd, J = 2.1, 8.9 Hz, 1H) 5.85-5.91 (m, 2H) 4.86-4.92 (m, 2H) 1.40 
(s, 9H); HRMS (CI): Exact mass calcd for C13H17N3O6Cl [M+H]+, 346.0806, found 
346.0800.  
 
tert-butyl (R)-1-(3,4-dichlorophenyl)-2-nitroethylcarbamate (168j). A solution of 
imine (100.0 mg, 364.8 µmol) and H,Quin-BAM•TfOH (18.9 mg, 36.5 µmol) in CH3NO2 
(0.4mL, 0.25M) was stirred at -20 °C. The solution was concentrated and purified by 
flash chromatography (Al2O3, 20% ethyl acetate in hexanes) to furnish the product as a 
white solid (58.0 mg, 47 %) which was determined to be 76% ee by chiral HPLC analysis 
(Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 13.2 min, tr(minor) = 9.4 
min); Mp = 122-124 °C; Rf = 0.57 (40% EtOAc/hexanes); IR (film) 3346, 2978, 2928, 
1689, 1549, 1520, 1170 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.2 Hz, 1H), 
7.39 (d, J = 2.1 Hz, 1H), 7.13 (dd, J = 2.1, 8.2 Hz, 1H) 5.29-5.35 (m, 2H) 4.79 (m, 1H) 
4.66 (dd, J = 12.8, 4.9 Hz, 1H) 1.41 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 154.8, 
137.5, 133.7, 133.2, 131.4, 128.8, 125.9, 81.4, 78.6, 52.1, 28.5; HRMS (CI): Exact mass 
calcd for C13H17N2O4Cl2 [M+H] +, 335.0565, found 335.0574.  
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[1-(3,4-Difluoro-phenyl)-2-nitro-ethyl]-carbamic acid tert-butyl ester (168k). A 
solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitromethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (Al2O3, 25% ethyl acetate in hexanes) to furnish the 
product as a white solid (24.2 mg, 80 %) and was determined to be 84% ee by chiral 
HPLC analysis ([α]D25 -9.4 (c 1.0, CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 
mL/min, tr(major) = 9.0 min, tr(minor) = 12.5 min); Mp = 100-102 °C; Rf = 0.47 (50% 
EtOAc/hexanes); IR (film) 3351, 2978, 2932, 1687, 1540, 1519, 1370, 1284, 1165 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.23-7.15 (m, 2H), 7.08-7.06 (m, 1H), 5.42 (d, J = 5.4 Hz, 
1H), 4.83 (m, 1H), 4.70 (ddd, J = 12.8, 4.7, 4.7 Hz, 1H), 1.46 (s, 9H); 13C NMR (100 
MHz, CDCl3) ppm 154.8, 151.7, 149.3, 134.3, 122.7, 118.3, 115.9, 81.4, 78.8, 52.1, 28.5; 
HRMS (CI): Exact mass calcd for C13H16F2N2O4 [M+H]+, 303.1156, found 303.1153. 
 
tert-butyl (R)-1-(4-(trifluoromethyl)phenyl)-2-nitroethylcarbamate (168l). A solution 
of imine (100.0 mg, 366.0 µmol) and H,Quin-BAM•TfOH (19.0 mg, 36.6 µmol) in 
CH3NO2 (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (Al2O3, 40% ethyl acetate in hexanes) to furnish the 
product as a white solid (73 mg, 60 %) which was determined to be 78% ee by chiral 
HPLC analysis (Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 15.4 min, 
tr(minor) = 10.3 min); Mp = 124-126 °C; Rf = 0.25 (40% EtOAc/hexanes); IR (film) 
3354, 2978, 1687, 1542, 1527, 1328, 1169, 1128, 1069 cm-1; 19F NMR (376 MHz, 
CDCl3) δ -63.2; 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.2 
Hz, 2H), 5.46-5.53 (m, 2H) 4.87 (m, 1H) 4.75 (d, J = 9.1 Hz, 1H) 1.45 (s, 9H); 13C NMR 
(100 MHz, CDCl3) ppm 154.9, 141.2, 131.2, 127.0, 126.4, 122.6, 81.3, 78.8, 52.6, 28.5; 
HRMS (CI): Exact mass calcd for C14H18F3N2O4 [M+H] +, 335.1219, found 335.1220.  
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[2-Nitro-1-(3-trifluoromethyl-phenyl)-ethyl]-carbamic acid tert-butyl ester (168m). 
A solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) 
in nitromethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated 
and purified by flash chromatography (Al2O3, 25% ethyl acetate in hexanes) to furnish 
the product as a white solid (22.0 mg, 66 %) and was determined to be 71% ee by chiral 
HPLC analysis ([α]D25 -21.0 (c 1.0, CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 
mL/min, tr(major) = 6.8 min, tr(minor) = 8.3 min). Mp = 90-92 °C; Rf = 0.47 (50% 
EtOAc/hexanes); IR (film) 3357, 2985, 2935, 1690, 1557, 1520, 1330, 1167, 1126 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.63-7.59 (m, 2H), 7.54-7.53 (m, 2H), 5.47 (bm, 2H), 4.88 
(bm, 1H), 4.76 (d, J = 12.9 Hz, 1H), 1.46 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 
154.9, 138.4, 131.8, 130.0, 130.0, 125.8, 123.4, 81.4, 78.8, 52.7, 28.4; HRMS (CI): Exact 
mass calcd for C14H18F3N2O4 [M+H]+, 335.1219, found 335.1202.  
 
[2-Nitro-1-(2-trifluoromethyl-phenyl)-ethyl]-carbamic acid tert-butyl ester (168n). A 
solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitromethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (Al2O3, 25% ethyl acetate in hexanes) to furnish the 
product as a white solid (30.0 mg, 90 %) and was determined to be 73% ee by chiral 
HPLC analysis ([α]D25 -9.8 (c 1.0, CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 
mL/min, tr(major) = 9.2 min, tr(minor) = 16.2 min); Mp = 97-99 °C; Rf = 0.45 (50% 
EtOAc/hexanes); IR (film) 3311, 2981, 2928, 1695, 1557, 1368, 1314, 1164, 1125, 1037 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.8 Hz, 1H), 7.63-7.54 (m, 2H), 7.48 
(dd, J = 7.7, 7.4 Hz, 1H), 5.80 (ddd, J = 7.0, 6.3, 6.3 Hz, 1H), 5.58 (m, 1H), 4.75 (m, 2H), 
1.41 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 154.6, 132.9, 129.0, 127.7, 127.0, 125.6, 
122.9, 81.2, 79.0, 64.3, 49.8, 28.4; HRMS (CI): Exact mass calcd for C14H18F3N2O4 
[M+H]+, 335.1219, found 335.1209.  
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4-(1-tert-Butoxycarbonylamino-2-nitro-ethyl)-benzoic acid methyl ester (168o). A 
solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitromethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (Al2O3, 25% ethyl acetate in hexanes) to furnish the 
product as a white solid (20.0 mg, 62 %) and was determined to be 80% ee by chiral 
HPLC analysis ([α]D25 -23.3 (c 1.0, CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 
mL/min, tr(major) = 19.8 min, tr(minor) = 25.6 min). Mp = 166-168 °C; Rf = 0.40 (50% 
EtOAc/hexanes); IR (film) 3364, 2978, 1717, 1684, 1553, 1522, 1281, 1168, 1110 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.5 Hz, 2H), 7.37(d, J = 8.2 Hz, 2H), 5.40 
(bm, 2H), 4.83 (bm, 1H), 4.71 (d, J = 11.3 Hz, 1H), 3.89 (s, 3H), 1.41 (s, 9H); 13C NMR 
(100 MHz, CDCl3) ppm 166.6, 154.9, 142.0, 130.7, 130.6, 126.5, 81.1, 78.8, 52.7, 52.5, 
28.4; HRMS (CI): Exact mass calcd for C15H21N2O6 [M+H]+, 325.1400, found 325.1399. 
 
tert-butyl (R)-2-nitro-1-(2-nitrophenyl)ethylcarbamate (168p). A solution of imine 
(100.0 mg, 400.0 µmol) and H,Quin-BAM•TfOH (20.7 mg, 40.0 µmol) in CH3NO2 (0.4 
mL, 0.25M) was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (Al2O3, 50% ethyl acetate in hexanes) to furnish the product as a white 
solid (71.0 mg, 57 %) which was determined to be 70% ee by chiral HPLC analysis 
(Chiralcel® OD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 16.4 min, tr(minor) = 
18.7 min); Mp = 158-160 °C; Rf = 0.5 (80% EtOAc/hexanes); IR (film) 3367, 2974, 
1684, 1550, 1521, 1275, 763 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 7.7 Hz, 
1H), 7.69 (dd, J = 7.9, 7.3 Hz, 1H), 7.60 (d, J = 6.7 Hz, 1H), 7.54 (ddd, J = 7.1, 7.0, 1.3, 
1H) 5.92 (m, 2H) 4.90-4.99 (m, 2H) 1.42 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 
154.7, 148.2, 134.4, 133.1, 129.8, 129.6, 126.0, 81.2, 78.5, 50.2, 28.4; HRMS (CI): Exact 
mass calcd for C13H18N3O6 [M+H] +, 312.1196, found 312.1186.  
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tert-butyl (R)-2-nitro-1-(3-nitrophenyl)ethylcarbamate (168q). A solution of imine 
(25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in CH3NO2 (0.4 
mL, 0.25M) was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (Al2O3, 60% ethyl acetate in hexanes) to furnish the product as a white 
solid (20.1 mg, 65 %) which was determined to be 95% ee by chiral HPLC analysis 
(Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 19.0min, tr(minor) = 13.1 
min); Mp = 140-142 °C; Rf = 0.38 (80% EtOAc/hexanes); IR (film) 3356, 2978, 1681, 
1551, 1524, 1351 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.21-8.23 (m, 2H), 7.70 (d, J = 7.8 
Hz, 1H), 7.60 (dd, J = 7.9, 8.6 Hz, 1H), 5.61 (d, J = 7.5 Hz, 1H) 5.50 (d, J = 5.2 Hz, 1H) 
4.92 (m, 1H) 4.80 (dd, J = 13.0, 4.3 Hz, 1H) 1.46 (s, 9H); 13C NMR (100 MHz, CDCl3) 
ppm 154.9, 148.9, 139.6, 132.7, 130.5, 123.9, 121.6, 81.6, 78.6, 52.3, 28.5; HRMS (CI): 
Exact mass calcd for C13H17N3O6 [M] +, 311.1117, found 311.1118.  
 
tert-butyl (R)-2-nitro-1-(4-nitrophenyl)ethylcarbamate (168r). A solution of imine 
(50.1 mg, 200.0 µmol) and H,Quin-BAM•TfOH (10.4 mg, 20.0 µmol) in CH3NO2 (0.4 
mL, 0.25M) was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (Al2O3, 40% ethyl acetate in hexanes) to furnish the product as a yellow 
solid (38.1 mg, 61 %) which was determined to be 82% ee by chiral HPLC analysis 
(Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL / min, tr(major) = 45.3 min, tr(minor) = 
22.4 min); Mp = 132-134 °C; Rf = 0.38 (60% EtOAc/hexanes); IR (film) 3353, 2924, 
2850, 1701, 1560, 1523 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.5 Hz, 2H), 
7.52 (d, J = 8.5 Hz, 2H), 5.54 (bs, 1H), 5.47 (m, 1H), 4.89 (m, 1H), 4.77 (dd, J = 13.1, 
4.3 Hz, 1H), 1.44 (s, 1H); 13C NMR (100 MHz, CDCl3) ppm 148.2, 144.3, 127.5, 124.6, 
81.5, 78.5, 52.3, 28.4; HRMS (EI): Exact mass calcd for C13H17N3O6 [M] +, 311.1117, 
found 311.1116.  
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(1-Naphthalen-2-yl-2-nitro-propyl)-carbamic acid tert-butyl ester (169c). A solution 
of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitroethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (20.1 mg, 62 %) and a 9:1 mixture of diastereomers; the major 
diastereomer was determined to be 44% ee by chiral HPLC analysis (Chiralcel® AD, 95:5 
hexanes:i-PrOH, 1 mL/min, tr(major) = 25.3 min, tr(minor) = 22.7 min); Mp = 136-138 
°C; Rf = 0.78 (40% EtOAc/hexanes); IR (film) 3368, 3058, 2978, 2932, 1701 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.82-7.86 (m, 3H), 7.71 (s, 1H), 7.48-7.53 (m, 2H), 7.34 (dd, 
J = 8.5, 1.5 Hz, 1H), 5.36-5.43 (m, 2H), 5.02 (bs, 1H)1.57 (d, J = 6.7 Hz, 3H), 1.44 (s, 
9H); 13C NMR (100 MHz, CDCl3) ppm 155.1, 134.0, 133.3 (2), 129.2, 128.2, 127.9, 
126.9, 126.8, 126.5, 124.3, 85.9, 80.8, 57.8, 28.5, 15.4; HRMS (EI): Exact mass calcd for 
C18H22N2O4 [M]+, 330.1580, found 330.1572. 
 
(1-Naphthalen-1-yl-2-nitro-propyl)-carbamic acid tert-butyl ester (169d). A solution 
of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitroethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a colorless oil (23.1 mg, 71 %) and a 6:1 mixture of diastereomers; the major 
diastereomer was determined to be 56% ee by chiral HPLC analysis (Chiralcel® AD, 
90:10 hexanes:i-PrOH, 1 mL/min, tr(major) = 11.7 min, tr(minor) = 10.8 min); Rf = 0.73 
(40% EtOAc/hexanes); IR (film) 3347, 3052, 2979, 2933, 1701 cm-1; 1H NMR (400 
MHz, CDCl3) δ 8.24 (d, J = 8.5 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.84 (d, J = 7.9 Hz, 
1H), 7.62 (dd, J = 7.6, 7.0 Hz, 1H), 7.54 (dd, J = 7.3, 7.3 Hz, 1H), 7.40-7.48 (m, 2H), 
6.43 (d, J = 7.3 Hz, 1H), 6.29 (dd, J = 8.5, 6.1 Hz, 1H), 5.15 (bs, 1H), 1.57 (d, J = 7.3 Hz, 
3H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 155.2, 134.2, 133.4, 130.8, 129.5, 
135 
129.4, 127.5, 126.4, 125.4, 123.3, 122.8, 84.6, 80.8, 53.1, 28.4, 14.9; HRMS (EI): Exact 
mass calcd for C18H22N2O4 [M]+, 330.1580, found 330.1571. 
 
 tert-butyl (1R,2S)-2-nitro-1-phenylpropylcarbamate (169e). A solution of imine 
(100.0 mg, 487 µmol) and H,Quin-BAM•TfOH (25.3 mg, 48.7 µmol) in CH3CH2NO2 
(1.6 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and purified by 
flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the product as a 
white solid (93.7 mg, 69 %) and a 14:1 mixture of diastereomers , the major of which was 
determined to be 59% ee by chiral HPLC analysis (Chiralcel® AD, 90:10 hexanes:i-
PrOH, 1 mL / min, tr(major) = 10.1 min, tr(minor) = 9.3 min); Mp = 143-145 °C; Rf = 
0.61 (40% EtOAc/hexanes); IR (film) 3383, 2975, 2938, 1684, 1544 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.28-7.32 (m, 3H), 7.20-7.23(m, 2H), 5.35 (bs, 1H), 5.18 (dd, J = 8.5, 6.1 
Hz, 1H), 4.89 (bs, 1H), 1.49 (d, J = 6.7 Hz, 3H), 1.39 (s, 9H); 13C NMR (100 MHz, 
CDCl3) ppm 155.2, 136.7, 129.2, 128.8, 127.1, 86.0, 80.7, 57.7, 28.4, 15.5; HRMS (EI): 
Exact mass calcd for C14H21N2O4 [M+H]+, 281.1501, found 281.1491. 
 
tert-butyl (1R,2S)-1-(4-chlorophenyl)-2-nitropropylcarbamate (169f). A solution of 
imine (100.0 mg, 417 µmol) and H,Quin-BAM•TfOH (21.6 mg, 41.7 µmol) in 
CH3CH2NO2 (0.8 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (77.8 mg, 59 %) and a 17:1 mixture of diastereomers , the major 
of which was determined to be 82% ee by chiral HPLC analysis (Chiralcel® AD, 95:5 
hexanes:i-PrOH, 1 mL / min, tr(major) = 25.5 min, tr(minor) = 16.7 min); Mp = 142-144 
°C; Rf = 0.66 (40% EtOAc/hexanes); IR (film) 3393, 2981, 2935, 1682, 1524 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 7.6 Hz, 2H), 5.39 (bs, 
1H), 5.15 (dd, J = 8.9, 5.8 Hz, 1H), 4.89 (bs, 1H), 1.52 (d, J = 7.0 Hz, 3H), 1.42 (s, 9H); 
13C NMR (100 MHz, CDCl3) ppm 155.0, 135.1, 134.8, 129.3, 128.5, 85.8, 81.0, 57.1, 
136 
28.4, 15.5; HRMS (EI): Exact mass calcd for C14H20ClN2O4 [M+H]+, 315.1112, found 
315.1117. 
 
Acetic acid 4-(1-tert-butoxycarbonylamino-2-nitro-propyl)-phenyl ester (169g). A 
solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitroethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (30.6 mg, 95 %) and a 13:1 mixture of diastereomers; the major 
diastereomer was determined to be 77% ee by chiral HPLC analysis ([α]D25 -11.0 (c 1.0, 
CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL/min, tr(major) = 15.5 min, tr(minor) 
= 14.1 min). Mp = 115-117 °C; Rf = 0.51 (40% EtOAc/hexanes); IR (film) 3374, 2980, 
2934, 1770, 1699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 7.0 Hz, 2H), 7.10(d, J 
= 6.7 Hz, 2H), 5.29 (bs, 1H), 5.20 (dd, J = 8.9, 5.8 Hz, 1H), 4.90 (bs, 1H), 2.29 (s, 3H), 
1.53 (d, J = 6.7 Hz, 3H), 1.42 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 169.4, 155.0, 
151.0, 134.2, 128.2, 122.4, 85.8, 80.9, 57.1, 28.5, 21.3, 15.5; HRMS (CI): Exact mass 
calcd for C16H23N2O6 [M+H]+, 339.1556, found 339.1540. 
 
 tert-butyl (1R,2S)-2-nitro-1-(4-(trifluoromethoxy)phenyl)propylcarbamate (169h). 
A solution of imine (100.0 mg, 346 µmol) and H,Quin-BAM•TfOH (19.0 mg, 34.5 µmol) 
in CH3CH2NO2 (1.6 mL, 0.25M) was stirred at -20 °C. The solution was concentrated 
and purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (62.5 mg, 50 %) and a 19:1 mixture of diastereomers , the major 
of which was determined to be 81% ee by chiral HPLC analysis (Chiralcel® AD, 95:5 
hexanes:i-PrOH, 1 mL / min, tr(major) = 19.7 min, tr(minor) = 12.1 min); Mp = 113-115 
°C; Rf = 0.22 (20% EtOAc/hexanes); IR (film) 3373, 2989, 2941, 1680, 1518 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.2 Hz, 2H), 7.17(d, J = 8.2 Hz, 2H), 5.35 (bs, 
1H), 5.17 (dd, J = 8.5, 5.8 Hz, 1H), 4.88 (bs, 1H) 1.51 (d, J = 6.7 Hz, 3H), 1.39 (s, 9H); 
13C NMR (100 MHz, CDCl3) ppm 155.0, 149.5, 148.3, 128.6, 121.5, 85.7, 81.0, 57.0, 
137 
28.4, 15.5; HRMS (EI): Exact mass calcd for C15H20F3N2O5[M+H]+, 365.1324, found 
365.1315. 
 
[1-(3,4-Difluoro-phenyl)-2-nitro-propyl]-carbamic acid tert-butyl ester (169k). A 
solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitroethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (21.4 mg, 65 %) and a 18:1 mixture of diastereomers; the major 
diastereomer was determined to be 86% ee by chiral HPLC analysis ([α]D25 -17.8 (c 1.0, 
CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL/min, tr(major) = 9.6 min, tr(minor) = 
7.2 min); Mp = 136-138 °C; Rf = 0.68 (40% EtOAc/hexanes); IR (film) 3363, 2986, 
2941, 1678 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.16 (ddd, J = 8.5, 8.2, 8.2 Hz, 1H), 7.08 
(ddd, J = 9.8, 7.3, 2.1 Hz, 1H), 6.97-7.00 (m, 1H) 5.36 (d, J = 8.5 Hz, 1H), 5.12 (dd, J = 
8.5, 5.8 Hz, 1H), 4.88 (bs, 1H), 1.53 (d, J = 6.7 Hz, 3H), 1.43 (s, 9H); 13C NMR (100 
MHz, CDCl3) ppm 154.9, 151.8, 149.3, 133.8, 123.4, 118.2, 116.3, 85.6, 81.2, 56.8, 28.4, 
15.6; HRMS (CI): Exact mass calcd for C14H19F2N2O4 [M+H]+, 317.1313, found 
317.1324. 
 
 tert-butyl (1R,2S)-1-(4-(trifluoromethyl)phenyl)-2-nitropropylcarbamate (169l). A 
solution of imine (100.0 mg, 366 µmol) and H,Quin-BAM•TfOH (19.0 mg, 36.6 µmol) 
in CH3CH2NO2 (1.6 mL, 0.25M) was stirred at -20 °C. The solution was concentrated 
and purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (67.5 mg, 53 %) and a 19:1 mixture of diastereomers , the major 
of which was determined to be 84% ee by chiral HPLC analysis (Chiralcel® OD, 90:10 
hexanes:i-PrOH, 1 mL / min, tr(major) = 11.8 min, tr(minor) = 7.6 min); Mp = 137-139 
°C; Rf = 0.65 (40% EtOAc/hexanes); IR (film) 3373, 2987, 1682, 1544 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.63 (d, J = 8.2 Hz, 2H), 7.37(d, J = 8.2 Hz, 2H), 5.39 (bs, 1H), 
5.24 (dd, J = 8.5, 5.8 Hz, 1H), 4.93 (bs, 1H), 1.54 (d, J = 6.7 Hz, 3H), 1.43 (s, 9H); 13C 
138 
NMR (100 MHz, CDCl3) ppm 155.0, 140.1, 131.1, 127.6, 157.4, 122.6, 85.6, 57.2, 28.4, 
15.4; HRMS (EI): Exact mass calcd for C15H20F3N2O4 [M+H]+, 349.1375, found 
349.1375. 
 
[2-Nitro-1-(3-trifluoromethyl-phenyl)-ethyl]-carbamic acid tert-butyl ester (169m). 
A solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) 
in nitroethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (26.9 mg, 84 %) and a 12:1 mixture of diastereomers; the major 
diastereomer was determined to be 69% ee by chiral HPLC analysis ([α]D25 -7.1 (c 1.0, 
CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL/min, tr(major) = 6.1 min, tr(minor) = 
5.6 min). Mp = 96-98 °C; Rf = 0.67 (40% EtOAc/hexanes); IR (film) 3328, 2982, 2937, 
1704 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 7.9 Hz, 1H), 7.48-7.52 (m, 2H), 
7.44 (d, J = 7.9 Hz, 1H), 5.42 (bs, 1H), 5.26 (dd, J = 8.2, 5.8 Hz, 1H), 4.93 (bs, 1H), 1.54 
(d, J = 6.7 Hz, 3H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 154.9, 137.8, 135.4, 
131.4, 130.5, 129.8, 125.7, 123.9, 85.6, 81.2, 57.3, 28.4, 15.7; HRMS (CI): Exact mass 
calcd for C15H20F3N2O4 [M+H]+, 349.1375, found 349.1368.  
 
[2-Nitro-1-(2-trifluoromethyl-phenyl)-propyl]-carbamic acid tert-butyl ester (169n). 
A solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) 
in nitroethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (20.4 mg, 64 %) and a 6:1 mixture of diastereomers; the major 
diastereomer was determined to be 83% ee by chiral HPLC analysis ([α]D25 -10.0° (c 1.0, 
CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL/min, tr(major) = 12.9 min, tr(minor) 
= 15.7 min); Mp = 88-90 °C; Rf = 0.58 (40% EtOAc/hexanes); IR (film) 3272, 2982, 
2935, 1704 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 7.6 Hz, 1H), 7.56-7.59 (m, 
2H), 7.45 (dd, J = 7.9, 7.6 Hz, 1H), 5.69 (bs, 1H), 5.02-5.10 (m, 2H), 1.60 (d, J = 6.7 Hz, 
139 
3H), 1.41 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 154.7, 132.6, 128.9, 128.1, 127.0, 
125.5, 122.8, 87.1, 84.6, 81.0, 53.5, 28.3, 15.6; HRMS (CI): Exact mass calcd for 
C15H20F3N2O4 [M+H]+, 349.1375, found 349.1389.  
 
4-(1-tert-Butoxycarbonylamino-2-nitro-propyl)-benzoic acid methyl ester (169o). A 
solution of imine (25.0 mg, 100.0 µmol) and H,Quin-BAM•TfOH (5.2 mg, 10.0 µmol) in 
nitroethane (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (15.6 mg, 49 %) and a 20:1 mixture of diastereomers; the major 
diastereomer was determined to be 88% ee by chiral HPLC analysis ([α]D25 -17.9 (c 1.0, 
CHCl3) Chiralcel® AD, 90:10 hexanes:i-PrOH, 1 mL/min, tr(major) = 18.4 min, tr(minor) 
= 15.4 min). Mp = 121-123 °C; Rf = 0.57 (40% EtOAc/hexanes); IR (film) 3362, 2980, 
1718 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.5 Hz, 2H), 7.32(d, J = 8.2 Hz, 
2H), 5.41 (d, J = 8.9 Hz, 1H), 5.25 (dd, J = 8.9, 5.5 Hz, 1H), 4.92 (bs, 1H), 3.91 (s, 3H), 
1.52 (d, J = 7.0 Hz, 3H), 1.42 (s, 9H); 13C NMR (100 MHz, CDCl3) ppm 166.6, 155.0, 
141.6, 130.7, 130.4, 127.2, 85.6, 81.0, 57.4, 52.5, 28.4, 15.3; HRMS (CI): Exact mass 
calcd for C16H23N2O6 [M+H]+, 339.1556, found 339.1544. 
 
tert-butyl (1R,2S)-2-nitro-1-(2-nitrophenyl)propylcarbamate (169p). A solution of 
imine (50.0 mg, 200 µmol) and H,Quin-BAM•TfOH (10.4 mg, 20.1 µmol) in 
CH3CH2NO2 (0.8 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a colorless oil (40.4 mg, 62 %) and a 7:1 mixture of diastereomers , the major 
of which was determined to be 82% ee by chiral HPLC analysis (Chiralcel® OJ, 90:10 
hexanes:i-PrOH, 1 mL / min, tr(major) = 11.7 min, tr(minor) = 13.4 min); Rf = 0.43 (40% 
EtOAc/hexanes); IR (film) 3340, 2980, 1703, 1553 cm-1; 1H NMR (400 MHz, CDCl3) δ 
8.06 (d, J = 7.6 Hz, 1H), 7.63(dd, J = 7.6, 6.7 Hz, 1H), 7.49-7.53 (m 2H), 5.66-5.74 (m, 
2H), 5.24 (bs, 1H), 1.64 (d, J = 6.7 Hz, 3H), 1.40 (s, 9H); 13C NMR (100 MHz, CDCl3) 
140 
ppm 155.1, 148.4, 134.6, 132.2, 130.1, 129.7126.4, 84.6, 81.1, 56.4, 28.5, 16.4; HRMS 
(EI): Exact mass calcd for C14H20N3O6 [M+H]+, 326.1352, found 326.1357. 
 
tert-butyl (1R,2S)-2-nitro-1-(3-nitrophenyl)propylcarbamate (169q). A solution of 
imine (100.0 mg, 400 µmol) and H,Quin-BAM•TfOH (20.7 mg, 39.9 µmol) in 
CH3CH2NO2 (1.6 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a white solid (66.3 mg, 51 %) and a 11:1 mixture of diastereomers , the major 
of which was determined to be 89% ee by chiral HPLC analysis (Chiralcel® AD, 90:10 
hexanes:i-PrOH, 1 mL / min, tr(major) = 11.9 min, tr(minor) = 9.7 min); Mp = 146-148 
°C; Rf = 0.61 (40% EtOAc/hexanes); IR (film) 3369, 2985, 1683, 1517 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.20 (ddd, J = 7.8, 1.7, 1.6 Hz, 1H), 8.15 (s, 1H), 7.54-7.62 (m, 2H), 
5.52(bs, 1H), 5.30 (dd, J = 8.5, 8.5 Hz, 1H), 4.95 (bs, 1H), 1.58 (d, J = 6.8 Hz, 3H), 1.43 
(s, 9H); 13C NMR (100 MHz, CDCl3) ppm 154.9, 148.7, 148.6, 133.4, 130.3, 123.9, 
122.1, 85.5, 81.4, 57.0, 28.4, 15.5; HRMS (EI): Exact mass calcd for C14H19N3O6[M]+, 
325.1274, found 325.1269. 
 
tert-butyl (1R,2S)-2-nitro-1-(4-nitrophenyl)propylcarbamate (169r). A solution of 
imine (50.0 mg, 200 µmol) and H,Quin-BAM•TfOH (10.4 mg, 20.1 µmol) in 
CH3CH2NO2 (0.4 mL, 0.25M) was stirred at -20 °C. The solution was concentrated and 
purified by flash chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the 
product as a yellow oil (38.9 mg, 60 %) and a 7:1 mixture of diastereomers , the major of 
which was determined to be 90% ee by chiral HPLC analysis (Chiralcel® AD, 80:20 
hexanes:i-PrOH, 1 mL / min, tr(major) = 13.1 min, tr(minor) = 7.5 min); Rf = 0.60 (40% 
EtOAc/hexanes); IR (film) 3385, 2981, 2935, 1699, 1557 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.23 (d, J = 8.7 Hz, 2H), 7.44 (d, J = 8.7 Hz, 2H), 5.49 (bs, 1H), 5.27 (dd, J 
=7.1,6.2 Hz, 1H), 4.94 (bs, 1H), 1.55 (d, J = 6.7 Hz, 3H), 1.43 (s, 9H); 13C NMR (100 
141 
MHz, CDCl3) ppm 154.9, 148.3, 128.3, 124.4, 123.7, 85.4, 81.4, 57.2, 28.4, 18.3; HRMS 
(EI): Exact mass calcd for C14H20N3O6 [M+H]+, 326.1352, found 326.1351.  
 
tert-Butyl (1R,2S)-2-nitro-1-(3-nitrophenyl)butylcarbamate. A solution of imine (25.0 
mg, 100 µmol) and H,Quin-BAM·TfOH (5.2 mg, 10.0 µmol) in 1-nitropropane (0.4 mL, 
0.25 M) was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the product as a white 
solid (10.1 mg, 34%) and a 10:1 mixture of diastereomers; the major diastereomer was 
determined to be 89% ee by chiral HPLC analysis ([α]D25 -14.9 (c 1.0, acetone) (Chiralcel® 
AD, 95:5 hexanes:iPrOH, 1 mL/min, tr(major) = 19.1 min, tr(minor) = 17.7 min); mp = 
143-145 °C; Rf = 0.61 (40% EtOAc/hexanes); IR (film) 3370, 2979, 2935, 1683 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.20 (d, J = 7.7 Hz, 1H), 8.14 (s, 1H), 7.60-7.53 (m, 2H), 
5.30-5.25 (m, 2H), 4.76 (bs, 1H), 2.04-2.10 (m, 1H), 1.94-1.88 (m, 1H), 1.43 (s, 9H), 
1.02 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) ppm 154.8, 148.7, 144.1, 133.5, 
130.3, 124.0, 122.1, 92.7, 81.9, 56.4, 28.5, 23.7, 10.6; HRMS (ESI): Exact mass calcd for 
C15H21N3O6Na [M+Na]+ 362.1323. Found 362.1326. 
 
tert-Butyl (1R,2S)-2-nitro-1-(3-nitrophenyl)pentylcarbamate. A solution of imine 
(25.0 mg, 100 µmol) and H,Quin-BAM·TfOH (5.2 mg, 10.0 µmol) in 1-nitrobutane (0.4 
mL, 0.25 M) was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (SiO2, 20% ethyl acetate in hexanes) to furnish the product as a white 
solid (5.0 mg, 18%) and a 13:1 mixture of diastereomers; the major diastereomer was 
determined to be 90% ee by chiral HPLC analysis ([α]D25 -17.9 (c 1.0, acetone) (Chiralcel® 
AD, 90:10 hexanes:iPrOH, 1 mL/min, tr(major) = 8.6 min, tr(minor) = 7.8 min); mp = 
130-132 °C; Rf = 0.59 (40% EtOAc/hexanes); IR (film) 3328, 2970, 2934, 2877, 1702 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 7.9 Hz, 1H), 8.14 (s, 1H), 7.53-7.60 (m, 
2H), 5.30 (bs, 1H), 5.25 (bs, 1H), 4.84 (bs, 1H), 2.09-2.00 (m, 1H), 1.76-1.79 (m, 1H), 
1.56-1.31 (m, 2H), 1.43 (s, 9H), 0.95 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
142 
ppm 130.2, 123.9, 122.0, 90.9, 32.0, 28.4, 19.4, 13.6; HRMS (ESI): Exact mass calcd for 
C16H23N3O6Na [M+Na]+ 376.1479. Found 376.1480. 
 
tert-Butyl (R)-2-amino-1-phenylethylcarbamate. A solution of 1,2-diodoethane (137.6 
mg, 488 µmol) in THF (1 mL) was added dropwise to samarium powder (79.1 mg, 526 
µmol) in a flame-dried, argon purged round bottom flask. The suspension was stirred for 
an additional 2 h at room temperature resulting in a color change to a deep blue color. A 
solution of carbamate (20.0 mg, 75.1 µmol) in MeOH/H2O (1 mL, 1:1) was then added 
all at once. After 4 h, a solution of oxalic acid (133 mg) in H2O (2 mL) was added which 
immediately formed a brown precipitate. Filtration and addition of 1 M NaOH (1 mL), 
followed by extraction with ethyl acetate, drying (Na2SO4) and concentration gave the 
desired amine as a yellow oil (16.3 mg, 92%). The optical rotation [α]D25 -16.8 (c 0.6, 
CHCl3) is consistent with the (R)-enantiomer reported previously.162
 
(1R,2S)-1-Phenylpropane-1,2-diamine. A solution of 1,2-diodoethane (522.9 mg, 1.86 
mmol) in THF (3 mL) was added dropwise to samarium powder (300.4 mg, 2.0 mmol) in 
a flame-dried, argon purged round bottom flask. The suspension was stirred for an 
additional 2 h at room temperature resulting in a color change to a deep blue color. A 
solution of carbamate (80.0 mg, 285 µmol) in MeOH/H2O (3 mL, 1:1) was then added all 
at once. After 4 h, a solution of oxalic acid (400 mg) in H2O (2 mL) was added which 
immediately formed a brown precipitate. Filtration and addition of 1 M NaOH (4 mL) 
followed by extraction with ethyl acetate, drying (Na2SO4) and concentration gave the 
protected diamine as a yellow oil. To a solution of the diamine in CH2Cl2 at 0 °C was 
added TFA (0.2 mL) and the solution was allowed to warm to room temperature 
overnight. Addition of 1 M NaOH (5 ml) followed by extraction with CH2Cl2, drying of 
the organic phase, and concentration furnished the desired diamine as a yellow oil (12.7 
                                                 
162 O’Brien, P. M.; Sliskovic, D. R.; Blankley, C. J.; Roth, B. D.; Wilson, M. W.; Hamelehle, K. L.; Krause, 
B. R.; Stanfield, R. L. J. Med. Chem. 1994, 37, 1810-1822. 
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mg, 30% over two steps). The 
1
H NMR spectrum and optical rotation ([α]D25 +7.4 (c 1.0, 1 
M HCl)) were consistent with literature values.163
 
(R)-Benzyl 1-(4-chlorophenyl)-2-nitroethylcarbamate. A solution of imine (13.7 mg, 
50.0 µmol) and H,Quin-BAM·TfOH (2.6 mg, 5.0 µmol) in nitromethane (0.2 mL, 0.25 
M) was stirred at -20 °C for 12 days. The solution was concentrated and purified by flash 
chromatography (Al2O3, 20% ethyl acetate in hexanes) to furnish the carbamate as a 
yellow oil (11.4 mg, 68%), which was determined to be 62% ee by chiral HPLC analysis 
(Chiralcel® AD, 90:10 hexanes:iPrOH, 1 mL/min, tr(major) = 42.9 min, tr(minor) = 27.8 
min); Rf = 0.32 (20% EtOAc/hexanes); IR (film) 3319, 3036, 2960, 2922, 2856, 1707, 
1555, 1489, 1380, 1261, 1135, 1054, 825, 743, 694 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.38-7.33 (m, 7H), 7.27-7.25 (m, 2H), 5.68 (d, J = 6.4 Hz, 1H), 5.43 (dd, J = 6.4, 6.0 Hz, 
1H), 4.86 (s, 1H), 4.71 (dd, J = 13.2, 13.2 Hz, 1H), 3.74 (d, J = 14.0 Hz, 1H), 3.72 (d, J = 
14.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) ppm 155.6, 136.0, 135.1, 132.7, 131.1, 
129.7, 128.9, 128.5, 128.0, 78.6, 68.4, 52.8; HRMS (EI): Exact mass calcd for 
C16H15ClN2O4 [M+H]+ 335.0793. Found 335.0795.  
 
(R)-Benzyl 1-(4-chlorophenyl)-2-nitroethylcarbamate. A solution of imine (25.0 mg, 
96.0 µmol) and H,Quin-BAM·TfOH (5.0 mg, 10.0 µmol) in nitromethane (0.4 mL, 0.25 
M) was stirred at 25 °C for 4 days. The solution was concentrated and purified by flash 
chromatography (Al2O3, 20% ethyl acetate in hexanes) to furnish the sulfonamide as a 
white solid (9.7 mg, 31%), which was determined to be 57% ee by chiral HPLC analysis 
(Chiralcel® OD, 90:10 hexanes:iPrOH, 1 mL/min, tr(major) = 45.2 min, tr(minor) = 38.3 
min); Rf = 0.32 (20% EtOAc/hexanes); IR (film) 3243, 2355, 1555 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.85 (d, J = 8.2 Hz, 2H), 7.47-7.41 (m, 5H), 7.31-7.28 (m, 2H), 5.77 (d, J 
= 7.8 Hz, 1H), 5.20 (ddd, J = 6.7, 6.7, 6.7 Hz, 1H), 5.07-5.00 (m, 1H), 4.90-4.83 (m, 1H); 
                                                 
163 Gust, R.; Gelbcke, M.; Angermaier, B.; Bachmann, H.; Krauser, R; Schoneneberger, H. Inorganica 
Chimica Acta  1997, 264, 145-160. 
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13C NMR (100 MHz, CDCl3) ppm 144.3, 136.7, 135.5, 130.0, 129.4, 129.2, 127.4, 126.7, 
79.2, 55.7, 21.8; HRMS (EI): Exact mass calcd for C15H16N2O4S [M+H]+ 321.0904. 
Found 321.0903.  
 
(R)-N-Benzhydryl-1-(4-chlorophenyl)-2-nitroethanamine. A solution of imine (30.6 
mg, 100.0 µmol) and H,Quin-BAM·TfOH (5.2 mg, 10.0 µmol) in nitromethane (0.4 mL, 
0.25 M) was stirred at -20 °C. The solution was concentrated and purified by flash 
chromatography (Al2O3, 20% ethyl acetate in hexanes) to furnish the carbamate as a 
yellow oil (14.3 mg, 39%), which was determined to be 7% ee by chiral HPLC analysis 
(Chiralcel® AD, 90:10 hexanes:iPrOH, 1 mL/min, tr(major) = 6.1 min, tr(minor) = 7.1 
min); Rf = 0.36 (20% EtOAc/hexanes); IR (film) 3025, 2845, 1555, 1495, 1380, 1092, 
825, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 7.2 
Hz, 2H), 7.26 (m, 5H), 7.21 (d, J = 8.0 Hz, 1H), 4.60 (dd, J = 13.2, 12.0 Hz, 2H), 4.49 
(dd, J = 12.4, 12.0 Hz, 1H), 4.33 (dd, J = 9.6, 9.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
ppm 143.7, 141.9, 136.6, 129.7, 129.0, 128.8, 127.8, 127.3, 80.7, 63.8, 57.8; HRMS (EI): 
Exact mass calcd for C21H19ClN2O2 [M+H]+ 367.1208. Found 367.1200.  
 
Ethyl(3-methylbut-2-enyl)sulfane (245). To a suspension of NaH (426 mg, 18 mmol) in 
tetrahydrofuran (20 mL) at 0 °C was added ethanethiol (1.32 mL, 18 mmol) and the 
mixture was stirred until H2 evolution subsided (20-30 min). Neat 1-chloro-3-methyl-2-
butene (2.0 mL, 18 mmol) was then added dropwise to the solution of sodium mercaptan 
and the solution was warmed to room temperature over the course of 1 h. Dilution with 
water (~5 mL) and extraction with dichloromethane gave, after drying with Na2SO4 and 
concentration, a yellow liquid. Purification by distillation (67 °C at 20 mm Hg) furnished 
the product as a colorless liquid (1.1124g, 48%).164
                                                 
164 Piras, P.; Stirling, C. J. Chem. Soc. Perkin Trans. II 1987, 9, 1265. 
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Ethyl(3-methylbut-2-enyl)sulfane (247). To a solution of NCS (4.8 g, 36.1 mmol) in 
dichloromethane (180 mL) at -40 °C165 was added sulfide (5.6 mL, 36.1 mmol). After 15 
min indole (1.06 g, 9.0 mmol) was added all at once, resulting in the solution to change to 
a bright yellow color. The solution was slowly warmed to room temperature over the 
course of 1 h, then heated at 35 °C for an additional 1 h. Concentration and purification 
by flash chromatography (SiO2, 40% benzene in hexanes) furnished the product as a 
colorless oil (2.88 mg, 33%).
 
2-(2-Methylbut-3-en-2-yl)-1H-indole (248). To a solution of sulfide 247 (10 mg, 41 
µmol) in acetic acid was added zinc dust (50 mg, 760 µmol) and the suspension was 
heated to 120 °C for 25 h. Concentration and purification by flash chromatography (SiO2, 
5% ethyl acetate in hexanes) furnished the product as a yellow oil (4.2 mg, 56%).3 
 
N,N-Dimethyl(2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)methanamine (237). To a 
cooled (5 °C) solution of dimethylamine (275 µL of 40% aqueous solution, 2.2 mmol) in 
acetic acid (0.5 mL) was added formaldehyde (163 µL of 37% aqueous solution, 2.2 
mmol). The solution was swirled several times and added to a new argon-purged flask 
containing indole 248. The solution was stirred at room temperature overnight, then 
quenched with 3M NaOH (10 mL). Extraction with dichloromethane followed by drying 
with Na2SO4 and concentration gave the crude product as a brown oil (402.2 mg, 76%). 
166
  
                                                 
165 A temperature of -40 ºC during sulfide addition is crucial, as -30 ºC led to appreciably lower yields. 
166 Houghton, E.; Saxton, J. E. J. Chem. Soc. C 1969, 1003. 
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Pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester (249). To a solution of (S)-proline (1.0 
g, 8.7 mmol) in 2M NaOH (4.3 mL) at 0 °C was added simultaneously 
benzylchloroformate (976 µL, 8.7 mmol) and 2M NaOH (4.3 mL). The reaction was 
stirred at 0 °C for 3h, then allowed to warm to room temperature. After washing with 
diethyl ether (10 mL), the aqueous layer was acidified using 2 M HCl. Extraction with 
ethyl acetate (3 x 20 mL), drying with Na2SO4, and concentration gave the product as a 
colorless oil (1.48 g, 68%). No further purification was performed.167
 
2-[(1-Benzyloxycarbonyl-pyrrolidine-2-carbonyl)-amino]-malonic acid dimethyl 
ester (250). To a solution of the acid (2.17 g, 8.7 mmol) and 
dimethylaminomalonate·hydrochloride salt (1.60 g, 8.7 mmol) in dichloromethane (90 
mL) was added triethylamine (1.82 mL) and the solution was cooled to 0 °C for 30 m. 
EDC (2.0 g, 10.4 mmol) and DMAP (255 mg, 2.1 mmol) were then added all at once and 
the solution was allowed to warm to room temperature overnight. Dilution of the crude 
reaction mixture with dichloromethane, washing with water, drying (MgSO4), 
concentration and purification by flash chromatography (SiO2, 60% ethyl acetate in 
hexanes) furnished the malonic acid as a white solid (2.8 g, 85%); mp = 67-69 °C; Rf = 
0.50 (80% EtOAc/hexanes); IR (film) 3297, 2955, 2881, 1745, 1709, 1656, 1540 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.31-7.35 (m, 5H), 5.18-5.08 (m, 3H), 4.44-4.36 
(m, 1H), 3.78 (s, 6H), 3.59-3.44 (m, 2H), 2.33-1.88 (m, 4H); 13C NMR (100 MHz, 
CDCl3) ppm 171.9, 166.6, 156.1, 136.7, 128.6, 128.1, 127.9, 67.4, 60.4, 56.4, 53.5, 47.1, 
28.8, 24.6; HRMS (CI): Exact mass calcd for C18H22N2O7 [M]+ 378.1422. Found 
378.1412. 
                                                 
167 Corey, E. J.; Shibata, S.; Bakshi, R. K. J. Org. Chem. 1988, 53, 2861. 
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1,4-Dioxo-octahydro-pyrrolo[1,2-a]pyrazine-3-carboxylic acid methyl ester (236). To 
a solution of 250 (100 mg, 0.26 mmol) in methanol (14 mL) was added 10% Pd/C (60 
mg). The flask was purged with H2 and the mixture was stirred at 70 °C under an 
atomosphere of H2 for 3h. The product was filtered throught celite, quenched with sat. 
NaHCO3 and extracted with chloroform. Drying with Na2SO4 and concentration gave a 
yellow oil which was dissolved in toluene and stirred with 2-hydroxypyridine (cat. amt.) 
at 100 °C. Concentration and purification by flash chromatography (SiO2, 80% ethyl 
acetate in hexanes) furnished the product as a colorless oil (17.6 mg, 31%).168
 
(S)-Methyl 3-((2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)methyl)-1,4-dioxo-
octahydropyrrolo[1,2-a]pyrazine-3-carboxylate (251). To a solution of indole 237 
(402.2 mg, 2.2 mmol) and piperazinedione 236 (460.6 mg, 2.2 mmol) in acetonitrile (10 
mL) was added tri-n-butyl phosphine (541 µL). The solution was heated to 80 °C for 20h, 
then concentrated, taken up in 0.5M HCl, and extracted with dichloromethane. Drying 
with Na2SO4 followed by concentration and purification by flash chromatography (SiO2, 
60% ethyl acetate in hexanes) furnished the product as an off-white solid and a 2:1 
mixture of diastereomers (127.5 mg, 22%).2     
 
                                                 
168 Kardassis, G.; Brungs, P.; Steckhan, E. Tetrahedron 1998, 54, 3471. 
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epi-Deoxybrevianamide E (205). To a solution of 251 (118 mg, 0.29 mmol) in methanol 
(1 mL) was added 3M NaOH (143 µL, 0.43 mmol). The solution was stirred at room 
temperature for 2 days, then concentrated and several drops of 3M HCl added, which 
afforded a white precipitate. Extraction with dichloromethane, drying with Na2SO4 and 
concentration gave the product as a colorless oil which was taken up in dioxane (1 mL) 
and heated at 75 °C for 6 h. Concentration of the reaction mixture furnished the crude 
product as an oil (96 mg, 95%) and a 9:1 mixture of diastereomers.169
 
(3R,8aS)-1-Methoxy-3-((2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)methyl)-6,7,8,8a-
tetrahydropyrrolo[1,2-a]pyrazin-4(3H)-one (222). A solution of 205 (134.4 mg, 380 
µmol) in dichloromethane (3 mL) was stirred at 0 °C for 10 m. Me3OBF4 (169.8 mg, 1.2 
mmol) was then added and the suspension was stirred at 0 °C for 12 h. The crude product 
was partitioned between dichloromethane and aq. NaHCO3 and extracted with 
dichloromethane. Drying with Na2SO4, concentration, and purification by pipette column 
(SiO2. ethyl acetate) furnished the product as a yellow oil (40.5 mg, 55%).1b 
(S)-1-Methoxy-3-((2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)methyl)-6,7-
dihydropyrrolo[1,2-a]pyrazin-4(3H)-one (223). To a solution of 222 (75.6 mg, 210 
µmol) in toluene (5 mL) at -78 °C was added a solution of DDQ (57.1 mg, 250 µmol) in 
toluene (2 mL). The solution was stirred at -78 °C for 8 h, then was allowed to warm to 
room temperature overnight, followed by heating at 95 °C for 3 h. Concentration and 
purification by pipette column (SiO2, 25% ethyl acetate in dichloromethane) furnished 
the product as a yellow oil (26.1 mg, 34%).1b 
                                                 
169 Ritchie, R.; Saxton, J. E.; Tetrahedron 1981, 37, 4295. 
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225. To a solution of amidate 223 (3.0 mg, 7 µmol) in methanol (0.5 mL) at 0 ºC was 
added 20% aqueous KOH (125 µL). The solution was stirred at 0 ºC for 30 min, then 
warmed to room temperature for an additional 30 min, monitoring by TLC to confirm 
consumption of amidate. The solution was concentrated, extracted with dichloromethane 
and the organic layers dried (Na2SO4) to give crude azadiene in solution. H,3-Quin-
BAM·HOTf (4.3 mg, 7 µmol) was added and the solution was concentrated to remove all 
traces of solvent. The neat reaction mixture was allowed to stand at room temperature 
until the azadiene was fully consumed as determined by 1H NMR. (~48 h) The product 
was then quenched with 1 M NaOH, extracted with dichloromethane and dried (Na2SO4). 
Concentration gave a 2.1:1 mixture of two diastereomers that were purified, but not 
separated, by flash chromatography (SiO2, 20% ethyl acetate in dichloromethane); the 
major diastereomer was determined to be 35% ee by chiral HPLC analysis (Chiralcel® 
OD-H, 80:20 hexanes:iPrOH, 1 mL/min, tr(d1e1) = 9.6 min, tr(d1e2) = 18.0 min). 
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Appendix 2 
 
Figure 39. Numbering System for 118c 
 
 
Note: Data were collected on a Bruker SMART 6000 sealed-tube system comprising a  
three-circle platform goniostat, an HOG crystal monochromator, a four kilopixel by four 
kilopixel single-chip CCD-based detector, a K761 high voltage generator, and a PC 
interface running Bruker's SMART software. 
 
Table 28. Fractional Coordinates and Isotropic Thermal Parameters for 118c 
          Atom           x             y             z           Uiso  
   
          S(1)         1000(1)       2352(1)      -2688(1)       28(1)  
          O(1)         2036(3)       1739(1)      -2701(2)       36(1)  
          O(2)         1357(3)       2961(1)      -1935(2)       35(1)  
          O(3)          452(3)       2594(2)      -3716(2)       51(1)  
          C(19)        -451(4)       1858(2)      -2094(3)       35(1)  
          F(1)         -821(2)       1225(1)      -2663(2)       50(1)  
          F(2)         -144(3)       1632(2)      -1100(2)       55(1)  
          F(3)        -1577(2)       2310(2)      -2076(2)       58(1)  
          S(2)         4531(1)       -327(1)       8104(1)       25(1)  
          O(4)         4102(3)       -909(1)       7324(2)       35(1)  
          O(5)         4894(3)       -596(2)       9162(2)       38(1)  
          O(6)         3656(3)        361(1)       8085(2)       33(1)  
          C(20)        6156(4)         29(2)       7613(3)       31(1)  
          F(4)         6016(3)        261(1)       6604(2)       49(1)  
          F(5)         6635(2)        632(1)       8199(2)       50(1)  
          F(6)         7142(2)       -522(1)       7665(2)       46(1)  
          N(1A)        2245(3)        402(2)        281(2)       27(1)  
          N(2A)        3338(3)       1519(2)       -248(2)       24(1)  
          N(3A)        -761(3)       -338(2)       1765(2)       28(1)  
154 
          N(4A)        -454(3)        782(2)       2780(2)       28(1)  
          C(1A)        1508(3)        -83(2)       1032(3)       23(1)  
          C(2A)         -84(3)          8(2)        864(2)       22(1)  
          C(3A)        -593(4)       -351(2)       -198(3)       30(1)  
          C(4A)        -127(4)      -1193(2)       -340(3)       32(1)  
          C(5A)        1441(4)      -1268(2)       -180(3)       32(1)  
          C(6A)        1940(4)       -926(2)        906(3)       30(1)  
          C(7A)        2523(3)       1162(2)        457(3)       23(1)  
          C(8A)        2016(3)       1599(2)       1299(3)       24(1)  
          C(9A)        2436(3)       2356(2)       1395(3)       25(1)  
          C(10A)       3328(4)       2703(2)        676(3)       29(1)  
          C(11A)       3766(3)       2277(2)       -154(3)       26(1)  
          C(12A)       4687(4)       2561(2)       -991(3)       36(1)  
          C(13A)       -921(3)         49(2)       2705(3)       22(1)  
          C(14A)      -1574(3)       -313(2)       3552(3)       28(1)  
          C(15A)      -1792(4)        103(2)       4462(3)       32(1)  
          C(16A)      -1345(4)        876(2)       4527(3)       32(1)  
          C(17A)       -688(4)       1187(2)       3679(3)       30(1)  
          C(18A)       -167(4)       2014(2)       3691(3)       42(1)  
          N(1B)        3733(3)       1347(2)       5499(2)       25(1)  
          N(2B)        2190(3)        373(2)       5893(2)       23(1)  
          N(3B)        5294(3)       2414(2)       3258(2)       30(1)  
          N(4B)        5375(3)       1176(2)       2533(2)       25(1)  
          C(1B)        4843(3)       1706(2)       4906(3)       24(1)  
          C(2B)        4218(3)       2204(2)       3975(2)       24(1)  
          C(3B)        3522(4)       2940(2)       4397(3)       27(1)  
          C(4B)        4511(4)       3409(2)       5137(3)       31(1)  
          C(5B)        5043(4)       2919(2)       6083(3)       31(1)  
          C(6B)        5777(3)       2189(2)       5673(3)       28(1)  
          C(7B)        3082(3)        681(2)       5206(3)       22(1)  
          C(8B)        3276(3)        286(2)       4242(3)       25(1)  
          C(9B)        2550(3)       -389(2)       4059(3)       27(1)  
          C(10B)       1653(4)       -696(2)       4789(3)       30(1)  
          C(11B)       1480(3)       -311(2)       5718(3)       28(1)  
          C(12B)        592(4)       -572(2)       6592(3)       39(1)  
          C(13B)       5779(4)       1928(2)       2488(3)       24(1)  
          C(14B)       6658(4)       2205(2)       1723(3)       30(1)  
          C(15B)       7087(4)       1699(2)        955(3)       34(1)  
          C(16B)       6646(4)        933(2)        968(3)       29(1)  
          C(17B)       5830(3)        692(2)       1771(3)       25(1)  
          C(18B)       5383(4)       -140(2)       1867(3)       32(1)  
   
          H(1NA)        267(4)         19(2)        -35(3)       41(11)  
          H(2NA)        354(4)        121(2)        -79(3)       24(9)  
          H(3NA)        -93(4)        -83(2)        172(3)       29(10)  
          H(1A)         178             9           178           5(7)  
          H(2A)         -31            57            85          14(8)  
          H(3A)         -25            -4           -79          25(9)  
          H(3B)        -162           -33           -25          15(8)  
          H(4A)         -58          -153            18          37(10)  
          H(4B)         -42          -137          -107          29(10)  
          H(5A)         190           -99           -76          28(9)  
          H(5B)         171          -182           -21          59(13)  
          H(6A)         155          -124           149          41(11)  
          H(6B)         297           -96            98          16(8)  
          H(8A)         140           138           179          29(9)  
          H(9A)         211           266           197          21(8)  
          H(10A)        362           323            77          41(11)  
          H(12A)        495           310           -84         110(20)  
          H(12B)        419           253          -169         110(20)  
          H(12C)        552           224          -100         110(20)  
          H(14A)       -186           -84           350          12(8)  
          H(15A)       -224           -13           504          48(12)  
155 
          H(16A)       -150           118           515          61(13)  
          H(18A)         84           202           360          89(18)  
          H(18B)        -37           226           437          62(13)  
          H(18C)        -64           230           310          62(14)  
          H(1NB)        353(4)        151(2)        611(3)       29(10)  
          H(2NB)        210(3)         57(2)        647(3)       17(9)  
          H(3NB)        545(3)        281(2)        318(2)        5(8)  
          H(1BA)        542           129           460          22(9)  
          H(2BA)        350           189           357          34(10)  
          H(3BA)        320           327           378          37(10)  
          H(3BB)        270           279           479          29(9)  
          H(4C)         531           359           473          41(11)  
          H(4D)         402           387           540          24(9)  
          H(5C)         426           276           652          29(9)  
          H(5D)         570           323           654          39(11)  
          H(6C)         662           235           530          23(8)  
          H(6D)         608           186           629          36(10)  
          H(8B)         389            48           373          15(8)  
          H(9B)         266           -66           341          21(8)  
          H(10B)        117          -117           464          30(9)  
          H(12D)         -6           -16           676          71(16)  
          H(12E)        118           -69           723          76(16)  
          H(12F)          7          -104           636          40(11)  
          H(14B)        695           273           173          70(15)  
          H(15B)        768           187            42          40(11)  
          H(16B)        691            58            43          17(8)  
          H(18D)        558           -42           121          49(12)  
          H(18E)        438           -16           198          38(11)  
          H(18F)        590           -38           248          37(10)  
   
          Notes:  
            1) Fractional coordinates are X 10**4 for non-hydrogen 
atoms and X 10**3 for hydrogen atoms.  Uiso values are all 
X 10**3.  
            2) Isotropic values for those atoms refined anisotropically  
            are calculated as one third of the trace of the  
orthogonalized  
            Uij tensor.  
            3) Parameters without standard deviations were not varied.  
 
 
Table 29. Anisotropic Thermal Parameters for 118c 
    Atom      U11        U22        U33        U23        U13        U12  
   
    S(1)     35(1)      22(1)      27(1)      -1(1)       5(1)       0(1)  
    O(1)     38(2)      26(1)      45(2)      -5(1)      11(1)       2(1)  
    O(2)     41(2)      21(1)      42(2)      -6(1)       0(1)       2(1)  
    O(3)     76(2)      46(2)      31(2)       8(1)      -9(1)      -7(2)  
    C(19)    33(2)      36(2)      36(2)      -3(2)       8(2)      -3(2)  
    F(1)     50(1)      35(1)      66(2)     -14(1)      12(1)     -15(1)  
    F(2)     62(2)      59(2)      44(1)      14(1)      17(1)      -6(1)  
    F(3)     31(1)      48(1)      95(2)     -14(1)      13(1)       7(1)  
    S(2)     26(1)      20(1)      28(1)      -2(1)       5(1)       2(1)  
    O(4)     35(1)      22(1)      46(2)     -10(1)       3(1)      -1(1)  
    O(5)     51(2)      31(1)      33(1)       6(1)       8(1)       4(1)  
    O(6)     34(1)      29(1)      37(1)      -9(1)       1(1)      12(1)  
    C(20)    35(2)      27(2)      33(2)      -1(2)       7(2)       2(2)  
    F(4)     58(2)      55(2)      37(1)      11(1)      17(1)      -2(1)  
    F(5)     46(1)      41(1)      62(2)     -12(1)      11(1)     -21(1)  
156 
    F(6)     29(1)      51(2)      57(1)      -5(1)       3(1)      12(1)  
    N(1A)    32(2)      19(1)      32(2)      -6(1)      14(1)      -6(1)  
    N(2A)    26(2)      17(1)      29(2)      -3(1)       1(1)      -2(1)  
    N(3A)    32(2)      23(2)      28(2)      -4(1)       9(1)      -6(1)  
    N(4A)    28(2)      28(2)      27(2)      -6(1)       3(1)      -2(1)  
    C(1A)    26(2)      17(2)      28(2)      -3(1)       7(2)      -2(1)  
    C(2A)    26(2)      18(2)      23(2)      -5(1)       3(1)      -1(1)  
    C(3A)    26(2)      31(2)      33(2)      -2(2)       0(2)      -3(2)  
    C(4A)    39(2)      27(2)      29(2)      -8(2)       8(2)     -11(2)  
    C(5A)    35(2)      19(2)      42(2)     -11(2)      15(2)      -4(2)  
    C(6A)    27(2)      17(2)      45(2)      -1(2)       2(2)       2(1)  
    C(7A)    20(2)      20(2)      29(2)       2(1)       0(1)      -3(1)  
    C(8A)    20(2)      25(2)      26(2)       0(1)       3(1)       3(1)  
    C(9A)    32(2)      17(2)      27(2)      -3(1)      -2(1)       3(2)  
    C(10A)   34(2)      21(2)      32(2)       1(2)      -3(2)       0(2)  
    C(11A)   24(2)      23(2)      31(2)       3(2)      -2(1)      -4(2)  
    C(12A)   40(2)      29(2)      39(2)       9(2)       2(2)      -9(2)  
    C(13A)   19(2)      25(2)      22(2)      -2(1)       1(1)       1(1)  
    C(14A)   22(2)      30(2)      31(2)      -2(2)       2(1)       1(2)  
    C(15A)   25(2)      42(2)      29(2)       3(2)       1(2)       1(2)  
    C(16A)   28(2)      43(2)      25(2)     -11(2)       1(2)       2(2)  
    C(17A)   24(2)      35(2)      30(2)      -7(2)      -3(2)       3(2)  
    C(18A)   46(2)      36(2)      45(2)     -15(2)       5(2)      -9(2)  
    N(1B)    32(2)      22(2)      21(2)       1(1)       7(1)      -2(1)  
    N(2B)    25(2)      21(1)      21(2)      -2(1)       3(1)      -2(1)  
    N(3B)    44(2)      14(2)      34(2)       4(1)      14(1)      -2(1)  
    N(4B)    26(2)      24(1)      26(2)       0(1)       3(1)       1(1)  
    C(1B)    26(2)      24(2)      24(2)       3(1)       6(1)      -2(1)  
    C(2B)    26(2)      21(2)      25(2)      -1(1)       4(1)       2(1)  
    C(3B)    32(2)      19(2)      31(2)       1(1)      10(2)       2(2)  
    C(4B)    36(2)      22(2)      36(2)      -6(2)      12(2)      -1(2)  
    C(5B)    35(2)      29(2)      30(2)      -3(2)       5(2)     -13(2)  
    C(6B)    26(2)      28(2)      31(2)       4(2)       0(2)      -8(2)  
    C(7B)    20(2)      20(2)      25(2)       3(1)      -1(1)       5(1)  
    C(8B)    28(2)      23(2)      25(2)       1(1)       3(2)       2(2)  
    C(9B)    32(2)      20(2)      28(2)      -3(1)      -2(1)       7(2)  
    C(10B)   29(2)      19(2)      41(2)      -3(2)      -4(2)      -2(2)  
    C(11B)   23(2)      25(2)      34(2)       5(2)      -2(1)      -2(2)  
    C(12B)   37(2)      31(2)      49(2)       1(2)      10(2)     -13(2)  
    C(13B)   26(2)      26(2)      21(2)       1(1)       4(1)       4(1)  
    C(14B)   34(2)      28(2)      29(2)       5(2)       7(2)       2(2)  
    C(15B)   32(2)      37(2)      32(2)       7(2)      13(2)       8(2)  
    C(16B)   26(2)      30(2)      32(2)      -3(2)       4(2)       9(2)  
    C(17B)   19(2)      30(2)      25(2)      -4(1)      -2(1)       5(1)  
    C(18B)   31(2)      30(2)      34(2)      -8(2)       1(2)      -6(2)  
   
    Form of the anisotropic thermal parameter:  
       exp{ -2 pi**2 [ h**2 (a*)**2 U11 + ... + 2 h k (a*) (b*) U12 ] }  
    All values are X 10**3  
 
 
Table 30. Bond distances for 118c 
           A            B            Distance  
   
           S(1)         O(3)         1.429(3)  
           S(1)         O(2)         1.442(2)  
           S(1)         O(1)         1.453(3)  
           S(1)         C(19)        1.824(4)  
           C(19)        F(2)         1.323(4)  
           C(19)        F(3)         1.336(4)  
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           C(19)        F(1)         1.341(4)  
           S(2)         O(5)         1.430(3)  
           S(2)         O(4)         1.445(3)  
           S(2)         O(6)         1.454(2)  
           S(2)         C(20)        1.814(4)  
           C(20)        F(4)         1.326(4)  
           C(20)        F(6)         1.341(4)  
           C(20)        F(5)         1.342(4)  
           N(1A)        C(7A)        1.353(4)  
           N(1A)        C(1A)        1.465(4)  
           N(1A)        H(1NA)       0.98(4)  
           N(2A)        C(7A)        1.357(4)  
           N(2A)        C(11A)       1.373(4)  
           N(2A)        H(2NA)       0.90(4)  
           N(3A)        C(13A)       1.367(4)  
           N(3A)        C(2A)        1.456(4)  
           N(3A)        H(3NA)       0.86(4)  
           N(4A)        C(13A)       1.343(4)  
           N(4A)        C(17A)       1.352(4)  
           C(1A)        C(6A)        1.522(4)  
           C(1A)        C(2A)        1.544(5)  
           C(1A)        H(1A)        1.0000  
           C(2A)        C(3A)        1.526(4)  
           C(2A)        H(2A)        1.0000  
           C(3A)        C(4A)        1.532(5)  
           C(3A)        H(3A)        0.9900  
           C(3A)        H(3B)        0.9900  
           C(4A)        C(5A)        1.518(5)  
           C(4A)        H(4A)        0.9900  
           C(4A)        H(4B)        0.9900  
           C(5A)        C(6A)        1.538(5)  
           C(5A)        H(5A)        0.9900  
           C(5A)        H(5B)        0.9900  
           C(6A)        H(6A)        0.9900  
           C(6A)        H(6B)        0.9900  
           C(7A)        C(8A)        1.401(4)  
           C(8A)        C(9A)        1.371(5)  
           C(8A)        H(8A)        0.9500  
           C(9A)        C(10A)       1.406(5)  
           C(9A)        H(9A)        0.9500  
           C(10A)       C(11A)       1.356(5)  
           C(10A)       H(10A)       0.9500  
           C(11A)       C(12A)       1.486(5)  
           C(12A)       H(12A)       0.9800  
           C(12A)       H(12B)       0.9800  
           C(12A)       H(12C)       0.9800  
           C(13A)       C(14A)       1.404(5)  
           C(14A)       C(15A)       1.369(5)  
           C(14A)       H(14A)       0.9500  
           C(15A)       C(16A)       1.402(5)  
           C(15A)       H(15A)       0.9500  
           C(16A)       C(17A)       1.370(5)  
           C(16A)       H(16A)       0.9500  
           C(17A)       C(18A)       1.511(5)  
           C(18A)       H(18A)       0.9800  
           C(18A)       H(18B)       0.9800  
           C(18A)       H(18C)       0.9800  
           N(1B)        C(7B)        1.351(4)  
           N(1B)        C(1B)        1.466(4)  
           N(1B)        H(1NB)       0.84(4)  
           N(2B)        C(7B)        1.352(4)  
           N(2B)        C(11B)       1.376(4)  
           N(2B)        H(2NB)       0.80(3)  
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           N(3B)        C(13B)       1.374(4)  
           N(3B)        C(2B)        1.447(4)  
           N(3B)        H(3NB)       0.70(3)  
           N(4B)        C(17B)       1.354(4)  
           N(4B)        C(13B)       1.356(4)  
           C(1B)        C(6B)        1.530(5)  
           C(1B)        C(2B)        1.547(4)  
           C(1B)        H(1BA)       1.0000  
           C(2B)        C(3B)        1.539(4)  
           C(2B)        H(2BA)       1.0000  
           C(3B)        C(4B)        1.528(5)  
           C(3B)        H(3BA)       0.9900  
           C(3B)        H(3BB)       0.9900  
           C(4B)        C(5B)        1.523(5)  
           C(4B)        H(4C)        0.9900  
           C(4B)        H(4D)        0.9900  
           C(5B)        C(6B)        1.542(5)  
           C(5B)        H(5C)        0.9900  
           C(5B)        H(5D)        0.9900  
           C(6B)        H(6C)        0.9900  
           C(6B)        H(6D)        0.9900  
           C(7B)        C(8B)        1.405(4)  
           C(8B)        C(9B)        1.371(5)  
           C(8B)        H(8B)        0.9500  
           C(9B)        C(10B)       1.391(5)  
           C(9B)        H(9B)        0.9500  
           C(10B)       C(11B)       1.355(5)  
           C(10B)       H(10B)       0.9500  
           C(11B)       C(12B)       1.489(5)  
           C(12B)       H(12D)       0.9800  
           C(12B)       H(12E)       0.9800  
           C(12B)       H(12F)       0.9800  
           C(13B)       C(14B)       1.392(5)  
           C(14B)       C(15B)       1.376(5)  
           C(14B)       H(14B)       0.9500  
           C(15B)       C(16B)       1.387(5)  
           C(15B)       H(15B)       0.9500  
           C(16B)       C(17B)       1.369(5)  
           C(16B)       H(16B)       0.9500  
           C(17B)       C(18B)       1.505(5)  
           C(18B)       H(18D)       0.9800  
           C(18B)       H(18E)       0.9800  
           C(18B)       H(18F)       0.9800  
 
 
Table 31. Bond Angles for 118c 
           A            B            C            Angle  
   
           O(3)         S(1)         O(2)         116.22(17)  
           O(3)         S(1)         O(1)         115.22(16)  
           O(2)         S(1)         O(1)         113.21(15)  
           O(3)         S(1)         C(19)        104.26(18)  
           O(2)         S(1)         C(19)        103.74(16)  
           O(1)         S(1)         C(19)        101.82(16)  
           F(2)         C(19)        F(3)         107.6(3)  
           F(2)         C(19)        F(1)         107.6(3)  
           F(3)         C(19)        F(1)         106.7(3)  
           F(2)         C(19)        S(1)         112.2(3)  
           F(3)         C(19)        S(1)         111.8(3)  
           F(1)         C(19)        S(1)         110.6(3)  
           O(5)         S(2)         O(4)         116.69(16)  
           O(5)         S(2)         O(6)         113.28(15)  
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           O(4)         S(2)         O(6)         114.09(15)  
           O(5)         S(2)         C(20)        104.22(17)  
           O(4)         S(2)         C(20)        103.27(16)  
           O(6)         S(2)         C(20)        103.13(16)  
           F(4)         C(20)        F(6)         107.5(3)  
           F(4)         C(20)        F(5)         107.6(3)  
           F(6)         C(20)        F(5)         107.3(3)  
           F(4)         C(20)        S(2)         111.9(3)  
           F(6)         C(20)        S(2)         111.3(2)  
           F(5)         C(20)        S(2)         110.9(2)  
           C(7A)        N(1A)        C(1A)        123.0(3)  
           C(7A)        N(1A)        H(1NA)       114(2)  
           C(1A)        N(1A)        H(1NA)       123(2)  
           C(7A)        N(2A)        C(11A)       123.9(3)  
           C(7A)        N(2A)        H(2NA)       112(2)  
           C(11A)       N(2A)        H(2NA)       124(2)  
           C(13A)       N(3A)        C(2A)        122.6(3)  
           C(13A)       N(3A)        H(3NA)       120(2)  
           C(2A)        N(3A)        H(3NA)       116(2)  
           C(13A)       N(4A)        C(17A)       118.4(3)  
           N(1A)        C(1A)        C(6A)        109.6(3)  
           N(1A)        C(1A)        C(2A)        111.3(3)  
           C(6A)        C(1A)        C(2A)        110.9(3)  
           N(1A)        C(1A)        H(1A)        108.3  
           C(6A)        C(1A)        H(1A)        108.3  
           C(2A)        C(1A)        H(1A)        108.3  
           N(3A)        C(2A)        C(3A)        111.8(3)  
           N(3A)        C(2A)        C(1A)        109.3(3)  
           C(3A)        C(2A)        C(1A)        110.7(3)  
           N(3A)        C(2A)        H(2A)        108.3  
           C(3A)        C(2A)        H(2A)        108.3  
           C(1A)        C(2A)        H(2A)        108.3  
           C(2A)        C(3A)        C(4A)        113.7(3)  
           C(2A)        C(3A)        H(3A)        108.8  
           C(4A)        C(3A)        H(3A)        108.8  
           C(2A)        C(3A)        H(3B)        108.8  
           C(4A)        C(3A)        H(3B)        108.8  
           H(3A)        C(3A)        H(3B)        107.7  
           C(5A)        C(4A)        C(3A)        111.1(3)  
           C(5A)        C(4A)        H(4A)        109.4  
           C(3A)        C(4A)        H(4A)        109.4  
           C(5A)        C(4A)        H(4B)        109.4  
           C(3A)        C(4A)        H(4B)        109.4  
           H(4A)        C(4A)        H(4B)        108.0  
           C(4A)        C(5A)        C(6A)        110.6(3)  
           C(4A)        C(5A)        H(5A)        109.5  
           C(6A)        C(5A)        H(5A)        109.5  
           C(4A)        C(5A)        H(5B)        109.5  
           C(6A)        C(5A)        H(5B)        109.5  
           H(5A)        C(5A)        H(5B)        108.1  
           C(1A)        C(6A)        C(5A)        112.5(3)  
           C(1A)        C(6A)        H(6A)        109.1  
           C(5A)        C(6A)        H(6A)        109.1  
           C(1A)        C(6A)        H(6B)        109.1  
           C(5A)        C(6A)        H(6B)        109.1  
           H(6A)        C(6A)        H(6B)        107.8  
           N(1A)        C(7A)        N(2A)        116.7(3)  
           N(1A)        C(7A)        C(8A)        124.8(3)  
           N(2A)        C(7A)        C(8A)        118.5(3)  
           C(9A)        C(8A)        C(7A)        117.8(3)  
           C(9A)        C(8A)        H(8A)        121.1  
           C(7A)        C(8A)        H(8A)        121.1  
           C(8A)        C(9A)        C(10A)       122.4(3)  
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           C(8A)        C(9A)        H(9A)        118.8  
           C(10A)       C(9A)        H(9A)        118.8  
           C(11A)       C(10A)       C(9A)        118.8(3)  
           C(11A)       C(10A)       H(10A)       120.6  
           C(9A)        C(10A)       H(10A)       120.6  
           C(10A)       C(11A)       N(2A)        118.5(3)  
           C(10A)       C(11A)       C(12A)       125.4(3)  
           N(2A)        C(11A)       C(12A)       116.1(3)  
           C(11A)       C(12A)       H(12A)       109.5  
           C(11A)       C(12A)       H(12B)       109.5  
           H(12A)       C(12A)       H(12B)       109.5  
           C(11A)       C(12A)       H(12C)       109.5  
           H(12A)       C(12A)       H(12C)       109.5  
           H(12B)       C(12A)       H(12C)       109.5  
           N(4A)        C(13A)       N(3A)        117.9(3)  
           N(4A)        C(13A)       C(14A)       121.7(3)  
           N(3A)        C(13A)       C(14A)       120.3(3)  
           C(15A)       C(14A)       C(13A)       119.1(3)  
           C(15A)       C(14A)       H(14A)       120.5  
           C(13A)       C(14A)       H(14A)       120.5  
           C(14A)       C(15A)       C(16A)       119.2(3)  
           C(14A)       C(15A)       H(15A)       120.4  
           C(16A)       C(15A)       H(15A)       120.4  
           C(17A)       C(16A)       C(15A)       118.6(3)  
           C(17A)       C(16A)       H(16A)       120.7  
           C(15A)       C(16A)       H(16A)       120.7  
           N(4A)        C(17A)       C(16A)       122.9(3)  
           N(4A)        C(17A)       C(18A)       115.3(3)  
           C(16A)       C(17A)       C(18A)       121.9(3)  
           C(17A)       C(18A)       H(18A)       109.5  
           C(17A)       C(18A)       H(18B)       109.5  
           H(18A)       C(18A)       H(18B)       109.5  
           C(17A)       C(18A)       H(18C)       109.5  
           H(18A)       C(18A)       H(18C)       109.5  
           H(18B)       C(18A)       H(18C)       109.5  
           C(7B)        N(1B)        C(1B)        124.2(3)  
           C(7B)        N(1B)        H(1NB)       114(3)  
           C(1B)        N(1B)        H(1NB)       122(3)  
           C(7B)        N(2B)        C(11B)       124.2(3)  
           C(7B)        N(2B)        H(2NB)       120(2)  
           C(11B)       N(2B)        H(2NB)       116(2)  
           C(13B)       N(3B)        C(2B)        124.0(3)  
           C(13B)       N(3B)        H(3NB)       114(3)  
           C(2B)        N(3B)        H(3NB)       119(3)  
           C(17B)       N(4B)        C(13B)       117.2(3)  
           N(1B)        C(1B)        C(6B)        109.5(3)  
           N(1B)        C(1B)        C(2B)        110.4(3)  
           C(6B)        C(1B)        C(2B)        111.5(3)  
           N(1B)        C(1B)        H(1BA)       108.5  
           C(6B)        C(1B)        H(1BA)       108.5  
           C(2B)        C(1B)        H(1BA)       108.5  
           N(3B)        C(2B)        C(3B)        110.1(3)  
           N(3B)        C(2B)        C(1B)        110.0(3)  
           C(3B)        C(2B)        C(1B)        111.1(3)  
           N(3B)        C(2B)        H(2BA)       108.6  
           C(3B)        C(2B)        H(2BA)       108.6  
           C(1B)        C(2B)        H(2BA)       108.6  
           C(4B)        C(3B)        C(2B)        112.0(3)  
           C(4B)        C(3B)        H(3BA)       109.2  
           C(2B)        C(3B)        H(3BA)       109.2  
           C(4B)        C(3B)        H(3BB)       109.2  
           C(2B)        C(3B)        H(3BB)       109.2  
           H(3BA)       C(3B)        H(3BB)       107.9  
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           C(5B)        C(4B)        C(3B)        110.8(3)  
           C(5B)        C(4B)        H(4C)        109.5  
           C(3B)        C(4B)        H(4C)        109.5  
           C(5B)        C(4B)        H(4D)        109.5  
           C(3B)        C(4B)        H(4D)        109.5  
           H(4C)        C(4B)        H(4D)        108.1  
           C(4B)        C(5B)        C(6B)        109.7(3)  
           C(4B)        C(5B)        H(5C)        109.7  
           C(6B)        C(5B)        H(5C)        109.7  
           C(4B)        C(5B)        H(5D)        109.7  
           C(6B)        C(5B)        H(5D)        109.7  
           H(5C)        C(5B)        H(5D)        108.2  
           C(1B)        C(6B)        C(5B)        112.8(3)  
           C(1B)        C(6B)        H(6C)        109.0  
           C(5B)        C(6B)        H(6C)        109.0  
           C(1B)        C(6B)        H(6D)        109.0  
           C(5B)        C(6B)        H(6D)        109.0  
           H(6C)        C(6B)        H(6D)        107.8  
           N(1B)        C(7B)        N(2B)        117.5(3)  
           N(1B)        C(7B)        C(8B)        124.5(3)  
           N(2B)        C(7B)        C(8B)        118.0(3)  
           C(9B)        C(8B)        C(7B)        117.9(3)  
           C(9B)        C(8B)        H(8B)        121.1  
           C(7B)        C(8B)        H(8B)        121.1  
           C(8B)        C(9B)        C(10B)       122.7(3)  
           C(8B)        C(9B)        H(9B)        118.7  
           C(10B)       C(9B)        H(9B)        118.7  
           C(11B)       C(10B)       C(9B)        118.9(3)  
           C(11B)       C(10B)       H(10B)       120.6  
           C(9B)        C(10B)       H(10B)       120.6  
           C(10B)       C(11B)       N(2B)        118.4(3)  
           C(10B)       C(11B)       C(12B)       125.5(3)  
           N(2B)        C(11B)       C(12B)       116.1(3)  
           C(11B)       C(12B)       H(12D)       109.5  
           C(11B)       C(12B)       H(12E)       109.5  
           H(12D)       C(12B)       H(12E)       109.5  
           C(11B)       C(12B)       H(12F)       109.5  
           H(12D)       C(12B)       H(12F)       109.5  
           H(12E)       C(12B)       H(12F)       109.5  
           N(4B)        C(13B)       N(3B)        116.5(3)  
           N(4B)        C(13B)       C(14B)       122.8(3)  
           N(3B)        C(13B)       C(14B)       120.7(3)  
           C(15B)       C(14B)       C(13B)       118.4(3)  
           C(15B)       C(14B)       H(14B)       120.8  
           C(13B)       C(14B)       H(14B)       120.8  
           C(14B)       C(15B)       C(16B)       119.6(3)  
           C(14B)       C(15B)       H(15B)       120.2  
           C(16B)       C(15B)       H(15B)       120.2  
           C(17B)       C(16B)       C(15B)       118.9(3)  
           C(17B)       C(16B)       H(16B)       120.5  
           C(15B)       C(16B)       H(16B)       120.5  
           N(4B)        C(17B)       C(16B)       123.1(3)  
           N(4B)        C(17B)       C(18B)       115.3(3)  
           C(16B)       C(17B)       C(18B)       121.6(3)  
           C(17B)       C(18B)       H(18D)       109.5  
           C(17B)       C(18B)       H(18E)       109.5  
           H(18D)       C(18B)       H(18E)       109.5  
           C(17B)       C(18B)       H(18F)       109.5  
           H(18D)       C(18B)       H(18F)       109.5  
           H(18E)       C(18B)       H(18F)       109.5  
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Table 32. Torsion Angles for 118c 
           A      B         C          D     Torsion Angle  
   
           O(3)       S(1)       C(19)      F(2)         -176.3(3)  
           O(2)       S(1)       C(19)      F(2)          -54.2(3)  
           O(1)       S(1)       C(19)      F(2)           63.6(3)  
           O(3)       S(1)       C(19)      F(3)          -55.3(3)  
           O(2)       S(1)       C(19)      F(3)           66.8(3)  
           O(1)       S(1)       C(19)      F(3)         -175.4(3)  
           O(3)       S(1)       C(19)      F(1)           63.5(3)  
           O(2)       S(1)       C(19)      F(1)         -174.4(2)  
           O(1)       S(1)       C(19)      F(1)          -56.6(3)  
           O(5)       S(2)       C(20)      F(4)          176.3(2)  
           O(4)       S(2)       C(20)      F(4)           53.9(3)  
           O(6)       S(2)       C(20)      F(4)          -65.1(3)  
           O(5)       S(2)       C(20)      F(6)           56.0(3)  
           O(4)       S(2)       C(20)      F(6)          -66.4(3)  
           O(6)       S(2)       C(20)      F(6)          174.5(2)  
           O(5)       S(2)       C(20)      F(5)          -63.5(3)  
           O(4)       S(2)       C(20)      F(5)          174.1(2)  
           O(6)       S(2)       C(20)      F(5)           55.1(3)  
           C(7A)      N(1A)      C(1A)      C(6A)        -153.3(3)  
           C(7A)      N(1A)      C(1A)      C(2A)          83.6(4)  
           C(13A)     N(3A)      C(2A)      C(3A)        -153.9(3)  
           C(13A)     N(3A)      C(2A)      C(1A)          83.2(4)  
           N(1A)      C(1A)      C(2A)      N(3A)        -167.3(3)  
           C(6A)      C(1A)      C(2A)      N(3A)          70.4(3)  
           N(1A)      C(1A)      C(2A)      C(3A)          69.2(3)  
           C(6A)      C(1A)      C(2A)      C(3A)         -53.1(4)  
           N(3A)      C(2A)      C(3A)      C(4A)         -69.1(4)  
           C(1A)      C(2A)      C(3A)      C(4A)          53.0(4)  
           C(2A)      C(3A)      C(4A)      C(5A)         -54.1(4)  
           C(3A)      C(4A)      C(5A)      C(6A)          54.1(4)  
           N(1A)      C(1A)      C(6A)      C(5A)         -67.4(4)  
           C(2A)      C(1A)      C(6A)      C(5A)          55.9(4)  
           C(4A)      C(5A)      C(6A)      C(1A)         -56.5(4)  
           C(1A)      N(1A)      C(7A)      N(2A)         173.3(3)  
           C(1A)      N(1A)      C(7A)      C(8A)          -7.6(5)  
           C(11A)     N(2A)      C(7A)      N(1A)        -177.0(3)  
           C(11A)     N(2A)      C(7A)      C(8A)           3.9(5)  
           N(1A)      C(7A)      C(8A)      C(9A)         177.5(3)  
           N(2A)      C(7A)      C(8A)      C(9A)          -3.4(4)  
           C(7A)      C(8A)      C(9A)      C(10A)          0.9(5)  
           C(8A)      C(9A)      C(10A)     C(11A)          1.3(5)  
           C(9A)      C(10A)     C(11A)     N(2A)          -1.0(5)  
           C(9A)      C(10A)     C(11A)     C(12A)        178.9(3)  
           C(7A)      N(2A)      C(11A)     C(10A)         -1.6(5)  
           C(7A)      N(2A)      C(11A)     C(12A)        178.5(3)  
           C(17A)     N(4A)      C(13A)     N(3A)         175.8(3)  
           C(17A)     N(4A)      C(13A)     C(14A)         -3.2(5)  
           C(2A)      N(3A)      C(13A)     N(4A)           1.3(5)  
           C(2A)      N(3A)      C(13A)     C(14A)       -179.6(3)  
           N(4A)      C(13A)     C(14A)     C(15A)          2.7(5)  
           N(3A)      C(13A)     C(14A)     C(15A)       -176.3(3)  
           C(13A)     C(14A)     C(15A)     C(16A)         -0.6(5)  
           C(14A)     C(15A)     C(16A)     C(17A)         -0.8(5)  
           C(13A)     N(4A)      C(17A)     C(16A)          1.8(5)  
           C(13A)     N(4A)      C(17A)     C(18A)       -178.4(3)  
           C(15A)     C(16A)     C(17A)     N(4A)           0.2(5)  
           C(15A)     C(16A)     C(17A)     C(18A)       -179.6(3)  
           C(7B)      N(1B)      C(1B)      C(6B)        -153.3(3)  
           C(7B)      N(1B)      C(1B)      C(2B)          83.6(4)  
           C(13B)     N(3B)      C(2B)      C(3B)        -157.2(3)  
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           C(13B)     N(3B)      C(2B)      C(1B)          80.1(4)  
           N(1B)      C(1B)      C(2B)      N(3B)        -167.3(3)  
           C(6B)      C(1B)      C(2B)      N(3B)          70.8(3)  
           N(1B)      C(1B)      C(2B)      C(3B)          70.6(3)  
           C(6B)      C(1B)      C(2B)      C(3B)         -51.3(4)  
           N(3B)      C(2B)      C(3B)      C(4B)         -67.9(4)  
           C(1B)      C(2B)      C(3B)      C(4B)          54.1(4)  
           C(2B)      C(3B)      C(4B)      C(5B)         -58.0(4)  
           C(3B)      C(4B)      C(5B)      C(6B)          57.7(4)  
           N(1B)      C(1B)      C(6B)      C(5B)         -69.1(4)  
           C(2B)      C(1B)      C(6B)      C(5B)          53.3(4)  
           C(4B)      C(5B)      C(6B)      C(1B)         -56.3(4)  
           C(1B)      N(1B)      C(7B)      N(2B)         172.7(3)  
           C(1B)      N(1B)      C(7B)      C(8B)          -7.0(5)  
           C(11B)     N(2B)      C(7B)      N(1B)        -178.3(3)  
           C(11B)     N(2B)      C(7B)      C(8B)           1.4(5)  
           N(1B)      C(7B)      C(8B)      C(9B)         179.5(3)  
           N(2B)      C(7B)      C(8B)      C(9B)          -0.1(5)  
           C(7B)      C(8B)      C(9B)      C(10B)         -0.7(5)  
           C(8B)      C(9B)      C(10B)     C(11B)          0.5(5)  
           C(9B)      C(10B)     C(11B)     N(2B)           0.7(5)  
           C(9B)      C(10B)     C(11B)     C(12B)       -178.2(3)  
           C(7B)      N(2B)      C(11B)     C(10B)         -1.6(5)  
           C(7B)      N(2B)      C(11B)     C(12B)        177.4(3)  
           C(17B)     N(4B)      C(13B)     N(3B)         179.2(3)  
           C(17B)     N(4B)      C(13B)     C(14B)         -1.9(5)  
           C(2B)      N(3B)      C(13B)     N(4B)         -10.9(5)  
           C(2B)      N(3B)      C(13B)     C(14B)        170.1(3)  
           N(4B)      C(13B)     C(14B)     C(15B)          2.7(5)  
           N(3B)      C(13B)     C(14B)     C(15B)       -178.5(3)  
           C(13B)     C(14B)     C(15B)     C(16B)         -0.5(5)  
           C(14B)     C(15B)     C(16B)     C(17B)         -2.3(5)  
           C(13B)     N(4B)      C(17B)     C(16B)         -1.0(5)  
           C(13B)     N(4B)      C(17B)     C(18B)        178.6(3)  
           C(15B)     C(16B)     C(17B)     N(4B)           3.1(5)  
           C(15B)     C(16B)     C(17B)     C(18B)       -176.5(3)  
 
 
Table 33. Summary of X-Ray Crystallographic Data for 118c 
Empirical Formula                 C19 H25 F3 N4 O3 S  
 
      Color of Crystal:                 colorless  
   
      Crystal Dimensions were:          0.20 x 0.20 x 0.10 mm.  
   
Space Group:                      P2(1)  
 
      Cell Dimensions (at 128(2) K; 5820 reflections)  
                           a =            9.6256(10)  
                           b =           17.2404(17)  
                           c =           12.5115(13)  
                       alpha =           90  
                        beta =           92.696(2)  
                       gamma =           90  
   
      Z (Molecules/cell):                 4  
   
      Volume:                           2074.0(4)  
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      Calculated Density:               1.430  
   
      Wavelength:                       0.71073  
   
      Molecular Weight:                 446.49  
   
      F(000):                           936  
   
      Linear Absorption Coefficient:    0.211  
 
 
 
Figure 40. Numbering System for 118e 
 
Note: Data were collected on a Bruker SMART 6000 sealed-tube system comprising a  
three-circle platform goniostat, an HOG crystal monochromator, a four kilopixel by four 
kilopixel single-chip CCD-based detector, a K761 high voltage generator, and a PC 
interface running Bruker's SMART software. 
 
Table 34. Fractional Coordinates and Isotropic Thermal Parameters for 118e 
          Atom           x             y             z           Uiso  
   
          N(1)          253(1)       4431(3)       3529(3)       29(1)  
          N(2)         -702(1)       4753(3)       2199(3)       32(1)  
          N(3)        -1296(1)       6041(3)       -256(3)       34(1)  
          N(4)        -1655(1)       4111(3)         74(2)       31(1)  
          C(1)          709(2)       3649(3)       4243(3)       28(1)  
          C(2)         1244(2)       4178(4)       4990(3)       33(1)  
          C(3)         1675(2)       3371(4)       5690(3)       40(1)  
          C(4)         1603(2)       2072(4)       5674(4)       42(1)  
          C(5)         1083(2)       1548(4)       4934(3)       38(1)  
          C(6)          625(2)       2337(4)       4199(3)       32(1)  
          C(7)           73(2)       1852(4)       3414(3)       35(1)  
          C(8)         -361(2)       2643(3)       2765(3)       33(1)  
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          C(9)         -273(1)       3989(3)       2828(3)       27(1)  
          C(10)        -689(1)       6144(3)       2123(3)       30(1)  
          C(11)        -687(2)       6760(4)       3368(3)       38(1)  
          C(12)        -687(2)       8200(4)       3290(3)       39(1)  
          C(13)       -1210(2)       8659(4)       2163(4)       41(1)  
          C(14)       -1239(2)       8021(4)        906(3)       39(1)  
          C(15)       -1234(2)       6588(3)       1008(3)       31(1)  
          C(16)       -1550(2)       4934(4)       -713(3)       32(1)  
          C(17)       -1704(2)       4647(4)      -2072(3)       39(1)  
          C(18)       -1951(2)       3526(4)      -2534(4)       40(1)  
          C(19)       -2069(1)       2622(4)      -1713(3)       36(1)  
          C(20)       -2295(2)       1414(4)      -2115(3)       40(1)  
          C(21)       -2375(2)        575(4)      -1254(4)       45(1)  
          C(22)       -2225(2)        930(4)         40(4)       39(1)  
          C(23)       -1999(2)       2101(4)        465(3)       37(1)  
          C(24)       -1905(1)       2967(4)       -396(3)       31(1)  
          S(1)          917(1)       7919(1)       3095(1)       37(1)  
          O(1)          958(2)       7748(4)       1868(3)       86(1)  
          O(2)          637(1)       9036(3)       3240(3)       46(1)  
          O(3)          770(1)       6801(3)       3624(3)       67(1)  
          C(25)        1661(2)       8172(4)       4186(4)       48(1)  
          F(1)         1880(1)       9188(4)       3841(4)       98(1)  
          F(2)         1698(1)       8372(4)       5370(3)       79(1)  
          F(3)         1991(1)       7185(3)       4196(3)       71(1)  
          C(1S)           0          4378(7)          0          59(2)  
          C(2S)           0          2958(7)          0          44(1)  
          C(3S)        -499(2)       2271(5)       -625(4)       51(1)  
          C(4S)        -500(2)        971(5)       -618(4)       59(1)  
          C(5S)           0           292(8)          0          61(2)  
   
          H(1N)          36(2)        525(5)        353(5)       60(14)  
          H(2N)        -109(2)        442(5)        162(5)       61(14)  
          H(3N)        -120(2)        648(5)        -71(4)       48(13)  
          H(2)          131           507           501          40  
          H(3)          204           372           621          47  
          H(4)          191           154           617          50  
          H(5)          103            66           492          46  
          H(7)            1            96           335          42  
          H(8)          -73           231           226          40  
          H(10)         -34           642           195          36  
          H(11A)       -103           648           354          45  
          H(11B)        -34           648           410          45  
          H(12A)        -33           849           318          46  
          H(12B)        -69           856           410          46  
          H(13A)       -119           959           208          50  
          H(13B)       -156           846           233          50  
          H(14A)       -159           829            20          46  
          H(14B)        -91           830            69          46  
          H(15)        -157           633           121          37  
          H(17)        -163           524          -263          47  
          H(18)        -205           334          -342          48  
          H(20)        -239           117          -299          48  
          H(21)        -253           -24          -153          54  
          H(22)        -228            35            63          47  
          H(23)        -191           233           134          44  
          H(1SA)         39           469            49          88  
          H(1SB)        -26           469            40          88  
          H(1SC)        -13           469           -89          88  
          H(3SA)        -85           271          -107          62  
          H(4SA)        -85            53          -104          70  
          H(5S)           0           -70(9)          0          73  
   
          Notes:  
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            1) Fractional coordinates are X 10**4 for non-hydrogen  
atoms and X 10**3 for hydrogen atoms.  Uiso values are all  
X 10**3.  
            2) Isotropic values for those atoms refined anisotropically  
            are calculated as one third of the trace of the  
orthogonalized  
            Uij tensor.  
            3) Parameters without standard deviations were not varied.  
 
Table 35. Anisotropic displacement parameters for 118e 
    Atom      U11        U22        U33        U23        U13        U12  
   
    N(1)     27(1)      29(2)      26(1)      -1(1)       5(1)       0(1)  
    N(2)     28(2)      36(2)      27(1)       3(1)       6(1)      -2(1)  
    N(3)     43(2)      35(2)      25(1)       5(1)      14(1)      -2(2)  
    N(4)     30(1)      38(2)      25(1)       1(1)       8(1)       0(1)  
    C(1)     27(2)      37(2)      18(2)      -2(1)       5(1)       4(1)  
    C(2)     33(2)      36(2)      30(2)      -6(1)       9(1)       1(2)  
    C(3)     31(2)      51(2)      29(2)      -6(2)       3(2)       4(2)  
    C(4)     36(2)      46(2)      34(2)       0(2)       3(2)      10(2)  
    C(5)     40(2)      34(2)      35(2)      -3(2)       6(2)       8(2)  
    C(6)     34(2)      37(2)      24(2)       0(1)      11(1)       4(2)  
    C(7)     41(2)      29(2)      32(2)       2(1)      11(2)      -4(2)  
    C(8)     34(2)      36(2)      26(2)       0(1)       8(1)      -3(2)  
    C(9)     29(2)      35(2)      18(1)       2(1)       9(1)       0(2)  
    C(10)    26(2)      35(2)      27(2)       1(1)       7(1)       1(2)  
    C(11)    37(2)      49(2)      25(2)      -1(2)       8(1)       4(2)  
    C(12)    37(2)      42(2)      35(2)      -8(2)      11(2)       4(2)  
    C(13)    43(2)      36(2)      42(2)      -4(2)      13(2)       6(2)  
    C(14)    39(2)      40(2)      32(2)       3(2)       8(2)       3(2)  
    C(15)    33(2)      34(2)      24(2)      -2(1)       8(1)       1(2)  
    C(16)    30(2)      36(2)      29(2)       2(1)      10(1)       3(2)  
    C(17)    42(2)      49(2)      25(2)       5(2)      11(2)      -1(2)  
    C(18)    36(2)      50(2)      29(2)       0(2)       8(2)       0(2)  
    C(19)    26(2)      47(2)      30(2)      -3(2)       5(1)       3(2)  
    C(20)    35(2)      45(2)      35(2)      -7(2)       6(2)      -2(2)  
    C(21)    39(2)      40(2)      50(2)      -9(2)      10(2)      -3(2)  
    C(22)    28(2)      44(2)      42(2)       5(2)       9(2)      -2(2)  
    C(23)    29(2)      45(2)      33(2)       3(2)       8(2)       1(2)  
    C(24)    25(2)      36(2)      31(2)      -1(2)       9(1)       2(2)  
    S(1)     43(1)      31(1)      32(1)      -3(1)       9(1)       3(1)  
    O(1)    111(3)     109(3)      37(2)      -3(2)      27(2)      57(3)  
    O(2)     44(2)      43(2)      47(2)      -8(1)      14(1)       2(1)  
    O(3)     44(2)      45(2)      83(2)      15(2)     -10(2)     -13(2)  
    C(25)    42(2)      43(3)      64(3)      -5(2)      26(2)      -6(2)  
    F(1)     58(2)      76(2)     166(4)      17(2)      50(2)     -17(2)  
    F(2)     45(2)     127(3)      49(2)     -26(2)      -3(1)       2(2)  
    F(3)     48(2)      67(2)      90(2)     -13(2)      14(1)      15(1)  
    C(1S)    67(4)      59(4)      69(4)       0         46(4)       0  
    C(2S)    39(3)      65(4)      33(2)       0         20(2)       0  
    C(3S)    37(2)      72(3)      44(2)      -5(2)      14(2)       5(2)  
    C(4S)    45(2)      68(3)      58(3)     -10(2)      13(2)      -6(2)  
    C(5S)    56(4)      53(4)      70(5)       0         18(3)       0  
   
    Form of the anisotropic thermal parameter:  
       exp{ -2 pi**2 [ h**2 (a*)**2 U11 + ... + 2 h k (a*) (b*) U12 ] }  
    All values are X 10**3  
 
Table 36. Bond lengths [Å] for 118e 
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           A            B            Distance  
   
           N(1)         C(9)         1.348(4)  
           N(1)         C(1)         1.399(4)  
           N(1)         H(1N)        0.91(6)  
           N(2)         C(9)         1.322(5)  
           N(2)         C(10)        1.473(5)  
           N(2)         H(2N)        1.01(5)  
           N(3)         C(16)        1.339(5)  
           N(3)         C(15)        1.480(4)  
           N(3)         H(3N)        0.80(5)  
           N(4)         C(16)        1.331(4)  
           N(4)         C(24)        1.374(5)  
           C(1)         C(6)         1.399(5)  
           C(1)         C(2)         1.410(5)  
           C(2)         C(3)         1.373(5)  
           C(2)         H(2)         0.9500  
           C(3)         C(4)         1.383(6)  
           C(3)         H(3)         0.9500  
           C(4)         C(5)         1.378(6)  
           C(4)         H(4)         0.9500  
           C(5)         C(6)         1.412(5)  
           C(5)         H(5)         0.9500  
           C(6)         C(7)         1.436(5)  
           C(7)         C(8)         1.353(5)  
           C(7)         H(7)         0.9500  
           C(8)         C(9)         1.436(5)  
           C(8)         H(8)         0.9500  
           C(10)        C(11)        1.533(5)  
           C(10)        C(15)        1.544(4)  
           C(10)        H(10)        1.0000  
           C(11)        C(12)        1.524(6)  
           C(11)        H(11A)       0.9900  
           C(11)        H(11B)       0.9900  
           C(12)        C(13)        1.525(5)  
           C(12)        H(12A)       0.9900  
           C(12)        H(12B)       0.9900  
           C(13)        C(14)        1.534(5)  
           C(13)        H(13A)       0.9900  
           C(13)        H(13B)       0.9900  
           C(14)        C(15)        1.516(6)  
           C(14)        H(14A)       0.9900  
           C(14)        H(14B)       0.9900  
           C(15)        H(15)        1.0000  
           C(16)        C(17)        1.453(5)  
           C(17)        C(18)        1.347(6)  
           C(17)        H(17)        0.9500  
           C(18)        C(19)        1.429(5)  
           C(18)        H(18)        0.9500  
           C(19)        C(20)        1.402(6)  
           C(19)        C(24)        1.420(4)  
           C(20)        C(21)        1.376(6)  
           C(20)        H(20)        0.9500  
           C(21)        C(22)        1.403(5)  
           C(21)        H(21)        0.9500  
           C(22)        C(23)        1.370(6)  
           C(22)        H(22)        0.9500  
           C(23)        C(24)        1.409(5)  
           C(23)        H(23)        0.9500  
           S(1)         O(2)         1.414(3)  
           S(1)         O(1)         1.422(3)  
           S(1)         O(3)         1.429(4)  
           S(1)         C(25)        1.836(4)  
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           C(25)        F(2)         1.308(5)  
           C(25)        F(1)         1.327(5)  
           C(25)        F(3)         1.331(5)  
           C(1S)        C(2S)        1.500(10)  
           C(1S)        H(1SA)       0.9800  
           C(1S)        H(1SB)       0.9800  
           C(1S)        H(1SC)       0.9800  
           C(2S)        C(3S)        1.393(6)  
           C(2S)        C(3S)#1      1.393(6)  
           C(3S)        C(4S)        1.373(7)  
           C(3S)        H(3SA)       0.9500  
           C(4S)        C(5S)        1.389(6)  
           C(4S)        H(4SA)       0.9500  
           C(5S)        C(4S)#1      1.389(6)  
           C(5S)        H(5S)        1.05(9)  
   
           Symmetry transformations used to generate equivalent atoms:  
              #1 -x,y,-z      
 
Table 37. Bond Angles for 118e 
           A            B            C            Angle  
   
           C(9)         N(1)         C(1)         123.3(3)  
           C(9)         N(1)         H(1N)        125(3)  
           C(1)         N(1)         H(1N)        112(3)  
           C(9)         N(2)         C(10)        127.5(3)  
           C(9)         N(2)         H(2N)        122(3)  
           C(10)        N(2)         H(2N)        110(3)  
           C(16)        N(3)         C(15)        124.9(3)  
           C(16)        N(3)         H(3N)        119(3)  
           C(15)        N(3)         H(3N)        116(3)  
           C(16)        N(4)         C(24)        119.7(3)  
           N(1)         C(1)         C(6)         118.9(3)  
           N(1)         C(1)         C(2)         120.4(3)  
           C(6)         C(1)         C(2)         120.7(3)  
           C(3)         C(2)         C(1)         118.1(4)  
           C(3)         C(2)         H(2)         121.0  
           C(1)         C(2)         H(2)         121.0  
           C(2)         C(3)         C(4)         122.4(4)  
           C(2)         C(3)         H(3)         118.8  
           C(4)         C(3)         H(3)         118.8  
           C(5)         C(4)         C(3)         119.8(4)  
           C(5)         C(4)         H(4)         120.1  
           C(3)         C(4)         H(4)         120.1  
           C(4)         C(5)         C(6)         120.0(4)  
           C(4)         C(5)         H(5)         120.0  
           C(6)         C(5)         H(5)         120.0  
           C(1)         C(6)         C(5)         119.0(3)  
           C(1)         C(6)         C(7)         118.3(3)  
           C(5)         C(6)         C(7)         122.7(4)  
           C(8)         C(7)         C(6)         120.9(3)  
           C(8)         C(7)         H(7)         119.6  
           C(6)         C(7)         H(7)         119.6  
           C(7)         C(8)         C(9)         120.4(3)  
           C(7)         C(8)         H(8)         119.8  
           C(9)         C(8)         H(8)         119.8  
           N(2)         C(9)         N(1)         122.1(3)  
           N(2)         C(9)         C(8)         119.8(3)  
           N(1)         C(9)         C(8)         118.1(3)  
           N(2)         C(10)        C(11)        111.3(3)  
           N(2)         C(10)        C(15)        108.6(3)  
           C(11)        C(10)        C(15)        107.9(3)  
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           N(2)         C(10)        H(10)        109.7  
           C(11)        C(10)        H(10)        109.7  
           C(15)        C(10)        H(10)        109.7  
           C(12)        C(11)        C(10)        111.9(3)  
           C(12)        C(11)        H(11A)       109.2  
           C(10)        C(11)        H(11A)       109.2  
           C(12)        C(11)        H(11B)       109.2  
           C(10)        C(11)        H(11B)       109.2  
           H(11A)       C(11)        H(11B)       107.9  
           C(11)        C(12)        C(13)        110.3(3)  
           C(11)        C(12)        H(12A)       109.6  
           C(13)        C(12)        H(12A)       109.6  
           C(11)        C(12)        H(12B)       109.6  
           C(13)        C(12)        H(12B)       109.6  
           H(12A)       C(12)        H(12B)       108.1  
           C(12)        C(13)        C(14)        110.6(3)  
           C(12)        C(13)        H(13A)       109.5  
           C(14)        C(13)        H(13A)       109.5  
           C(12)        C(13)        H(13B)       109.5  
           C(14)        C(13)        H(13B)       109.5  
           H(13A)       C(13)        H(13B)       108.1  
           C(15)        C(14)        C(13)        111.9(3)  
           C(15)        C(14)        H(14A)       109.2  
           C(13)        C(14)        H(14A)       109.2  
           C(15)        C(14)        H(14B)       109.2  
           C(13)        C(14)        H(14B)       109.2  
           H(14A)       C(14)        H(14B)       107.9  
           N(3)         C(15)        C(14)        108.8(3)  
           N(3)         C(15)        C(10)        113.6(3)  
           C(14)        C(15)        C(10)        110.1(3)  
           N(3)         C(15)        H(15)        108.0  
           C(14)        C(15)        H(15)        108.0  
           C(10)        C(15)        H(15)        108.0  
           N(4)         C(16)        N(3)         120.1(3)  
           N(4)         C(16)        C(17)        120.8(3)  
           N(3)         C(16)        C(17)        119.1(3)  
           C(18)        C(17)        C(16)        119.4(3)  
           C(18)        C(17)        H(17)        120.3  
           C(16)        C(17)        H(17)        120.3  
           C(17)        C(18)        C(19)        121.1(3)  
           C(17)        C(18)        H(18)        119.5  
           C(19)        C(18)        H(18)        119.5  
           C(20)        C(19)        C(24)        119.6(3)  
           C(20)        C(19)        C(18)        123.9(3)  
           C(24)        C(19)        C(18)        116.4(3)  
           C(21)        C(20)        C(19)        120.6(3)  
           C(21)        C(20)        H(20)        119.7  
           C(19)        C(20)        H(20)        119.7  
           C(20)        C(21)        C(22)        119.7(4)  
           C(20)        C(21)        H(21)        120.2  
           C(22)        C(21)        H(21)        120.2  
           C(23)        C(22)        C(21)        121.2(4)  
           C(23)        C(22)        H(22)        119.4  
           C(21)        C(22)        H(22)        119.4  
           C(22)        C(23)        C(24)        120.1(3)  
           C(22)        C(23)        H(23)        120.0  
           C(24)        C(23)        H(23)        120.0  
           N(4)         C(24)        C(23)        118.5(3)  
           N(4)         C(24)        C(19)        122.5(3)  
           C(23)        C(24)        C(19)        118.9(4)  
           O(2)         S(1)         O(1)         115.6(2)  
           O(2)         S(1)         O(3)         115.2(2)  
           O(1)         S(1)         O(3)         114.6(3)  
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           O(2)         S(1)         C(25)        103.33(19)  
           O(1)         S(1)         C(25)        103.9(2)  
           O(3)         S(1)         C(25)        101.67(19)  
           F(2)         C(25)        F(1)         106.3(4)  
           F(2)         C(25)        F(3)         107.9(4)  
           F(1)         C(25)        F(3)         108.1(3)  
           F(2)         C(25)        S(1)         111.7(3)  
           F(1)         C(25)        S(1)         110.9(3)  
           F(3)         C(25)        S(1)         111.7(3)  
           C(2S)        C(1S)        H(1SA)       109.5  
           C(2S)        C(1S)        H(1SB)       109.5  
           H(1SA)       C(1S)        H(1SB)       109.5  
           C(2S)        C(1S)        H(1SC)       109.5  
           H(1SA)       C(1S)        H(1SC)       109.5  
           H(1SB)       C(1S)        H(1SC)       109.5  
           C(3S)        C(2S)        C(3S)#1      117.2(7)  
           C(3S)        C(2S)        C(1S)        121.4(3)  
           C(3S)#1      C(2S)        C(1S)        121.4(3)  
           C(4S)        C(3S)        C(2S)        121.4(5)  
           C(4S)        C(3S)        H(3SA)       119.3  
           C(2S)        C(3S)        H(3SA)       119.3  
           C(3S)        C(4S)        C(5S)        121.0(5)  
           C(3S)        C(4S)        H(4SA)       119.5  
           C(5S)        C(4S)        H(4SA)       119.5  
           C(4S)#1      C(5S)        C(4S)        117.9(7)  
           C(4S)#1      C(5S)        H(5S)        121.1(4)  
           C(4S)        C(5S)        H(5S)        121.1(4)  
   
           Symmetry transformations used to generate equivalent atoms:  
              #1 -x,y,-z      
 
Table 38. Torsion Angles for 118e 
           A    B        C     D           Torsion Angle  
   
           C(9)       N(1)       C(1)       C(6)            2.2(5)  
           C(9)       N(1)       C(1)       C(2)         -177.9(3)  
           N(1)       C(1)       C(2)       C(3)          178.9(3)  
           C(6)       C(1)       C(2)       C(3)           -1.2(5)  
           C(1)       C(2)       C(3)       C(4)            0.7(6)  
           C(2)       C(3)       C(4)       C(5)            0.0(7)  
           C(3)       C(4)       C(5)       C(6)           -0.2(6)  
           N(1)       C(1)       C(6)       C(5)         -179.1(3)  
           C(2)       C(1)       C(6)       C(5)            1.0(5)  
           N(1)       C(1)       C(6)       C(7)            0.4(5)  
           C(2)       C(1)       C(6)       C(7)         -179.5(3)  
           C(4)       C(5)       C(6)       C(1)           -0.2(5)  
           C(4)       C(5)       C(6)       C(7)         -179.7(4)  
           C(1)       C(6)       C(7)       C(8)           -2.1(5)  
           C(5)       C(6)       C(7)       C(8)          177.4(3)  
           C(6)       C(7)       C(8)       C(9)            1.3(5)  
           C(10)      N(2)       C(9)       N(1)            1.2(5)  
           C(10)      N(2)       C(9)       C(8)         -178.2(3)  
           C(1)       N(1)       C(9)       N(2)          177.6(3)  
           C(1)       N(1)       C(9)       C(8)           -3.0(5)  
           C(7)       C(8)       C(9)       N(2)         -179.4(3)  
           C(7)       C(8)       C(9)       N(1)            1.2(5)  
           C(9)       N(2)       C(10)      C(11)         -76.4(4)  
           C(9)       N(2)       C(10)      C(15)         165.0(3)  
           N(2)       C(10)      C(11)      C(12)        -178.7(3)  
           C(15)      C(10)      C(11)      C(12)         -59.7(4)  
           C(10)      C(11)      C(12)      C(13)          58.3(4)  
           C(11)      C(12)      C(13)      C(14)         -54.5(4)  
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           C(12)      C(13)      C(14)      C(15)          55.5(4)  
           C(16)      N(3)       C(15)      C(14)        -149.3(3)  
           C(16)      N(3)       C(15)      C(10)          87.6(4)  
           C(13)      C(14)      C(15)      N(3)          176.8(3)  
           C(13)      C(14)      C(15)      C(10)         -58.0(4)  
           N(2)       C(10)      C(15)      N(3)          -58.1(4)  
           C(11)      C(10)      C(15)      N(3)         -178.9(3)  
           N(2)       C(10)      C(15)      C(14)         179.5(3)  
           C(11)      C(10)      C(15)      C(14)          58.8(4)  
           C(24)      N(4)       C(16)      N(3)         -178.7(3)  
           C(24)      N(4)       C(16)      C(17)           1.0(5)  
           C(15)      N(3)       C(16)      N(4)          -14.9(5)  
           C(15)      N(3)       C(16)      C(17)         165.4(3)  
           N(4)       C(16)      C(17)      C(18)          -0.8(5)  
           N(3)       C(16)      C(17)      C(18)         178.9(4)  
           C(16)      C(17)      C(18)      C(19)           0.7(6)  
           C(17)      C(18)      C(19)      C(20)        -176.3(4)  
           C(17)      C(18)      C(19)      C(24)          -0.8(5)  
           C(24)      C(19)      C(20)      C(21)           1.9(5)  
           C(18)      C(19)      C(20)      C(21)         177.3(4)  
           C(19)      C(20)      C(21)      C(22)          -0.5(6)  
           C(20)      C(21)      C(22)      C(23)           0.0(6)  
           C(21)      C(22)      C(23)      C(24)          -1.0(5)  
           C(16)      N(4)       C(24)      C(23)         178.5(3)  
           C(16)      N(4)       C(24)      C(19)          -1.2(5)  
           C(22)      C(23)      C(24)      N(4)         -177.2(3)  
           C(22)      C(23)      C(24)      C(19)           2.4(5)  
           C(20)      C(19)      C(24)      N(4)          176.8(3)  
           C(18)      C(19)      C(24)      N(4)            1.0(5)  
           C(20)      C(19)      C(24)      C(23)          -2.9(5)  
           C(18)      C(19)      C(24)      C(23)        -178.6(3)  
           O(2)       S(1)       C(25)      F(2)           57.7(4)  
           O(1)       S(1)       C(25)      F(2)          178.8(3)  
           O(3)       S(1)       C(25)      F(2)          -62.0(4)  
           O(2)       S(1)       C(25)      F(1)          -60.7(3)  
           O(1)       S(1)       C(25)      F(1)           60.4(4)  
           O(3)       S(1)       C(25)      F(1)          179.6(3)  
           O(2)       S(1)       C(25)      F(3)          178.6(3)  
           O(1)       S(1)       C(25)      F(3)          -60.3(4)  
           O(3)       S(1)       C(25)      F(3)           58.9(3)  
           C(3S)#1    C(2S)      C(3S)      C(4S)           0.4(3)  
           C(1S)      C(2S)      C(3S)      C(4S)        -179.6(3)  
           C(2S)      C(3S)      C(4S)      C(5S)          -0.9(6)  
           C(3S)      C(4S)      C(5S)      C(4S)#1         0.4(3)  
   
           Symmetry transformations used to generate equivalent atoms:  
              #1 -x,y,-z      
 
 
Table 39. Summary of X-Ray Crystallographic Data for 118e 
   Empirical Formula                 C28.50 H29 F3 N4 O3 S  
 
      Color of Crystal:                 colorless  
   
      Crystal Dimensions were:          0.17 x 0.13 x 0.11 mm.  
   
Space Group:                      C2  
 
      Cell Dimensions (at 130(2) K; 1487 reflections)  
                           a =           25.147(4)  
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                           b =           10.5601(16)  
                           c =           11.1691(17)  
                       alpha =           90  
                        beta =          111.682(8)  
                       gamma =           90  
   
      Z (Molecules/cell):                 4  
   
      Volume:                           2756.1(7)  
   
      Calculated Density:               1.361  
   
      Wavelength:                       0.71073  
   
      Molecular Weight:                 564.62  
   
      F(000):                           1180  
   
      Linear Absorption Coefficient:    0.175  
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